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Tuatara (Sphenodon punctatus) are unique, cold-adapted reptiles endemic to New 
Zealand. Recently, captive tuatara have been found to be affected by an emerging fungal 
pathogen, Paranannizziopsis australasiensis. P. australasiensis causes dermatitis in 
tuatara, and has caused fatal systemic mycosis in a bearded dragon (Pogona vitticeps), 
and in aquatic file snakes (Acrochordus spp). The discovery of P. australasiensis 
infections has prevented the release of tuatara from several captive institutions to 
offshore islands, and has negative implications for the long-term health and welfare of 
the animals.  
 
A review of the literature revealed that infections caused by organisms related to P. 
australasiensis are being recognised worldwide as emerging pathogens of reptiles. Little 
is known about the epidemiology of these often-fatal infections, and treatment with a 
range of antifungals has met with varying success. There has been little research on 
antifungal use in reptiles, and none on how environmental temperature affects the 
pharmacokinetics of antifungals.  
 
This study investigated the microbiological characteristics of P. australasiensis, primarily 
the growth rate of the fungus at different temperatures, and the Minimum Inhibitory 
Concentration (MIC) of various antifungal agents for P. australasiensis. It was 
determined that the optimal growth temperature for P. australasiensis encompasses 
the range from 20oC-30oC, with scant growth at 12oC, moderate growth at 15oC, and no 
growth at 37oC. The MICs of antifungals were tested at room temperature and at 37oC, 
and were not found to be significantly different. MICs of itraconazole and voriconazole 
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for three isolates of P. australasiensis were found to be low, at 0.12mg/L for itraconazole 
and <0.008mg/L for voriconazole. 
 
The single and multiple dose pharmacokinetics of itraconazole and voriconazole in 
tuatara were investigated at 12 and 20oC; these are the high and low ends of the 
tuatara’s preferred optimal temperature zone (POTZ). Results showed statistically 
significant differences in antifungal elimination half-life between temperatures. With 
the aid of population pharmacokinetic modelling, optimal dosing regimes for both 
antifungals were developed for tuatara of different weights. It was established that 
tuatara should be treated at 20oC, at the high end of POTZ, to facilitate rapid attainment 
of therapeutic antifungal concentrations, improve clinical outcomes and reduce the risk 
of adverse effects.  
 
While itraconazole demonstrated more predictable pharmacokinetics than voriconazole 
in tuatara, itraconazole treatment was associated with significant adverse effects. These 
included elevated bile acids and uric acid concentrations, and weight loss. While 
voriconazole appears to be safer, its pharmacokinetics are less predictable, with high 
inter-individual variability in tuatara administered the same dose rate (a phenomenon 
also observed in humans). While voriconazole may be a useful antifungal in clinically 
affected tuatara where dosage can be adjusted based on the response to treatment, its 
use in an asymptomatic quarantine setting may be limited. The use of higher 
voriconazole doses may increase the likelihood of maintaining therapeutic 
concentrations in all treated animals, however the risk of adverse effects increases 
concomitantly. Furthermore, there are currently no published reports of successful 
treatment of P. australasiensis in tuatara with voriconazole. 
vi 
 
This study also established haematologic and biochemical reference ranges in a group 
of tuatara. These demonstrated variability in several parameters based on sex and 
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Glossary of abbreviations 
ALP = Alkaline phosphatase 
ALT = Alanine aminotransferase 
AST = Aspartate aminotransferase 
CANV = Chrysosporium anamorph of Nannizziopsis vriesii 
CHL = Canterbury Health Laboratories 
CL = clearance 
CLSI = Clinical and Laboratory Standards Institute 
CK = Creatine kinase 
Css = steady-state concentration 
DNA = Deoxyribonucleic acid 
DRA = Disease Risk Analysis 
h = hour 
IM = intramuscular 
IV = intravenous 
Km = Michaelis-Menten constant 
L = litres 
L/h = litres per hour 
MIC = Minimum Inhibitory Concentration 
MPI = Ministry of Primary Industries 
mg = milligrams 
mg/L*h = milligrams per litre per hour 
mL = millilitres 
mol/L = moles per litre 
NONMEM = Nonlinear mixed effects modelling 
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NZVP = New Zealand Veterinary Pathology 
kg = kilogram 
Km = a measure of the affinity of a substrate (drug) for an enzyme. Traditionally it is the 
drug concentration at half of Vmax 
OH-itra = hydroxy-itraconazole 
PA = Paranannizziopsis australasiensis 
PCR = Polymerase Chain Reaction 
PO = per os., to be taken orally 
POTZ = Preferred Optimal Temperature Zone 
RSE = Relative standard error 
RUV = random unexplained variability 
SD = standard deviation 
SDA = Sabouraud Dextrose Agar 
SFD = Snake Fungal Disease 
SID = once daily 
Tmax = time to maximal plasma concentration 
T1/2 = elimination half-life 
µg = micrograms  
V = volume of distribution 




Glossary of definitions 
 
Absorption half-life 
The time taken for half the administered drug dose to be absorbed into the bloodstream. 
 
Acrodont 
Teeth that are attached to the jawbone without sockets. 
 
Area under the curve 
The area under the graphical curve in a linear drug concentration vs time plot. Is a 
measure of drug exposure over time. 
 
Bioavailability (oral) 
The percentage of orally administered drug that is absorbed through the gastrointestinal 
system, as compared to the same amount of drug administered intravenously. 
 
Bootstrap estimates 
A method of reliably estimating confidence intervals in a population using resampling 
from a population subset. 
 
Chrysosporium anamorph of Nannizziopsis vriesii (CANV) complex 
Group of primary reptile fungal pathogens comprised of organisms from the 
Nannizziopsis, Paranannizziopsis and Ophidiomyces spp. 
 
Elimination half-life (t1/2) 




When a constant proportion of drug is absorbed per unit time (cf zero order absorption). 
 
First-order elimination 
When a constant proportion of drug is eliminated per unit time (cf zero order 
elimination). Elimination mechanisms are non-saturable. 
 
Fomite 
An inanimate object or material on which disease-producing agents may be conveyed. 
 
Gastrointestinal transit time 
The time from ingestion of food to the defecation of its digested remains. 
 
Isolate/isolates (noun) 




The New Zealand Māori word for a set of people bound together by descent from a 
common ancestor or ancestors. Modern meaning: tribe. Is not capitalised. 
 
Km (Michaelis-Menten constant) 
a measure of the affinity of a substrate (drug) for an enzyme. Traditionally it is the drug 







Kinetics where there is a linear relationship between drug dose and plasma drug 
concentration. There is no saturable mechanism involved. 
 
Mass-specific metabolic rate 
The resting energy expenditure of an organism per unit of body mass per day, often 
expressed in kcal/kg/day. 
 
McFarland 
A measurement of cell concentration in solution by optical density. 
 
Minimum Inhibitory Concentration 
The lowest concentration of an antimicrobial substance that inhibits growth of the 
target organism. 
 
Mixed order elimination 
When first order (concentration-dependent, non-saturable) elimination is followed by 
zero order (saturable) elimination. 
 
Nonlinear mixed effect model (NONMEM) 
Pharmacokinetic modelling method that accounts for both fixed and random effects, 









Kinetics resulting from saturable drug transfer (usually protein binding, hepatic 
metabolic enzymes or active renal transport), where with increasing drug dose past the 
capacity of the enzymes to metabolise, plasma drug concentration increases by a factor 
higher than the increase in administered drug dose. The relationship between drug dose 
and plasma drug concentration is non-linear. 
 
One-compartment distribution 
A standard PK modelling approach, where the body is treated as a single homogenous 
compartment into which drugs are distributed. 
 
Paranannizziopsis australasiensis 
A primary dermal fungal pathogen of reptiles, found in tuatara and aquatic file snakes. 
 
Pharmacokinetics  
The study of absorption, distribution, metabolism and elimination of medications. 
 
Preferred Optimal Temperature Zone (POTZ) 
The temperature range at which an ectothermic species that allows for optimal 
biological function. This range is different for each species. 
 
Random unexplained variability (RUV) 
A measure of random error, which is always present in modelling and is unpredictable. 
Quantifying RUV gives a measure of how reliable model-based estimates are, and using 




Relative standard error (RSE) 
Mathematical tool for assessing reliability of an estimate. The higher an RSE, the less 
reliable the estimate (some sources quote an RSE of over 30% as unreliable). 
 
Residual error 
The difference between an observation and the model prediction of the observation. 
Used to describe what is leftover after all other sources of variability (such as between 
subject variability) have been accounted for. 
 
Snout-vent length 
The length of an animal when straight, from the tip of the snout to the cloaca. 
 
Steady-state concentration (Css) 
Drug concentration where the rate of drug input is equal to the rate of drug elimination. 
 
Time to maximal drug concentration (Tmax) 




The lowest concentration of a drug when multiple doses are administered; typically 








Maximum rate of drug metabolism, usually related to enzymatic saturation. Even if drug 
dosage is increased, the rate that the drug is metabolised cannot increase further and 
so drug accumulates. 
 
Zero order elimination 
When a constant amount of drug is eliminated per unit time (cf first order elimination). 




















1.1.1 Taxonomy, distribution and ecology 
 
Tuatara (Sphenodon punctatus) are the only extant members of the order 
Rhynchocephalia, a once widespread and moderately diverse group (Cree 2014). They 
are members of the superorder Lepidosauria, which includes modern lizards and snakes. 
The ancestors of tuatara probably diverged from snakes and lizards in the early Triassic, 
an estimated 240-250 million years ago (Evans and Jones 2010) (Figure 1.1). Sphenodon 
punctatus is currently the only recognised species of tuatara, although the Brothers 
Island subpopulation was briefly classified as a different species (S. guntheri) in the 
1990s on the basis of variation in blood proteins (Daugherty et al. 1990). Subsequent 
molecular studies have confirmed these animals all belong to the single species S. 
punctatus (Hay et al. 2010), and they are currently managed as a single species with 
distinct geographic variants. 
 
The name ‘tuatara’ is derived from the Maori language, where ‘tua’ means back or far 
side, and ‘tara’ means spike or spine. This is translated as ‘peaks on the back’, a 
reference to the tuatara’s spiny dorsal crest. The scientific name Sphenodon is derived 
from the Greek words for wedge (sphen) and tooth (odous), describing the wedge-
shaped acrodont teeth of tuatara. The species name punctatus refers to the large 
number of spots on the tuatara’s body. 
 
Tuatara superficially resemble terrestrial lizards but, as mentioned previously, belong to 
their own order. Size varies with location, with animals on larger islands consistently 
being bigger than their counterparts on smaller islands (Cree 2014). Males in the 
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northerly Poor Knights Islands have been found to weigh up to 1.1kg, with a snout-vent 
length of 311mm, while males on the cooler, southerly North Brothers Island reached 
655g and 256mm in snout-vent length in the same period (Cree 2014). Males are larger 
than females. The dorsal scales of tuatara are small, granular and usually an olive-brown 
colour, though green, orange and grey variants exist. The ventral scales are larger and 
pale grey coloured. The dorsal surface of the animal is covered in white-yellow spots, 
and there is a spiny crest that runs from head to tail, which is more prominent in males. 
Tuatara have acrodont dentition, with two parallel rows of teeth in the upper jaw 
interlocking with one row in the lower jaw. 
 
Figure 1.1 A diagram summarising recent views about the phylogenetic relationships of 
living amniotes. The branching indicates relative, not absolute, time scale. The 
placement of turtles is debated, with some recent molecular analyses suggesting a 






Prior to the arrival of Polynesians and rats, tuatara were widely distributed on both the 
North and South Islands of New Zealand. Today they are restricted to an estimated 32 
offshore islands and several mainland sanctuaries, totalling approximately 0.5% of their 
pre-human arrival distribution (Cree and Butler 1993). The majority of these islands are 
in northern New Zealand, with only five in the Cook Strait (between the North and South 
Islands) and no naturally occurring populations further south. Islands where tuatara are 
naturally present tend to be cliff-bound, temperate and largely or completely frost-free 
(Cree 2014). Mean annual temperatures on corresponding mainland latitudes range 
from 14.1-16.1oC in the north, and 12.1-14.0oC in Cook Strait (National Institute of Water 
and Atmospheric Research 2015). Larger islands are forested, but smaller islands may 
only have low, wind-shorn plants. Tuatara populations have survived in sheep pastures 
on Stephens Island (albeit at lower densities), including under dwellings and lighthouses 
(Newman 1986, Cree 2014). There are no tuatara on islands where Norway rats (Rattus 
norvegicus) or ship rats (Rattus rattus) have been introduced, though pacific rats (Rattus 
exulans) have co-existed with tuatara on nine islands prior to their eradication from all 
but one island (Cree 2014). Predation by pacific rats is thought to have played a large 
part in tuatara population declines (Worthy and Holdaway 1995, Towns et al. 2007). 
 
Tuatara are primarily nocturnal, but do emerge during the day to bask. Juvenile tuatara 
are diurnal for the first few months of life (Whitworth 2006). In forest environments 
tuatara show little activity in the morning, with a slight increase in the afternoon, and 
highest activity levels between 6pm and midnight (Gillingham and Miller 1991). 
Nocturnal emergence is highest when conditions are warm, calm and misty or raining, 
and appears to coincide with the time of highest density of invertebrate prey (Walls 
1983). Stephens Island tuatara are primarily insectivorous, eating mainly beetles with a 
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mix of other invertebrates. Other dietary items depend on the tuatara’s size, habitat and 
food availability, but include kawakawa (Macropiper excelsum) berries, frogs, skinks, 
geckos, fairy prion eggs and chicks, fluttering shearwater chicks, sparrows and even 
juvenile tuatara (Newman 1977, Walls 1981, Moore and Godfrey 2006, Bredwig and 
Nelson 2010).  
 
Figure 1.2 Distribution of free-living tuatara in 2011. Natural populations exist on 32 
islands (dark blue circles; the number of islands with tuatara in each major group is 
indicated). In addition, between 1995 and 2011 tuatara were translocated to seven 
islands and one large mainland sanctuary (light blue squares). Reproduced with 





1.1.2 Thermal physiology and metabolic rate 
 
Tuatara are nocturnal ectotherms, relying on environmental heat sources to raise their 
body temperature above that of their surroundings. Behaviours such as basking and 
burrowing are the most common methods of thermal regulation. Tuatara can raise their 
body temperatures by 9oC or more above the surrounding air temperature by basking, 
and at night may experience temperatures of 7oC or lower without adverse effects (Cree 
2014). Tuatara have a region of relative thermal independence between the 
temperatures of 12- 20oC, and within this temperature range metabolic rate does not 
increase in a linear fashion with temperature, and is lower than would otherwise be 
predicted (Cartland and Grimmond 1994). 
 
Wild tuatara have been observed to be nocturnally active when their body temperatures 
are between 5.5-20.5oC, but this can increase to 30oC when basking (Cree 2014). Cloacal 
temperature varies seasonally and by time of day, with temperatures found to average 
between 7.6-10.7oC in winter, and 11.5-23.9oC in summer in a wild population on 
Stephens Island (Cree et al. 1990). Recommended temperature ranges for captive 
animals range between 4-15oC in winter and 10-25oC in summer (Boardman and 
Blanchard 2006). Several studies have evaluated temperature preferences of captive 
tuatara placed in a thermal gradient, with mean selected temperatures of 20-22oC (Cree 
2014). In one study using juvenile tuatara, no significant differences were observed in 
the time it took animals to catch prey between 12 oC and 20oC, though it was significantly 
decreased at 5oC (Besson and Cree 2010). Gastrointestinal transit time was significantly 
slower at the lower temperatures, and results suggested there was no digestion of prey 
items at 5oC (Besson and Cree 2010). Studies on a wild population of tuatara on Stephens 
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Island report that gastric emptying time was 20-24 hours during summer, and up to 48 
hours in spring (Fraser 1993). No data on gastric emptying time in winter was available. 
 
Tuatara in cool conditions have been observed to survive for months without food, and 
studies of metabolic rates suggest that ectothermic reptiles’ energy demands may be 
one-thirtieth that of a similar sized endotherm on an annual basis (Werner and Whitaker 
1978). Metabolic rate in tuatara, as measured by oxygen consumption, varied 
depending on body mass, activity, and temperature, with juveniles having higher mass-
specific metabolic rates than adults (Cartland and Grimmond 1994). Tuatara are active 
at lower metabolic rates than many lizards that are not native to New Zealand, whose 
activity temperatures often range between 20 oC and 45oC (Thompson and Daugherty 
1998). Their metabolic rate at 13 oC is similar to that of lizards and some turtles at the 
same temperature, the difference being that tuatara are active at these temperatures, 
while many other reptiles are not (Cartland and Grimmond 1994, Thompson and 
Daugherty 1998).  
 
1.1.3 History of dermatitis in tuatara at Auckland Zoo 
 
Tuatara were first acquired by Auckland Zoo in 1922. A captive breeding program was 
subsequently initiated, with the first releases occurring in 1996, and animals were 
repatriated to offshore islands to bolster wild populations. After the first diagnosis of 
mycotic dermatitis caused by Paranannizziopsis australasiensis in 2010, tuatara releases 
from the zoo were halted to prevent transmission of this organism to wild populations. 
P. australasiensis dermatitis has not been found in any wild populations of tuatara or 




Dermatitis in tuatara at Auckland Zoo has been a regular presentation in captive animals. 
Lesions are typically minor and present as yellow-brown discolourations of individual or 
small groups of scales, commonly on the ventrum and flanks (Figure 1.3). These can 
progress to erosions and ulcerations in more severe cases (Figure 1.4). Historical medical 
records covering a 20 year period showed that 57% of tuatara at Auckland Zoo were 
diagnosed with dermatitis at least once during their time at the zoo, with a higher 
number of cases in winter than in summer (Jakob-Hoff 2014). In the period 2001-2009 
there were a total of 72 cases of dermatitis in tuatara, though it is unknown what 
proportion of these were actually caused by P. australasiensis. This gives an incidence 
rate of dermatitis of 0.27 cases per tuatara-year at risk for this nine-year period. 
 
Figure 1.3 Confirmed fungal skin lesions (arrowheads) on the ventrolateral gular region 




Figure 1.4  Brown discolouration typical of tuatara dermatitis cases, with progression 
to erosion and ulceration in some areas. 
 
 
Investigation of these conditions was often not undertaken due to the minor nature of 
the skin lesions, however when biopsies and cultures were performed, a range of 
bacteria and fungi, presumed to be commensals or secondary invaders, were isolated. 
It was not until 2010 that the causative fungus was isolated and identified from biopsy 
specimens via specialised culture methods, with the aid of collaborators at the 
University of Alberta Microfungus Collection and Herbarium in Canada. Since then, more 
cases have been diagnosed and treated successfully with antifungal medications. 
Diagnosis of P. australasiensis at Auckland Zoo is currently based on histopathological 
findings, macro-and microscopic appearance of fungi when cultured, and PCR and 




Prior to 2010, treatment of dermatitis in tuatara was largely empirical. The majority of 
cases resolved with topical and/or systemic treatment with a range of medications, 
commonly topical povidone-iodine with the addition of systemic enrofloxacin in more 
severe cases. These cases often required prolonged treatment, and relapses occurred. 
Since the diagnosis of primary fungal dermatitis caused by P. australasiensis, treatments 
have been more targeted with the use of itraconazole at 3-5 mg/kg PO SID for up to six 
weeks, with or without topical 1% terbinafine cream. Excisional biopsy has occasionally 
been curative in the absence of systemic treatment. 
 
1.2 Paranannizziopsis australasiensis and related infections 
 
Fungal dermatitis caused by P. australasiensis is now recognised as a newly emerging 
disease detected in tuatara (Sphenodon punctatus) at Auckland and Hamilton Zoos. P. 
australasiensis has also caused fatal dermatitis in a bearded dragon (Pogona barbata) 
at Auckland Zoo, and in several file snakes (Acrochordus sp.) at Melbourne Zoo (Sigler et 
al. 2013). Prior to speciation, P. australasiensis was known as the Chrysosporium 
anamorph of Nannizziopsis vriesii (CANV), of the family Onygenaceae and order 
Onygenales (Sigler et al. 2013). It is now known that there are many organisms from 
several genera that were previously classified under the CANV umbrella, and these 
organisms share many characteristics. This review examines characteristics of, and 
infections caused by, organisms previously known as CANV in reptiles. 
 
1.2.1 Molecular characteristics, host specificity and pathogenicity 
 
Members of the CANV complex are keratinophilic, ascomycetous fungi (Bowman et al. 
2007). Sigler et al. (2013) conducted genetic sequencing of fungal isolates that were part 
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of the CANV complex, and have reclassified them into three genera – Nannizziopsis, 
Paranannizzopsis, and Ophidiomyces, in the family Onygenales. This was based on DNA 
sequences from the internal transcribed spacer (ITS) and small subunit (SSU) regions of 
the nuclear ribosomal RNA (rRNA) gene (Sigler et al. 2013).  
 
Following sequencing, it was noted that each genus appears to display a level of host 
specificity (Sigler et al. 2013, Paré and Sigler 2016). Nannizziopsis species were isolated 
from lizards and crocodiles, but not snakes, while Ophidiomyces species were found only 
in snakes. Paranannizziopsis species showed less host specificity, and while members of 
this species have been isolated largely from highly aquatic snakes, P. australasiensis has 
been isolated from species as diverse as tuatara, bearded dragons, and file snakes (Sigler 
et al. 2013). 
 
Ophidiomyces ophiodiicola has been identified as the cause of disease in colubrids, 
elapids, boids, pythonids and acrochordids, and has been predominantly found in 
recently caught captive animals (Sigler et al. 2013). O. ophiodiicola has been identified 
as the cause of ‘snake fungal disease’ in wild crotalid snakes in Illinois, Virginia and New 
England (Allender et al. 2011, Sleeman 2013, Smith et al. 2013, Guthrie et al. 2016). O. 
ophiodiicola is currently the only described member of the genus Ophidiomyces. 
 
The number of cases of fungal dermatitis in reptiles caused by the CANV complex is high, 
compared to the number of cases reported to be caused by fungi that are commonly 
found on reptilian skin, such as Aspergillus and Penicillium species (Paré et al. 2006). 
 
Three studies have evaluated members of the CANV complex for their pathogenicity. 
Nannizziopsis dermatitidis was determined to be a primary pathogen in veiled 
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chameleons (Chamaeleo calyptratus), while Ophidiomyces ophiodiicola was 
experimentally determined to be the cause of snake fungal disease (SFD) in 
cottonmouths (Agkistrodon piscivorous) and corn snakes (Pantheropus guttatus) (Paré 
et al. 2006, Allender et al. 2015b, Lorch et al. 2015). All three studies concluded that 
while a breach in skin integrity increased the prevalence and severity of infection, it was 
not necessary for the development of disease. 
 
The study by Pare et al (2006) also evaluated environmental exposure to N. dermatitidis 
as a transmission route. A single unexposed control animal, and one exposed via a 
hanging gauze strip in the cage, developed N. dermatitidis infection. In this study, three 
cultures from cage top filters and one from a settle plate in the room also cultured N. 
dermatitidis, indicating the potential for aerosol spread and dissemination in the captive 
environment (Paré et al. 2006). It was considered that spread by this method was the 
likely cause of the case found in the unexposed control animal. The authors concluded 
that CANV complex infections are contagious, a view supported by other authors 
(Bowman et al. 2007), and can spread via indirect contact or fomites (Paré et al. 2006). 
This is consistent with a report of CANV (subsequently confirmed to be Ophidiomyces 
ophiodiicola) in brown tree snakes (Boiga irregularis), where four animals out of a group 
of 12 were affected, but there was no direct contact between several of the affected 
animals (Nichols et al. 1999). 
 
CANV complex organisms have not been commonly detected in humans. Human isolates 
tested by Sigler et al. (2013) were from the Nannizziopsis genus, and the majority were 
from HIV positive individuals. None of the species recovered from humans were 
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detected in reptiles, which may indicate there is little zoonotic risk associated with 




Little data has been compiled on the epidemiology of infections caused by the CANV 
complex, with the majority of information coming from case reports rather than a 
systematic review of a large number of cases. 
 
1.2.2.1 Prevalence 
The majority of cutaneous mycoses in squamates have been attributed to a wide variety 
of fungi of soil origin (Paré et al. 1997). Demonstrating a pathogenic role for these fungi 
is often difficult, as they are frequently isolated as contaminants (Paré et al. 1997, 
Nichols et al. 1999, Thomas et al. 2002).  
 
Infections caused by CANV complex organisms were not reported widely in the literature 
until very recently, however it has been postulated by several authors that infections 
are likely to be misdiagnosed or poorly recognised for a variety of reasons (Paré et al. 
1997, Nichols et al. 1999, Sigler et al. 2013). These include difficulty in culturing the 
organism, historical lack of availability of advanced molecular diagnostics, reluctance of 
many pet owners to pursue disease investigation, and the commonly-held belief that 
fungal infections in reptiles are secondary to underlying illness, injury or suboptimal 
husbandry (Abarca et al. 2008, Mitchell and Walden 2013). Bowman et al. (2007) suggest 
that CANV complex infections are common in pet bearded dragons, and have been 
colloquially known as ‘yellow fungus disease’. It has been suggested that CANV complex-
related infections may be more common than currently thought in crocodiles, but 
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cultures are often overgrown by environmental fungi such as Fusarium species and 
Purpureocillium lilacinum (Thomas et al. 2002, Sigler et al. 2013). 
 
Infections have been documented in squamates, tuatara and crocodilians, but not 
chelonians. The majority of cases in the literature have involved bearded dragons, 
however this may be due to the popularity of this species as a pet rather than a true 
species-specific susceptibility. More recently, infections involving wild snakes have 
become more widely reported, likely as more resources are directed to investigating this 
emerging fungal pathogen. 
 
Paré et al. (2003) solicited samples of shed squamate skin from zoological institutions 
and private veterinarians to determine if CANV organisms were part of the normal skin 
flora. All samples were from animals free of cutaneous lesions or other obvious disease 
and in good body condition. Samples were plated out and incubated at 28oC for five 
weeks, after which fungi were identified based on colony and microscopic 
characteristics. A total of 742 fungal isolates from 50 genera were obtained from 127 
reptiles, of which there was only a single isolate of a CANV complex fungus, giving a 
prevalence of 0.8%. This was from the shed of an African rock python (Python sebae) 
kept on newspaper substrate. The animal appeared healthy but failed to adapt to 
captivity, and subsequently died of malnutrition, with no evidence of fungal infection on 
post-mortem (Paré et al.2003). This was the first report of a CANV complex fungus 
isolated from an animal without visible cutaneous lesions, and was subsequently 
determined to be O. ophiodiicola (Sigler et al. 2013). With the development of more 
sensitive diagnostic methods, O. ophiodiicola has been detected in several 
asymptomatic corn snakes (Lorch et al. 2015) (Section 1.2.3.2). 
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Other findings of Paré et al.’s (2003) study included a discernible but weak trend for skin 
samples from the same institution to grow similar fungi, and it was thought that this 
may have been due to similarities in substrate and enclosure furniture. The authors 
further speculated that reptile fungal microflora is likely to reflect the fungal 
composition of their substrate. Although there has been very limited ecological and 
epidemiological data on CANV complex organisms published, several reports suggest 
the fungus is of environmental origin (Bowman et al. 2007, Thomas et al. 2002, Allender 
et al. 2011, Allender et al. 2015a). Sigler et al. (2013) report one strain of Nannizziopsis 
vriesii isolated from soil in California, however no published studies have further 
evaluated the source of infections.  
 
Paré et al. (2003) conclude that members of the CANV complex do not appear to be 
common constituents of normal healthy squamate cutaneous mycoflora. Samples for 
this study were submitted via mail, and other authors speculate it is possible that 
competition with other microflora, or temperature and humidity changes experienced 
during storage and transport, may have resulted in a lower detection rate of CANV 
complex organisms than would otherwise have occurred (Mitchell and Walden 2013). 
Culture is also a relatively insensitive diagnostic method for asymptomatic CANV 
infections. A later study on the pathogenicity of CANV in veiled chameleons revealed 
that the CANV (later speciated as N. dermatitidis) was isolated only twice from shed skin 
during the study, despite 14 animals being affected (Paré et al. 2006, Sigler et al. 2013). 
It is not clear in this study how many samples of shed skin were collected, and how many 




A study by White et al. (2010) evaluated the prevalence of CANV complex infections in 
reptiles with dermatological lesions. Lesions from 301 reptiles, from two institutions 
over a period of 16 years were reviewed. Of these lesions, four were suspected to be 
CANV complex infections, but only one was confirmed. The confirmed case was in a 
bearded dragon, and was diagnosed via histopathology, culture and PCR. This animal’s 
cage mate was diagnosed circumstantially. In the same study, another bearded dragon 
was diagnosed based on histopathology but cultured a Trichophyton species, and an 
Oustallet’s chameleon (Furcifer oustaleti) was diagnosed based on histopathology, but 
did not culture a CANV complex organism (White et al. 2010). None of the 82 snakes or 
36 chelonians in this review had CANV complex infections. The overall prevalence of 
CANV complex infections in this study was 1.3% for all animals, but increased to 4.5% 
for lizards. 
 
Ophidiomyces ophiodiicola has recently been found in wild populations of wild 
massasauga rattlesnakes (Sistrurus catenatus) (Allender et al. 2011). Disease was initially 
detected as part of an ongoing monitoring program in its ninth year. Prevalence in 
surveyed snakes from 2000-2007 was 0%, in 2008 was 4.4% (95% CI 1.1-13.2), and in 
2010 was 1.8% (95% CI 0-11.1%). A study conducted in Virginia reported a prevalence of 
26.7% of O. ophiodiicola in the 30 wild snakes captured for the study, however study 
sites were selected based on anecdotal reports of SFD-like lesions, and random 
representative sampling was not conducted (Guthrie et al. 2016). 
 
1.2.2.2 Risk factors 
Although both N. dermatitidis and O. ophiodiicola have been established as primary 
pathogens in veiled chameleons and snakes respectively (Paré et al. 2006, Allender et 
51 
 
al. 2015b, Lorch et al. 2015), these studies indicated that while a breach in skin integrity 
is not necessary for infection, it is associated with more severe disease.. Similar findings 
were made in a study of experimental Ophidiomyces ophiodiicola infection in corn 
snakes (Pantherophis guttatus), where lesions were detected more frequently in sites 
subject to abrasion (Lorch et al. 2015). It has not been experimentally determined 
whether all other CANV complex organisms are primary pathogens. Several authors 
suggest that pre-existing lesions or wounds may lead to subsequent infection by 
members of the CANV complex (Allender et al. 2011, Johnson et al. 2011). 
 
It has been proposed that suboptimal husbandry may contribute to the development or 
severity of infection with CANV complex organisms (Thomas et al. 2002, Bertelsen et al. 
2005, Johnson et al. 2011, Toplon et al. 2012). In particular, fungal infections are 
reported to be triggered by suboptimal temperatures (Fromtling et al. 1979), and in 
multiple cases a sudden decrease in environmental temperature was reported prior to 
infection becoming apparent (Thomas et al. 2002, Johnson et al. 2011). In an outbreak 
involving four of a group of 12 brown tree snakes, it was proposed that warm, humid 
conditions and access to water may have softened the ventral scales of the animals, 
making them less resistant to infection (Nichols et al. 1999), and unusually high rainfall 
was suggested as a contributing factor in an outbreak involving timber rattlesnakes 
(Clark et al. 2011). Cases have also been recorded when the animals appeared to be in 
good body condition, with adequate husbandry and no evidence of underlying disease 
or stressors (Bowman et al. 2007, Hellebuyck et al. 2010). 
 
Several authors have suggested that stress may be a contributing factor in acquiring 
CANV complex infections (Thomas et al. 2002, Bertelsen et al. 2005, Toplon et al. 2012). 
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In a case involving four tentacled snakes, the pH of the water was more alkaline than 
recommended for this species, and the authors speculate this may have predisposed 
them to infection (Bertelsen et al. 2005). Overcrowding may also cause stress and 
contribute to enhanced disease transmission via direct contact (Thomas et al. 2002, 
Toplon et al. 2012). In a commercial breeding colony of leopard geckos, it was noted 
that colour morphs were initially affected, and it has been suggested that these animals 
may have a less competent immune system than wild-type geckos, predisposing them 
to infection (Toplon et al. 2012). Several outbreaks were noted to involve recently 
caught wild animals (Thomas et al. 2002, Toplon et al. 2012). In these cases it is unknown 
whether infection was present subclinically when the animals were captured (and the 
stress of capture and transport may have increased susceptibility to disease), or if 
infection was acquired in captivity. One author suggested an asymptomatic carrier state 
may exist in bearded dragons, however no research has been done to support this 
hypothesis (Bowman et al. 2007). 
 
Cases in the same institution have occurred without direct contact with a clinically 
affected animal (Nichols et al. 1999, Thomas et al. 2002). While there were several 
outbreaks in which all in-contact animals were affected (Bertelsen et al. 2005, Hedley et 
al. 2010, Hellebuyck et al. 2010, Van Waeyenberghe 2010), in other cases in-contact 
animals were considered to be free of infection (Bowman et al. 2007, Johnson et al. 
2011).  
 
1.2.2.3 Fungal source 
The source of fungi in CANV complex infections is unknown, but several authors propose 
an environmental origin (Thomas et al. 2002, Bowman et al. 2007, Allender et al. 2011). 
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This is supported by the occurrence of infection in wild massasauga rattlesnakes in 
different locations from two discontiguous sites, occurring in different years (Allender 
et al. 2011), and by multiple snake species being affected in a single site in Virginia 
(Guthrie et al. 2016). One isolate of Nannizziopsis vriesii has been detected in soil in 
California (Sigler et al. 2013), however there are no reports of further investigation of 
fungal origin in the literature. Transmission of infection is suggested to occur by direct 
contact with affected animals, contaminated substrate or fomites, and by airborne 
dissemination (Nichols et al. 1999, Paré et al. 2006, Allender et al. 2011). A study by 
Allender et al. (2015a) concludes that O. ophiodiicola is likely to occur as an 
environmental saprobe (see below), and that it infects snakes opportunistically. While 
this study appears robust and the conclusions sound, care must be taken in 
extrapolating findings from one fungal species to another. 
 
Fungal ecology 
Very few published studies have been conducted to describe the ecology of CANV 
infections. The only in-depth study was conducted on O. ophiodiicola, under laboratory 
conditions (Allender et al. 2015a). In vitro, O. ophiodiicola demonstrated robust growth 
on a variety of dead materials and possessed a broad complement of enzymes allowing 
it to saprophytically utilise multiple complex carbon and nitrogen sources. Sparse fungal 
growth occurred on demineralised-deproteinated shrimp exoskeletons, leading to the 
conclusion that a protein source is necessary for prolific fungal growth. The fungus grew 
optimally when incubated at 25oC, with significant growth reduction at 14oC and 35oC, 
and complete growth inhibition at 7oC. Laboratory experiments demonstrated O. 
ophiodiicola’s ability to tolerate pH variation and most naturally occurring sulphur 
compounds, and to tolerate low matric potentials (water stress) occurring in soil 
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(Allender et al. 2015a). The data also suggest that the environmental presence of 
ammonium may be beneficial for the growth of O.ophiodiicola, suggesting that 
incomplete removal of animal waste products, primarily urine and urates, may 




Diagnosis of CANV complex infection often relies on a degree of clinical suspicion on 
behalf of the veterinarian. If a fungal culture and/or PCR is not performed, the cause of 
disease cannot be confirmed. Even when fungal cultures are obtained, in the absence of 
PCR they are often misdiagnosed as other fungal species, and this is discussed further 
below. 
 
1.2.3.1 Clinical signs and causative organisms 
Infections caused by CANV complex organisms are often aggressive and rapidly 
progressing, in contrast to those in tuatara which are not as severe (Masters et al. 2016). 
Lesions are characterised by hyperkeratosis, necrosis, vesicles, ulcers, and crusting, and 
often progress to fatal systemic disease (Sigler et al. 2013). Infections are contagious, 
and typically affect multiple animals housed in the same environment (Sigler et al. 2013). 
 
Symptoms of infection vary between species affected, fungus involved, and outbreak 
conditions. The causative fungi of several of the cases in this literature review have 
undergone speciation via DNA analysis by Sigler et al. (2013) since the original articles 
were first published, and this information is included where available. Clinical signs have 






Clinical signs of CANV complex infection in lizards range from focal skin thickening and 
retention of squames, to vesicular lesions, black skin discolouration, ulcerative 
dermatitis, focal swelling and bone necrosis (Paré et al. 1997, Martel et al. 2006, Abarca 
et al. 2008, Johnson et al. 2011). The majority of reported lesions have consisted of an 
ulcerative dermatitis, with varying degrees of crusting, swelling and necrosis. Lesion 
appearance, anatomical location and causative organism (where known) are detailed in 
Table 1.1. 
 
A literature review of infections in lizards shows that almost all lesions in these animals 
have been rapidly progressive, and have been noted to spread to distant anatomical 
sites as well as locally (Paré et al. 1997, Bowman et al. 2007, Johnson et al. 2011). 
Infection in lizards in the cases where fungal species information was available were all 
caused by members of the Nannizziopsis genus, except for one case in a coastal bearded 
dragon (Pogona barbata) caused by P. australasiensis (Sigler et al. 2013).  
 
Lesions in lizards are typically located on the limbs, ventrum or rostral head area. This 
may be because these areas are more frequently in contact with the substrate, and 
several authors speculate that CANV organisms originate from an environmental source 
(Thomas et al. 2002, Allender et al. 2011). It is possible that these anatomical locations 
are more prone to abrasion, facilitating entry of the fungus into the skin, or that the 
more humid microenvironment typically experienced on skin in closer contact with 






Lesions in snakes are primarily found on the head and ventral scales, although they can 
occur over the entire body. Infection tends to be rapidly progressive, and is variably 
characterised by subcutaneous swelling, crusting, retained shed, vesicles and plaque-
like lesions (Nichols et al. 1999, Eatwell 2010, McLelland et al. 2010, Allender et al. 2011, 
Sigler et al. 2013). Fungi can invade muscle and bone, and cases of pneumonia, ocular 
infection and systemic fungal dissemination attributed to O. ophiodiicola have been 
documented in colubrids in the USA (Rajeev et al. 2009, Sleeman 2013, Dolinski et al. 
2014). The nasolabial pits are a common site of infection in crotalid snakes, and have 
been proposed as a possible entrance site for systemic infection (Allender et al. 2015b). 
 
Infection in terrestrial snakes appears to be universally associated with Ophidiomyces 
ophiodiicola. This has previously been referred to as CANV or, in some cases, as various 
Chrysosporium species, prior to more accurate speciation through DNA analysis (Sigler 
et al. 2013). A recent paper by Pare and Sigler (2016) details historical infections caused 
by O. ophiodiicola in at least 25 snake species in three continents. Paranannizziopsis 
species have been associated with fatal dermatitis in aquatic snakes, and details of these 
infections are provided in Table 1.1 (Bertelsen et al. 2005, Sigler et al. 2013). 
 
Crocodiles 
Only one article has detailed CANV complex infection in saltwater crocodile hatchlings 
(Crocodylus porosus), and this covered multiple outbreaks in animals at the same facility 
(Thomas et al. 2002). Several affected animals initially had white flaky areas on the 
underside of the body and caudal thighs. After one month, these animals were found to 
have creamy, caseous masses on, and occasionally under, scales on the head, back and 
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feet. Different animals subsequently developed plaque-like lesions, however more 
details on the appearance and location of these lesions was not reported. A second 
outbreak at the same facility three years later was also characterised by plaque-like 
lesions (Thomas et al. 2002). Infection was caused by Nannizziopsis crocodili (Sigler et al. 
2013). 
 
Although multiple animals were affected in these outbreaks, this is the only report of 
CANV complex infections involving crocodiles, so care must be taken when interpreting 
these lesions as being representative of CANV complex infections in this species. 
 
Tuatara 
Lesions in tuatara (Sphenodon punctatus) have been more subtle and less progressive 
than in other species (Masters et al. 2016). The most common presentation is as 1-5mm 
diameter raised, nodular, yellow, crusting dermatitis, usually without ulceration. Lesions 
have been located on the gular region, ventrum, and ventrolateral tailbase. The 
causative organism has been diagnosed as Paranannizziopsis australasiensis (Sigler et al. 
2013).  
 
These lesions have now been diagnosed at multiple institutions in both the north and 
south islands of New Zealand (unpublished data), however it is possible that other 
presentations of disease may occur, or fungi may not be recognised or correctly 
diagnosed as members of the CANV complex. 
 
Other clinical signs 
Several authors have reported lethargy, anorexia and weight loss in animals infected by 
CANV complex organisms. Animals noted with these clinical signs include bearded 
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dragons and girdled lizards (Edgerton and Griffin 2009, Hellebuyck et al. 2010, Johnson 
et al. 2011, Masters et al. 2016), however it is possible more animals exhibited these 
symptoms and went unreported. 
 
Haematological changes 
Several affected animals had haematological changes noted. The most common 
haematologic abnormality reported was a leucocytosis, often due to a lymphocytosis 
(Paré et al. 1997, Bowman et al. 2007, Hellebuyck et al. 2010, Masters et al. 2016). Other 
less common abnormal findings included monocytosis, azurophilia, and basophilia 
(Bowman et al. 2007, Hellebuyck et al. 2010, Masters et al. 2016). The majority of cases 
in this review did not have haematology results reported.  
 
Isolation of the fungus from lesions via culture, and histopathological evidence of fungal 
invasion of the tissues, have been used as criteria to establish a member of the CANV 
complex as the causative agent of fungal dermatitis in some affected animals (Paré et 
al. 1997, Nichols et al. 1999, Bowman et al. 2007, Abarca et al. 2008, Hedley et al. 2010, 
Hellebuyck et al. 2010, Toplon et al. 2012). This has also been used to rule out a role for 
other fungi cultured from the same lesions, when the histologic appearance has not 





Table 1.1 Clinical signs, lesion location and causative organism in reviewed CANV cases. 
Species affected Lesion description Lesion location Causative organism Citation 
Parson’s chameleon 
(Calumma parsonii) 
Grey vesicular lesions containing clear fluid. 
Small brown crusted lesions. 
Left stifle and right elbow, progressing to all 
limbs, flanks and tail 
Nannizziopsis 
dermatitidis 
Paré et al. 1997 
Jewelled chameleon 
(Furcifer campani) 
Localised areas of black discolouration with 
white exfoliative squames 




Paré et al. 1997 
Jackson’s chameleon 
(Chamaeleo jacksonii) 
2cm scab Adjacent to left tailbase, progressing to ventral 
tailbase and causing hemipenal prolapse 
Nannizziopsis 
dermatitidis 
Paré et al. 1997 
Green iguana 
(Iguana iguana) 
Focal thickening of skin with retention of 
squames 
Distal aspect of left tarsus Nannizziopsis guarroi Abarca et al. 2008 
Green iguana 
(Iguana iguana) 
Deep, severe, crusting ulcerative dermatitis Dorsal anterior right thigh, extending from 
proximal thigh to mid tibia 
Nannizziopsis guarroi Abarca et al. 2008 
Bearded dragon (Pogona 
barbata) 
Swelling and ulceration, gingival recession and 
facial oedema 
Digit on left hindlimb, progressing to jaw and 
facial lesions 
Not speciated Johnson et al. 2011 
Bearded dragon (Pogona 
barbata) 
Superficial, crusty cheilitis, nodular lesions  Lip, progressing to rostral mandible with bony 
involvement and non-union fracture of 
mandibular symphysis 
Not speciated Johnson et al. 2011 
Bearded dragon (Pogona 
barbata) 
Deep, necrotic dermatitis with gingival 
recession 
Rostral mandible, progressing to right tarsus, 
left carpus, digits and cloaca 
Not speciated Johnson et al. 2011 
Bearded dragon (Pogona 
barbata) 
Deep, necrotic dermatitis Right rostral mandible, plantar aspect of D3 on 
the right hindleg and stump of previously 
amputated left forelimb 
Not speciated Johnson et al. 2011 
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Bearded dragon (Pogona 
barbata) 
Raised, nodular yellow lesions Beard, chin, ventral abdomen, right tarsus Paranannizziopsis 
australasiensis 
Masters et al. 2016 
Bearded dragon (Pogona 
barbata) 
Crusty dermatitis Left mandible Nannizziopsis 
barbata 
Johnson et al. 2011 
Bearded dragon (Pogona 
vitticeps) 
Yellow-black thickened skin, osteolysis Right side of beard, progressing to face and 
encircling tail 
Not speciated Edgerton and Griffin 
2009 
Bearded dragons (Pogona 
vitticeps) 
Undescribed dermatitis Head, hindlimbs and ventrum Nannizziopsis vriesii Van Waeyenberghe 
et al. 2010 
Bearded dragon (Pogona 
vitticeps) 
Crusting and periocular swelling, yellow 
discolouration and necrosis 
Periocular area, inguinal region Not speciated Hedley et al. 2010 
Bearded dragon (Pogona 
vitticeps) 
10mm subcutaneous mass Right flank Not speciated Hedley et al. 2010 
Bearded dragon  
(Pogona vitticeps) 
Focal swelling with raised, crusty skin lesion 
and painful maxillary gingival swelling 
Ventral to right eye, including maxillary gingiva Nannizziopsis guarroi Bowman et al. 2007 
Bearded dragon  
(Pogona vitticeps) 
Discoloured, necrotic skin Left caudoventral abdomen, extending to 
perineum and tailbase 
Nannizziopsis guarroi Bowman et al. 2007 
Bearded dragon  
(Pogona vitticeps) 
Marked swelling with thickened and creviced 
skin with serosanguinous exudate. Non-weight-
bearing. Osteolysis. 
Right forelimb, distal to elbow. Osteolysis of 
distal radius, ulna and carpus 
Nannizziopsis guarroi Bowman et al. 2007 
Leopard geckos 
(Eublepharis macularius) 
Punctate to 4mm diameter slightly raised, 
frequently dark red ulcerated nodules. 
Retained shed 
Ventral skin Nannizziopsis 
dermatitidis 
Toplon et al. 2012 
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Girdled lizards  
(Cordylus giganteus) 
Severe ulcerative dermatitis with localised loss 
of scales, eyelids adhered together with 
exudate 
Periocular region, side of face Nannizziopsis vriesii Hellebuyck et al. 
2010 
Ameiva lizard  
(Ameiva chaitzami) 
1.5 x 1cm2 hard, smooth, non-ulcerated mass 
covered by intact skin. Concurrent metabolic 
bone disease 
Left half of the skull, originated from nasal 
cavity or skull 




Crust with retained shed, progressing to severe 
ulceration 
Adjacent to cloaca, progressing to tail tip Ophidiomyces 
ophiodiicola 
McLelland et al. 
2010 
Tentacled snakes (Erpeton 
tentaculatum) 
Small, pale yellow-white dermal lesions. 
Improved every 14 days after each shed, then 
recurred 
Head and dorsum, tips of, or entire, scales Paranannizziopsis 
crustacea AND  
P. californiensis 
Bertelsen et al. 2005 
Brown tree snakes (Boiga 
irregularis) 
Erythema and oedema of scales, vesicles 
containing clear to cloudy serous fluid, 
rupturing to form raised, brown caseous 
plaques. Underlying skin haemorrhagic, dry and 
necrotic. White granular to powdery material 
between scales. 
Ventral scales, beginning where scales 




Nichols et al. 1999 
African rock python 
(Python sebae) 
None Normal shed Ophidiomyces 
ophiodiicola 
Paré et al. 2003 
Aquatic file snakes 
(Acrochordus sp.) 
Multifocal necrotising skin lesions Not reported Paranannizziopsis 
australasiensis 





Severe unilateral subcutaneous swelling, 
ulceration and crusting, deforming normal 
anatomy 
Head, obstructing nasolabial pits and 




Allender et al. 2011 
Boa constrictor 
(Constrictor constrictor) 
Necrotic dermatitis Mandible, maxilla, dorsal spine Not speciated Eatwell 2010 
Garter snake 
(Thamnophis sp.) 
1.3 x 2cm grayish-white cutaneous nodule. 
Swollen hemipenis with necrotic foci 
Ventrum, cranial to cloaca Ophidiomyces 
ophiodiicola 




Yellow to brown crusted skin lesions 1 to >7mm 
diameter 
Primarily head, also lateral and ventral body Ophidiomycies 
ophiodiicola 
McBride et al. 2015 
Saltwater crocodiles 
(Crocodylus porosus) 
White, flaky skin, progressing to creamy, 
caseous masses on and under scales, and 
leathery plaque-like lesions 
Underside of body, caudal thighs, snout, head, 
back, feet, underside of jaw and tail 
Nannizziopsis 
crocodilii 
Thomas et al. 2002 
Tuatara (Sphenodon 
punctatus) 
Small areas of raised, yellow, crusting 
dermatitis 








Several authors use a combination of histopathology, fungal culture and PCR to identify 
the causative organism (Abarca et al. 2008, Hellebuyck et al. 2010, Van Waeyenberghe 
et al. 2010, Toplon et al. 2012, Masters et al. 2016). PCR testing is usually done on 
cultured fungus, but has also been applied to DNA extracted directly from tissue 
(Allender et al. 2011). Using PCR has the added benefit of diagnosing the fungus to 
species level, as they cannot be reliably identified based on microbiological 
characteristics alone (Sigler et al. 2013, Paré and Sigler 2016). Without PCR, some cases 
may be provisionally identified to species level based on case signalment, for example, 
the only CANV complex organism reported to have infected terrestrial snakes has been 
Ophidiomyces ophiodiicola (Sigler et al. 2013). Recently, real-time PCR (qPCR) has been 
used to identify O. ophiodiicola from lesion swabs of infected snakes, and this appears 
to be more sensitive than conventional PCR (Allender et al. 2015c). 
 
Skin scrapings in affected tentacled snakes revealed bacteria and keratinocytes but no 
fungi (Bertelsen et al. 2005), so this method may not be suitable for ascertaining the 
presence of a fungal infection. A potassium hydroxide preparation of hyperplastic skin 
in a green iguana showed fungal hyphae (Abarca et al. 2008), however this does not 
prove that fungi are the primary cause of the dermatitis. These methods, if positive, may 
increase clinical suspicion of a fungal aetiology, but if negative, do not exclude mycosis. 
Several authors suggest that histopathological findings, in combination with clinical 
presentation, can be used to diagnose infections caused by the CANV complex (Eatwell 
2010, Hedley et al. 2010). In contrast to this, other authors emphasise the importance 
of obtaining good biopsy specimens for both histopathology and culture to confirm 
diagnosis (Bertelsen et al. 2005, Abarca et al. 2008). Identification of the fungus to 
species level may be important in investigating the epidemiology of the disease (Sigler 
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et al. 2013, Paré and Sigler 2016). Using a laboratory familiar with reptile mycoses for 
fungal identification may reduce the risk of mis-identification, and is recommended by 
several authors (Hedley et al. 2010, Toplon et al. 2012, Sigler et al. 2013). If this is not 
available, it is suggested that samples be retained for further specialist identification 
(Johnson et al. 2011, Paré and Sigler 2016). 
 
Diagnosis of P. australasiensis at Auckland Zoo is currently based on a combination of 
histopathological findings, culture and PCR of culture products from full thickness skin 
biopsies, and, more recently, from partially shed scales removed with forceps.  
 
1.2.3.2 Culture and microbiological characteristics 
CANV complex organisms can be isolated by routine fungal culture, but are often 
misdiagnosed as other fungal infections. CANV complex organisms have been 
misdiagnosed as several Trichophyton species, Trichosporon, Geotrichum, or geophilic 
and keratinophilic Chrysosporium or Malbranchea species (Paré et al. 1997, Nichols et 
al. 1999, Thomas et al. 2002, Bowman et al. 2007, Abarca et al. 2008, Hedley et al. 2010, 
White et al. 2010, Johnson et al. 2011). The sessile conidia of N. vriesii appear very 
similar to microconidia of various Trichophyton species, and this may explain the 
common mislabelling of CANV complex isolates as Trichophyton spp. (Paré et al. 1997).  
 
Bacteria have also been seen on histopathology in cases caused by members of the 
CANV complex (Thomas et al. 2002, Bertelsen et al. 2005, Paré et al. 2006), and in the 
absence of a fungal culture, bacteria may be implicated as the cause of the lesions. 
Bacterial contamination and growth has occurred on several cultures in cases of CANV 
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complex infection (Thomas et al. 2002, Edgerton and Griffin 2009, Hedley et al. 2010, 
Johnson et al. 2011).  
 
In an infection challenge conducted by Paré et al. (2006) in veiled chameleons, the 
fungus was cultured from frozen skin samples in only five out of 14 histopathologically 
suspicious infections. It is possible that sample handling in other cases may have 
affected the sensitivity of fungal culture, further leading to infection being under-
reported (Mitchell and Walden 2013). Cultures in these reviewed cases have largely 
been obtained from skin biopsies or post-mortem tissue, however one source reports 
successful culture from swabbing the skin of an affected girdled lizard (Hellebuyck et al. 
2010). By this method, organisms were demonstrated for seven weeks after treatment 
started. Follow-up swabs at weekly intervals have been recommended, to monitor for 
the presence of fungi (Van Waeyenberghe et al. 2010). TaqMan real-time PCR appears 
to be a more sensitive tool than culture for detection of O. ophiodiicola (Bohuski et al. 
2015). This was not the case when conventional PCR was compared to culture for 
detection of P. australasiensis, possibly due to limitations of the DNA extraction method 
or the small tissue sample size available for analysis (Humphrey et al. 2016). 
 
Culture has been successful on potato dextrose agar (PDA), phytone yeast extract, 
Mycosel agar, and Sabouraud dextrose agar (Paré et al. 1997, Thomas et al. 2002, 
Bertelsen et al. 2005, Abarca et al. 2008, Hellebuyck et al. 2010, Van Waeyenberghe et 
al. 2010, Sigler et al. 2013), however growth at different temperatures has varied 
(Abarca et al. 2008, Sigler et al. 2013). Several CANV complex isolates have not grown 
well at 35oC, and this was the case with P. australasiensis, which did not grow at all at 
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this temperature (Sigler et al. 2013). P. australasiensis has been grown successfully at 
both 25 oC and 30 oC (Alexander et al. 2014).  
 
It is important to recognise that a negative culture does not necessarily rule out 
infection. In one case, growth was unsuccessful on MacConkey agar, but samples from 
the same lesions have grown on Sabouraud dextrose agar (Abarca et al. 2008). Frozen 
thawed skin samples from affected massasauga rattlesnakes did not grow any fungi on 
Sabouraud agar, however PCR on DNA extracted from these tissues identified C. 
ophiodiicola (now known as O. ophiodiicola) (Allender et al. 2011).  
 
Fungal cultures can also grow contaminant fungi such as Aspergillus species (Edgerton 
and Griffin 2009), and without strong clinical suspicion of CANV complex infection, other 
fungi may be identified as the primary cause of disease. Toplon et al. (2012) recommend 
using selective media that includes cycloheximide and antibacterial antibiotics to 
improve the likelihood of culturing CANV complex organisms. 
 
In a study by Sigler et al. (2013), the CANV complex organisms shared several growth 
characteristics. All were moderately fast growing on potato dextrose agar (PDA) at 30oC. 
They had yellowish-white, velvety to powdery, dense, and sometimes zonate, colonies 
with uncoloured to yellowish reverse. All were cycloheximide tolerant, and perforated 
hairs. All produced aleuroconidia, and these resembled aleuroconidia also observed in 
some Chrysosporium and Trichophyton species (Sigler et al. 2013). This may be the cause 
of the misidentification of several CANV specimens as Chrysosporium and Trichophyton 
fungi (Sigler et al. 2013). All reptile isolates tested by Sigler et al. (2013) had urease 
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activity, hydrolysed milk solids, and had undulate hyphal branches. The majority of 
isolates were also observed to produce a skunk-like odour. 
 
Importantly, it is noted that morphological and growth characteristics are insufficient to 
differentiate between and within genera, and that DNA sequencing was required to 
confirm fungal species (Sigler et al. 2013, Allender et al. 2015a). Almost all CANV 
complex species produce arthroconidia in culture as well as in infected cutaneous 
tissues, and these are considered to be the primary mode of transmission of infections 
between reptiles (Sigler et al. 2013). 
 
Several isolates have been noted to produce aleuroconidia when cultured, and these 
have been found to be pyriform (tear-drop shaped) or clavate (club-shaped), usually 
single- but occasionally two-celled. They are borne sessile (formed directly on sides of 
hyphae, not on stalks) or at the end of branched, fertile hyphae (Paré et al. 1997, Nichols 
et al. 1999, Abarca et al. 2008). 
 
1.2.3.3 Histopathological findings 
Post-mortems were not conducted in all animals that died or were euthanased, however 
histological findings of both biopsies and post-mortems are similar between species. 
 
The majority of animals that underwent post mortem exhibited localised tissue 
destruction and fungal invasion, though there were three confirmed cases of systemic 
disease in two bearded dragons and a jewelled chameleon (Paré et al. 1997, Bowman et 
al. 2007, Johnson et al. 2011). One bearded dragon had a hepatic granuloma with 
intralesional hyphae (Bowman et al. 2007), while another had both granulomatous 
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hepatitis and myocarditis with intralesional fungal elements (Johnson et al. 2011). A 
jewelled chameleon had a granulomatous mass involving the caudal lung, kidney and 
coelomic cavity wall, with intralesional hyphae (Paré et al. 1997). It is unknown whether 
the lesions in the jewelled chameleon were a result of systemic spread, or inhalation of 
fungal spores. 
 
Cutaneous lesions are often characterised by epidermal hyperplasia or necrosis, with 
heterophilic or granulomatous inflammation (Nichols et al. 1999, Bertelsen et al. 2005, 
Paré et al. 2006, Bowman et al. 2007, Hedley et al. 2010, Hellebuyck et al. 2010, Allender 
et al. 2011, Johnson et al. 2011, Toplon et al. 2012). Lesions frequently penetrated the 
epidermis and dermis, with occasional involvement of deeper tissues including skeletal 
muscle and bone (Paré et al. 1997, Nichols et al. 1999, Paré et al. 2006, Allender et al. 
2011, Bowman et al. 2011). It is proposed that fungal proliferation in the dermis and 
deeper tissues may lead to dissemination of fungi and systemic infection (Paré et al. 
2006). Histopathology is an important component of disease investigation, as it 
distinguishes disease from mere presence of the fungal pathogen, as CANV complex 
organisms can occasionally be detected in asymptomatic animals (Paré et al. 2003, 
Bohuski et al. 2015). 
 
Animals in the N. dermatitidis experimental challenge involving veiled chameleons were 
euthanased sequentially to observe the gross and histological stages of infection (Paré 
et al. 2006). Animals that were euthanased earlier in the study had less severe lesions 
than those that completed the 42-day study. Fungal hyphae initially proliferated in the 
superficial layers of keratin, then penetrated downwards through the epidermis, dermis 
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and into skeletal muscle as infection progressed (Paré et al. 2006). It was noted that the 
animals with the most severe lesions were from the group of animals with scarified skin.  
 
Fungal hyphae have been observed both in granulomas and in the surrounding tissue, 
and are described as parallel-walled, branching and septate, with a diameter between 2 
and 6µm (Nichols et al. 1999, Thomas et al. 2002, Bertelsen et al. 2005, Bowman et al. 
2007, Hellebuyck et al. 2010, Paré et al. 2006, Toplon et al. 2012, Masters et al. 2016). 
Hyphae were usually numerous and visible on standard haematoxylin and eosin (H&E) 
staining, and in most reviewed cases Periodic Acid Schiff (PAS) or methenamine silver 
staining were used to better visualise fungal elements. Arthroconidia were observed 
histopathologically in several cases, indicative of active fungal proliferation (Nichols et 
al. 1999, Thomas et al. 2002, Paré et al. 2006, Toplon et al. 2012). These conidia were 
occasionally observed on the surface of lesions, providing a potential means of fungal 
transmission to in-contact animals. In lesions observed in brown tree snakes, 
arthroconidia were correlated with white, powdery areas that were seen grossly 
between the ventral scales (Nichols et al. 1999). 
 
1.2.4 Susceptibility testing 
 
Several papers have reported results of susceptibility testing for CANV complex 
organisms. Hellebuyck et al. (2010) reported low Minimum Inhibitory Concentrations 
(MICs) for itraconazole (0.5 mg/L), voriconazole (0.25 mg/L), amphotericin B (1 mg/L) 
and terbinafine (0.5 mg/L) against an isolate of Nannizziopsis vriesii using the broth 
microdilution method. Another study, using different testing methods, reported broad 
zones of inhibition around itraconazole, ketoconazole and terbinafine for an unspecified 
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CANV complex organism (Abarca et al. 2008). A recent study reported terbinafine MICs 
of 0.015 mg/L against two isolates of Ophidiomyces ophiodiicola, with an unspecified 
MIC testing method (Kane et al. 2017).   
 
A study involving 32 isolates of members of the CANV complex, of which three were 
from green iguanas, one from a giant girdled lizard, and 28 from bearded dragons, 
reported predominantly low MICs of itraconazole and voriconazole (Van Waeyenberghe 
et al. 2010) using the broth microdilution method. The MIC50, where 50% of isolates 
were inhibited, was 0.0313 mg/L for both itraconazole and voriconazole, while the MIC90 
was 0.25 mg/L for itraconazole, and 0.0625 mg/LL for voriconazole. One isolate in this 
study showed acquired resistance to itraconazole (Van Waeyenberghe et al. 2010). 
 
Three cases of infection with members of the CANV complex have used miconazole or 
clotrimazole topically (Bowman et al. 2007, Hellebuyck et al. 2010, Hedley et al. 2012), 
and another used a topical formulation containing nystatin, however there have been 
no susceptibility studies published for these drugs and CANV complex organisms.  
 
1.2.5 Treatment and outcome 
 
Treatment of CANV complex infections is often unsuccessful, as disease can progress 
rapidly and be slow to respond to therapy. Frequently there is a delay between 
observing clinical signs and initiating appropriate treatment, and this can be due to a 
low clinical suspicion of fungal disease, or inability to grow the organism from biopsy. 
Several cases in the literature were treated with antibiotics rather than antifungal 
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agents, and definitive diagnosis was obtained post-mortem (Nicholson et al. 1999, 
Bertelsen et al. 2005, Johnson et al. 2011). 
 
In this review, itraconazole was found to be the most commonly used systemic 
antifungal for treatment of infections caused by members of the CANV complex. The 
majority of animals treated with this drug were lizards, and dose rates ranged from 2.5 
to 10 mg/kg given orally once daily (Paré et al. 1997, Bowman et al. 2007, Edgerton and 
Griffin 2009, Eatwell 2010, Hedley et al. 2010, Van Waeyenberghe et al. 2010, White et 
al. 2010, Johnson et al. 2011, Masters et al. 2016). Of the 37 cases that used itraconazole, 
18 died or were euthanased, 17 recovered, one was receiving ongoing treatment at the 
time of writing, and one was lost to follow-up. Of the animals that died, itraconazole-
related hepatotoxicity is suggested as a cause in five animals (Van Waeyenberghe et al. 
2010). Several of the successfully treated cases received adjunctive treatment with 
topical antifungals including terbinafine and chlorhexidine, and multiple cases resolved 
with itraconazole and excisional biopsy or amputation of the affected limb.  
 
One author recommended pulse dosing of itraconazole, as this is commonly used in 
infections in humans, and may have less systemic side effects (Bowman et al. 2007). 
Edgerton and Griffin (2009) describe the use of pulse treatment with itraconazole, in 
combination with weekly lesion debridement and the application of topical antifungal 
agents. The affected bearded dragon had osteolytic lesions associated with fungal 
infection, requiring tail amputation. This case was ongoing at the time of publication, 
with no resolution but continuing treatment one year post-diagnosis. The maintenance 
itraconazole regime used was 5 mg/kg once daily with two weeks on, one week off, one 
week on, one week off, repeating up until the time of writing (Edgerton and Griffin 
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2009). It is important to note that a compounded itraconazole formulation was used in 
this case. A study in black-footed penguins (Spheniscus demersus) showed compounded 
itraconazole to have significantly decreased absorption and lower plasma 
concentrations than the commercially available formulation when given at the same 
dose rate (Smith et al. 2010).  
 
Voriconazole was used in a total of eight lizards, one of which died (Hellebuyck et al. 
2010, Van Waeyenberghe et al. 2010). This is a lower fatality rate than itraconazole-
treated animals, suggesting that voriconazole may be a safer, effective treatment, 
although confounding factors and differences in case severity may have skewed results. 
This hypothesis was tested by Van Waeyenberghe et al. (2010) in a study that treated 
14 similarly-affected CANV complex cases in bearded dragons, with seven animals 
administered itraconazole at 5 mg/kg PO SID and seven treated with voriconazole at 10 
mg/kg PO SID. Of these, five animals in the itraconazole treatment group died, and one 
in the voriconazole treatment group died. Of these six deaths, the animal in the 
voriconazole treatment group had disseminated fungal infection, while no fungus was 
seen histologically on the internal organs of the itraconazole-treated animals, and drug-
induced hepatotoxicity was the speculated cause of death based on increased AST levels 
in serum (Van Waeyenberghe et al. 2010). 
 
Ketoconazole was used successfully in the treatment of two green iguanas, in 
conjunction with topical terbinafine and chlorhexidine (Abarca et al. 2008). The only 
other ketoconazole-treated case in this review was lost to follow-up. Ketoconazole is 
not commonly used in reptiles, with the more selective and less hepatotoxic azoles used 
preferentially (Mitchell 2006). It is interesting to note that there were no recorded 
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fatalities with ketoconazole treatment, however the sample size is too small to evaluate 
this with any confidence. 
 
The pharmacokinetics of terbinafine as a nebulised single dose and a sustained 
subcutaneous implant have been evaluated in cottonmouths (Agkistrodon piscivorous) 
for the treatment of O. ophiodiicola (Kane et al. 2007). This study showed that both 
treatment modalities resulted in therapeutic plasma terbinafine concentrations against 
O. ophiodiicola (>0.015 mg/L), however there are currently no published reports on the 
successful application of these treatments to clinical cases of snake fungal disease.  
 
Topical terbinafine, chlorhexidine, clotrimazole and silver sulfadiazine have been used 
in conjunction with systemic treatments (Bowman et al. 2007, Abarca et al. 2008, 
Edgerton and Griffin 2009, Hedley et al. 2010, Masters et al. 2016). It is unclear what 
contribution these agents may have made to recovery, though several animals treated 
with topical iodine, as the only antifungal, did not recover (Nichols et al. 1999, Bertelsen 
et al. 2005, Johnson et al. 2011). A group of four tentacled snakes survived with disease 
for four months prior to death with topical iodine as the sole antifungal treatment, 
however these animals shed every 14 days, and the authors suggest this may have 
contributed to prolonging their survival by reducing fungal load (Bertelsen et al. 2005). 
 
Excisional biopsy has been clinically successful as a sole treatment in tuatara (Masters 
et al. 2016), and amputation of the affected limb in conjunction with a two week course 
of systemic itraconazole resulted in recovery in a bearded dragon (Bowman et al. 2007). 
However, many lesions are too large for excisional biopsy when presented, and others 
are in anatomical sites not amenable to surgical treatment, such as the head or cloaca. 
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In-water treatments have been attempted for several aquatic animals. In an outbreak 
involving saltwater crocodile hatchlings, saltwater baths did not improve the condition, 
and appeared to irritate the animals (Thomas et al. 2002). In the same outbreak, clinical 
success was achieved with a combination of plaque removal, topical iodine and 
temporary dry-docking. Formalin was then added to the water twice daily at a final 
concentration of 0.013% (Thomas et al. 2002). Using this treatment regime, ten animals 
died, and an unreported number of affected animals survived. Another author reports 
that acidification of exhibit water has led to resolution of infection in some, but not all, 
cases of infection in unspecified species of aquatic snakes (Sigler et al. 2013). The 
method and concentration of water acidification is not stated. Bertelsen et al. (2005) 
also speculate that failure to maintain an acidic environment was a contributing factor 
in fatal Paranannizziopsis crustacea infection in tentacled snakes. 
 
Several cases in the literature report infection without treatment, and the vast majority 
of these animals died or were euthanased (Thomas et al. 2002, Martel et al. 2006, 
Allender et al. 2011). All captive animals that did not receive systemic antifungals died, 
including those animals that received topical antifungals with or without systemic 
antibiotics (Nichols et al. 1999, Bertelsen et al. 2005, Johnson et al. 2011). There is a 
single report of a wild timber rattlesnake (Crotalus horridus) apparently recovering from 
dermatitis caused by O. ophiodiicola infection after several cycles of ecdysis with no 
other treatment (Smith et al. 2013).  
 
Van Waeyenberghe et al. (2010) emphasise the importance of pharmacokinetic studies 
to determine optimal treatment regimens using antifungals, and several authors 
recommend continuing treatment past the resolution of clinical signs (Bowman et al. 
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2007, Hellebuyck et al. 2010). Full details of the treatment and outcome of each 
reviewed case that received antifungal treatment are presented in Table 1.2. Medication 
was given orally unless otherwise stated. Those animals that did not receive antifungal 
treatment are not included in the table. 
 
Tuatara have lower metabolic rates than the other reptile species in the reviewed CANV 
complex cases. I hypothesise that tuatara’s lower metabolic rate translates to slower 
drug metabolism and elimination, meaning lower dose rates of antifungal agents will be 










Table 1.2 Treatment and outcome in reviewed cases of infection by members of the CANV complex. 
Species affected Treatment Outcome Citation 
Parson’s chameleon 
(Calumma parsonii) 
Itraconazole 10 mg/kg SID for 21 days Decreased appetite, condition loss, elevated serum CK 
and AST levels. Recovered 
Paré et al. 1997 
Jewelled chameleon 
(Furcifer campani) 
Itraconazole 10 mg/kg SID Died after 6 days, widespread systemic disease Paré et al. 1997 
Jackson’s chameleon 
(Chamaeleo jacksonii) 
Ketoconazole 25 mg/kg q48h Lost to follow-up Paré et al. 1997 
Green iguana  
(Iguana iguana) – two 
animals 
Ketoconazole 20 mg/kg SID 
Chlorhexidine 2% topically SID 
Terbinafine (dose rate not specified) topically SID 
Both recovered Abarca et al. 2008 
Bearded dragon  
(Pogona barbata) 
Itraconazole 5 mg/kg SID Died Johnson et al. 2011 
Bearded dragon  
(Pogona barbata) 
Topical iodine Euthanased within 4 months of onset Johnson et al. 2011 
Bearded dragon  
(Pogona barbata) 
Itraconazole 10 mg/kg SID Died after 3 weeks Masters et al. 2016 
Bearded dragon  
(Pogona vitticeps) 
Compounded itraconazole 5 mg/kg pulse dosing (see text for 
details). 
Silver sulfadiazine 1%, chlorhexidine 2% and terbinafine 1% 
topically (frequency not specified). 
Weekly lesion debridement 




Bearded dragons  
(Pogona vitticeps) 
Itraconazole 5 mg/kg SID 5/7 died, increased AST in 4 animals, suggested 
itraconazole induced hepatotoxicity 
Van Waeyenberghe  
et al. 2010 
Bearded dragons  
(Pogona vitticeps) 
Voriconazole 10 mg/kg SID 1/7 died, increased AST in 3/7 animals, suggested 
voriconazole-induced hepatotoxicity 
Van Waeyenberghe 
et al. 2010 
Bearded dragons  
(Pogona vitticeps) 
Itraconazole 10 mg/kg SID for 6 weeks 
Topical clotrimazole 1% BID 
F10 vivarium disinfection 
7/13 recovered, others euthanased Hedley et al. 2010 
Bearded dragon  
(Pogona vitticeps) 
Itraconazole 10 mg/kg SID for 6wks 
Topical chlorhexidine 0.125% (frequency not specified) 
 
Itraconazole 10 mg/kg SID 
Topical miconazole 2% SID 
Reduced appetite, apparent recovery, recurrence after 6 
months (see below). 
 
Anorexia and weight loss, died. 
Bowman et al. 2007 
Bearded dragon  
(Pogona vitticeps) 
Itraconazole 10 mg/kg SID 
Topical iodine SID 
Lesion improvement, weight loss and anorexia. Died. Bowman et al. 2007 
Bearded dragon  
(Pogona vitticeps) 
Amputation of affected limb 
Itraconazole 5 mg/kg q48h for 14 days 
Recovered Bowman et al. 2007 
Girdled lizard  
(Cordylus giganteus) 
Topical miconazole, nebulised amphotericin B (dose reate and 
frequency not specified for either medication) 
 





Hellebuyck et al. 
2010 
Three lizards of 
unspecified species 
Itraconazole, unspecified dosing regimen and duration One recovered 
One euthanased due to disease 
One lost to follow-up 
White et al. 2010 
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Brown tree snakes  
(Boiga irregularis) 
Topical iodine Died 3-14 days after onset Nichols et al. 1999 
Boa constrictor 
(Constrictor constrictor) 
Itraconazole 5 mg/kg SID 
Topical silver sulfadiazine 1% BID 
Died after 3 weeks Eatwell 2010 
Tentacled snakes  
(Erpeton tentaculatum) 
Topical iodine. Shed every 14 days. Died after 4 months Bertelsen et al. 2005 
Garter snake  
(Thamnophis sp) 






Plaque removal, topical iodine, temporary dry-docking 
Add formalin 0.013% to water BID 
No improvement 
 
10 died, unknown number of affected animals survived 
Thomas et al. 2002 
Tuatara  
(Sphenodon punctatus)  
Itraconazole 5 mg/kg SID for 4 weeks 
Topical terbinafine 1% SID for 3 weeks 
Resolved 
 




Itraconazole 5 mg/kg SID for 4 weeks 
Topical terbinafine 1% SID for 4 weeks 
Resolved 
 




Itraconazole 5 mg/kg SID for 2 weeks, then 2.5mg/kg for 2 weeks 
Resolved 
 
Masters et al. 2016 
Tuatara  
(Sphenodon punctatus) 
Itraconazole 3 mg/kg SID for 6 weeks Resolved Masters et al. 2016 
Tuatara  
(Sphenodon punctatus) 
Excisional biopsy only Resolved Masters et al. 2016 
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1.3 Impact of temperature on the pharmacokinetics of drugs in reptiles 
 
There are few published studies that explore impact of temperature variation on the 
pharmacokinetics of drugs and metabolites in reptiles, and none involving antifungal 
drugs. Most reptile drug formularies do not state at what temperature the dose rate and 
interval were determined, despite several studies showing significant variation in drug 
metabolism and elimination at different temperatures. When reptiles are unwell it is 
advisable to treat them at the higher end of their preferred optimal temperature zone 
(POTZ) (Cooper 2006), however this is not always possible. The effect of temperature on 
drug pharmacokinetics is also beginning to be explored in human medicine, as 
therapeutic hypothermia becomes more commonly used in various brain and cardiac 
injury management situations. 
 
The environmental temperature reptiles experience affects processes linked to 
metabolic rate, including gastrointestinal motility, enzyme activity, immune function 
and distribution and absorption of antibiotics (Mader et al. 1985, Hodge 1987, Caligiuri 
et al. 1990). Oxygen consumption and heart rate have been shown experimentally to 
increase at higher temperatures in tuatara and two species of snake, and it is reasonable 
to assume this occurs in other reptile species (Jacobson and Whitford 1970, Wilson and 
Lee 1970). 
 
1.3.1 Antibiotic studies in reptiles 
 
Several studies used the aminoglycoside antibiotic amikacin to test temperature-related 
variation in drug pharmacokinetics in snakes and tortoises (Mader et al. 1985, Caligiuri 
et al. 1990, Johnson et al. 1997). The aminoglycosides are predominantly eliminated 
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renally, so pharmacokinetics are likely to be affected by metabolic rate and renal 
perfusion and, therefore, temperature. A study using amikacin in gopher snakes 
(Pituophis melanoleucus catenifer) found significant differences in amikacin clearance 
and volume of distribution, but not half-life, at 25oC and 37oC (Mader et al. 1985). The 
larger volume of distribution at 37oC indicates the drug was distributed more widely to 
tissues, so was theoretically more effective in treating systemic infections. The same 
study also found the bacteria being targeted was twice as sensitive to amikacin in vitro 
at the higher temperature (Mader et al. 1985). A similar study in ball pythons (Python 
regius) showed no significant differences in amikacin pharmacokinetics at 25oC and 37oC 
(Johnson et al. 1997).  
 
In gopher tortoises (Gopherus polyphemus), amikacin clearance was slower and 
elimination half-life was longer at 20oC than 30oC, while volume of distribution remained 
the same at both temperatures (Caligiuri et al. 1990). Metabolic rate and oxygen 
consumption was lower in gopher tortoises housed at lower temperatures by a ratio of 
2:1, and this resulted in longer mean residence time and slower clearance of amikacin 
from the body at a ratio of almost 2:1 (Caligiuri et al. 1990), indicating that metabolic 
rate directly influenced pharmacokinetics in this study.  
 
These studies show some variation in outcome and conclusions, indicating that even 







1.3.2 Therapeutic hypothermia and drug pharmacokinetics in humans 
 
In humans, therapeutic hypothermia is employed as a tool to limit brain and myocardial 
ischaemic injury while stabilisation or repairs are performed. Hypothermia involves 
cooling until the core body temperature decreases from the normal 37oC to 32-34oC 
(Zhou and Poloyac 2011). In general, this mild hypothermia was found to significantly 
decrease clearance, but not protein binding, of a variety of drugs, resulting in an increase 
in drug and metabolite plasma concentrations. Hypothermia may increase the duration 
of effect of medications, and increase the likelihood of toxic effects if dosage is not 
adjusted appropriately (van den Broek et al. 2010, Zhou and Poloyac 2011). Specific 
alterations in drug pharmacokinetics during hypothermia may be metabolism and 
elimination route specific, and drugs that are highly metabolised and with a high 
clearance are more likely to be affected by hypothermia (van den Broek et al. 2010, Zhou 
and Poloyac 2010). Therapeutic drug monitoring is recommended in these situations, 
particularly when using drugs with a low therapeutic index, active metabolites, or high 
clearance (van den Broek et al. 2010) 
 
1.3.3 Metabolic rate and toxicity 
 
A study by Hodge (1978) showed that metabolic rate of the Florida banded water snake 
can be controlled by altering the ambient temperature, and that this affected the 
metabolism, clearance and maximum plasma concentration (Cmax) of intramuscularly-
administered gentamicin (Hodge 1978). Lower temperatures resulted in lower 
metabolic rate, higher Cmax and slower clearance of gentamicin. Lower metabolic rate 
resulted in decreased production of urates in both control and gentamicin groups, 
slower active transport of gentamicin and therefore lower intracellular gentamicin 
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concentrations (Hodge 1978). These lower concentrations meant that despite the higher 
plasma gentamicin concentrations and the longer time the drug spent in the body, there 
was less potential for nephrotoxic effects (Hodge 1978). This is important as it illustrates 
that the intuitive assumption that higher plasma concentrations of a drug result in 
increased potential for toxicity may not always be correct, and that toxicity is dependent 




1.4.1 Indications in humans and other species 
 
Itraconazole is a triazole antifungal that was first synthesized in 1980 (Hardin et al. 
1988). It has the molecular formula C35H38Cl2N8O4, and its structure is shown in Figure 
1.5. Itraconazole has a broad spectrum of antifungal activity and is most commonly used 
in the treatment of aspergillosis, candidiasis, fungal dermatitis and nail bed infections in 
humans and animals (Vantrubova et al. 2010). Itraconazole has been used with variable 
success in the treatment of CANV complex infections in several reptile species at dose 
rates of 5-10 mg/kg orally once daily (Paré et al. 1997, Bowman et al. 2007, van 
Waeyenberghe et al. 2010, Johnson et al. 2011). Itraconazole has also been used in 
lizards at lower, allometrically scaled dosages ranging from 0.4 mg/kg orally every 20 
hours to 1.7 mg/kg every 83 hours (Girling et al. 2009). These lower dose rates resulted 
in apparent resolution of Aspergillus infection, however itraconazole concentrations 
were not measured, and there were concomitant changes in husbandry which may have 





1.4.2 Mechanism of action 
 
Itraconazole binds to fungal but not mammalian cytochrome P450 enzymes (Mundell 
1990). The nitrogen atoms in itraconazole interact with fungal cytochrome P450 
(CYP)3A, inhibiting function of the enzyme lanosine 14-α-demethylase. This enzyme is 
essential in the conversion of lanosterol to ergosterol, an important compound in the 
fungal cell membrane and the equivalent of cholesterol in mammalian cells (Prentice 
and Glasmacher 2005, Vantrubova et al. 2010). This renders the fungi unable to multiply 
and accounts for itraconazole’s fungistatic activity. Itraconazole administration may also 
result in the intracellular accumulation of ergosterol precursors, potentially contributing 
to eventual cell rupture and the fungicidal activity of the drug (Mundell 1990). 
 





1.4.3 Formulation and absorption 
 
Itraconazole was initially available only in capsule form, and this is soluble only under 
very acidic conditions such as those in gastric secretions (Hardin et al. 1988, Orosz et al. 
1996, Prentice and Glasmacher 2005). Absorption of the capsule formulation improved 
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when administered with food and was dose-dependent (Barone et al. 1993, Prentice 
and Glasmacher 2005). Itraconazole is highly lipophilic and a weak base, and absorption 
of solid drug, as in capsules, is enhanced by administration with a fatty meal (Heykants 
et al. 1989, Orosz et al. 1996). It has also been suggested that differences in the anatomy 
and physiology of gastrointestinal tracts between species may affect the rate and extent 
of itraconazole absorption (Orosz et al. 1996).  
 
This difficulty in obtaining good absorption through oral administration of itraconazole 
led to practitioners using various methods in an attempt to enhance absorption. This 
has included use of commercial suspending vehicles, compounded vehicles, and 
administration of the drug dissolved in a combination of orange juice and hydrochloric 
acid, then mixed with gruel (Orosz et al. 1996, Smith et al. 2010). These methods do not 
result in absorption as efficient as that of the commercially available oral solution (Smith 
et al. 2010). 
 
The oral solution of itraconazole was developed in the late 1980s (Heykants et al. 1989) 
and is marketed as Sporanox® (Janssen-Cilag Pharmaceuticals, Auckland, New Zealand). 
The solution combined itraconazole with hydroxypropyl-β-cyclodextrin, a ring of 
substituted glucose molecules (Willems et al. 2001). When both the oral solution and 
the capsule formulation were administered with food, bioavailability of the oral solution 
was up to 37% higher than the capsule formulation. Administration in a fasted state 
increased bioavailability by a further 30% when compared to dosing with food (Willems 
et al. 2001). The oral solution was also noted to improve predictability of itraconazole 
blood concentrations compared with the oral capsules (Davis et al. 2005, Prentice and 
Glasmacher 2005). A new itraconazole formulation with higher bioavailability has 
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recently been developed, and initial pharmacokinetic studies are still being conducted 




Itraconazole is metabolised by the liver and is eliminated in gallbladder secretions and 
(up to 40%) in the urine (Prentice and Glasmacher 2005, Vantrubova et al. 2010). Hepatic 
metabolism is dose-dependent (Hardin et al. 1988, Barone et al. 1993) resulting in non-
linear pharmacokinetics. This means that if the dose is increased, the proportion of drug 
eliminated may change due to the drug saturating the metabolic pathways. 
  
Itraconazole has a large number of metabolites in humans, with the main metabolite 
being hydroxy-itraconazole (Heykants et al. 1989). Hydroxy-itraconazole has significant 
antifungal activity of a very similar spectrum of action to the parent compound, but may 
not be as potent in vivo (Heykants et al. 1989, Prentice and Glasmacher 2005). This raises 
the overall absolute oral bioavailability of itraconazole to at least 80% (Heykants et al. 
1989, Prentice and Glasmacher 2005). Human studies have shown hydroxy-itraconazole 
to attain approximately two times the plasma concentration of itraconazole (Heykants 
et al. 1989, Manire et al. 2003), however a study in Kemp’s ridley sea turtles 
(Lepidochelys kempii) showed hydroxy-itraconazole concentrations to be only 6% of 
itraconazole concentrations (Manire et al. 2003). It was postulated this could be a result 
of differences in drug metabolism due to lower metabolic rate or differences in 
cytochrome P-450 isoforms in sea turtle liver (Manire et al. 2003). Other studies in 
humans have found hydroxy-itraconazole concentrations to be between zero and 10 
times those of itraconazole, again demonstrating significant inter-patient variability 
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(Orosz and Frazier 1995, Manire et al. 2003). Human studies have shown that 
itraconazole does not induce its own metabolism (Heykants et al. 1989). 
 
1.4.5 Known pharmacokinetic profile in humans and selected other species 
 
Steady-state concentrations in healthy human volunteers were reached after 10-15 days 
of itraconazole therapy in several studies (Hardin et al. 1988, Heykants et al. 1989, 
Barone et al. 1993, Orosz et al. 1996), and after 7 days in another study (Cauwenbergh 
et al. 1988). Itraconazole displays non-linear pharmacokinetics with saturation of drug 
metabolism in humans at therapeutic doses (Prentice and Glasmacher 2005). 
 
Itraconazole has excellent tissue penetration, resulting in good bioavailability at the site 
of infection (Gamble et al. 1997, Heykants et al. 1989, Jones et al. 2000, Prentice and 
Glasmacher 2005). It also appears to be preferentially deposited in exudates such as pus, 
and can potentiate phagocytosis by leukocytes (Gamble et al. 1997, Heykants et al. 
1989). Itraconazole is relatively poorly distributed in the cerebrospinal fluid (CSF); 
however clinical success has been reported with use of itraconazole in central nervous 
system (CNS) disease. It has been hypothesized that the concentration of itraconazole 
in CSF does not reflect the concentration in brain parenchyma (Kethireddy and Andes 
2007).  
 
Itraconazole was found to accumulate in Amazon parrots at dosages of 10 mg/kg, 
suggesting saturable metabolism in this species. However, there was no accumulation 
at dosages of 5 mg/kg (Orosz et al. 1996), illustrating linear pharmacokinetics at lower 
doses. Studies in humans have determined itraconazole kinetics were non-linear, i.e. 
they show a disproportionately higher increase in plasma concentration when dose rate 
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was increased. It is thought this is due to saturation of first-pass sites for metabolism in 
the gut mucosa and liver (Heykants et al. 1989, Prentice and Glasmacher 2005). 
 
Significant inter-individual variation in metabolism has been shown in many species 
(Manire et al. 2003, Orosz and Frazier 1995). Itraconazole has been shown to accumulate 
in plasma in several species including bearded dragons, illustrated by an increase in 
trough concentrations over time (van Waeyenberghe et al. 2010). This may increase the 
risk of toxicity over prolonged periods of treatment. 
 
Disposition in skin 
The pharmacokinetic profile of itraconazole in the skin is unique and can result in 
significantly higher concentrations than those found in plasma (Cauwenbergh et al. 
1988, Willems et al. 2001, Vantrubova et al. 2010). Itraconazole is delivered to the skin 
via sebum, sweat and passive uptake by keratinocytes (Cauwenbergh et al. 1988). 
Although penetration into skin and nails is slow, it does not diffuse back into the plasma, 
and is removed only by exfoliation and nail regrowth (Cauwenbergh et al. 1988, 
Heykants et al. 1989, Orosz and Frazier 1995, Willems et al. 2001). Itraconazole 
concentrations in human skin differed depending on the region sampled, with lowest 
concentrations in palmar stratum corneum, moderate concentrations in the back 
stratum corneum and high concentrations and longer persistence in the beard region 
(Cauwenbergh et al. 1988). Itraconazole concentrations in sweat were low, but 
concentrations in the sebum were 5 to 10 times higher than plasma concentrations 
during treatment with itraconazole, and were still at therapeutic concentrations one 
week after stopping drug administration. Low concentrations of itraconazole were still 
present in the palmar stratum corneum when concentrations in sweat and sebum were 
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undetectable, indicating that low concentrations were incorporated directly into 
keratinocytes in the basal layer.  
 
It is thought that the main mechanism of itraconazole distribution to the skin is via 
sebaceous glands, followed by direct incorporation into keratinocytes, and a small 
amount via sweat (Cauwenbergh et al. 1988). A difference in thickness of the stratum 
corneum and in distribution of sweat and sebaceous glands in various parts of the body 
could therefore explain the differences in uptake on various body surfaces 
(Cauwenbergh et al. 1988, Heykants et al. 1989). High concentrations are also seen in 
human nails, and it is speculated this is as a result of drug diffusing via the nail bed 
(Cauwenbergh et al. 1988).  
 
Reptiles do not have sebaceous glands in their skin, so the assumption that itraconazole 
concentrations remain high in the skin even after dosing has ceased may not be 
applicable, although there may be some incorporated into the epidermis and scales. 
Lesions caused by members of the CANV complex often have a heterophilic serocellular 
crust (C. Harvey 2014 pers. comm.), and it is possible this exudate may contain 
significant amounts of itraconazole during treatment. Several authors state that 
concentration in the target tissues will more closely reflect clinical efficacy than will 
plasma concentrations (Cauwenbergh et al. 1988, Heykants et al. 1989, Gamble et al. 
1997), however it is not always possible to conduct studies to evaluate tissue drug 
concentrations, so plasma concentrations are used as a guide. 
 
Plasma protein binding 
The proportion of plasma protein binding of a drug affects its distribution and the 
amount of unbound drug available for use in the body. The “free drug hypothesis” states 
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that it is only the unbound proportion of drug that is available for antimicrobial activity 
(Theuretzbacher et al. 2006, Holford 2009). Plasma protein binding of itraconazole in 
humans is high at 99.8%, and is mainly bound to albumin (Heykants et al. 1989, Prentice 
and Glasmacher 2005, Willems et al. 2001). The lipophilic nature of itraconazole results 
in high tissue concentrations, including 10 times plasma concentrations in the skin, three 
times plasma in liver and 17 times plasma in fat (Jones et al. 2000, Willems et al. 2001). 
This also results in tissue concentrations remaining higher than plasma concentrations 
for some time after administration ceases (Willems et al. 2001). Particularly high 
concentrations are found in fluid containing organic material, such as pus and sputum 
(Heykants et al. 1989). Concentrations in tissues mostly composed of fluid, such as the 
aqueous humour, saliva and CSF, are negligible (Heykants et al. 1989). 
 
In rats and dogs, itraconazole concentrations in the brain tissue were significantly higher 
than the negligible concentrations found in CSF (Heykants et al. 1989). Several authors 
assert that this disproves the generally-held tenet that free drug concentration (i.e. the 
0.2% of itraconazole unbound to plasma proteins) alone accounts for antimicrobial 
activity, and that availability of drug to the infection site is related instead to tissue drug 
concentration (Heykants et al. 1989, Schäfer-Korting et al. 1995).  
 
It is very difficult to measure unbound drug in tissue as it involves measuring drug 
concentrations in intracellular spaces, and this is rarely done. The currently accepted 
practice then is to measure drug concentrations in tissue as a whole, which of course 
includes capillaries, blood present in those vessels, intracellular fluid as well as the tissue 
itself (N. Holford 2014 pers comm.). It remains to be seen whether this is an accurate 
method of assessing drug availability for antimicrobial action, and it is beyond the scope 
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of this review to explore this debate further. Total (bound and unbound) plasma 
concentration of itraconazole, coupled with clinical response, are the most commonly 




The elimination half-life of a drug is the amount of time it takes for plasma drug 
concentration to decrease by fifty percent (Sharma and McNeill 2009). The half-life of 
itraconazole in humans has been reported as 15-21 hours after a single dose, and 30-35 
hours following multiple doses of the capsule formulation (Heykants et al. 1989, Orosz 
et al. 1996). Chronic dosing of itraconazole in humans revealed significant accumulation, 
as evidenced by increasing trough concentrations throughout a 15 day study (Hardin et 
al. 1988). 
 
The half-life of itraconazole in Amazon parrots has been shown to be between 3.7 and 
7.2 hours, with no significant differences between days 1 and 14 of administration, or 
between dosing with 5 mg/kg or 10 mg/kg itraconazole (Orosz et al. 1996). In pigeons 
the half-life was 13.3 hours at an average dose rate of 10.3 mg/kg itraconazole (Lumeij 
et al. 1995), 5.8 hours in black-footed penguins (Smith et al. 2010), and 9.1 hours in 
Humboldt penguins (Spheniscus humboldti) (Bunting et al. 2009). Itraconazole’s half-life 
is significantly longer in the few reptile species tested, and in spiny lizards was 48.3 hours 
(Gamble et al. 1997), and in Kemp’s ridley sea turtles was 75 hours (Manire et al. 2003). 





Time to maximal drug concentration 
Time to maximal drug concentration (Tmax) using capsules in Amazon parrots varied 
between 3.7 and 6.9 hours (Orosz et al. 1996) when administered with an orange juice, 
hydrochloric acid and gruel mix, and in fasted domestic pigeons was 4 hours (Lumeij et 
al. 1995). In black-footed penguins given the itraconazole oral solution Tmax was 3.7 
hours, and in humans was 5.7 hours (Willems et al. 2001, Smith et al. 2010). 
 
Volume of distribution 
Volume of distribution of a drug is the ratio of the amount of drug in the body and the 
concentration of drug in the plasma (Sharma and McNeill 2009). A low volume of 
distribution indicates a drug stays largely in the plasma and is not distributed extensively 
to other tissues. Itraconazole has a high volume of distribution in humans, at 10.7L/kg 
(Heykants et al. 1989), 17 L/kg in dogs (Heykants et al. 1987) and 6.3 L/kg in horses (Davis 
et al. 2005) 
 
1.4.6 Adverse effects 
 
Itraconazole has a lack of endocrine side effects when compared to its predecessor 
ketoconazole, and is less toxic in humans than amphotericin B (Hardin et al. 1988, Orosz 
et al. 1996). The most common side effects in humans are abdominal pain, nausea, 
vomiting and dyspepsia (Manire et al. 2003).  
 
Itraconazole can cause an elevation in liver enzyme activity in serum, and these should 
be monitored during therapy. Liver damage may be severe enough to cause or 
contribute to mortality (van Waeyenberghe et al. 2010). In one clinical study on the 
treatment of infections caused by the CANV complex, five out of the seven bearded 
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dragons administered itraconazole at 5 mg/kg once daily died (van Waeyenberghe et al. 
2010). Lesions suggestive of itraconazole toxicity were not demonstrated on histological 
examination, however the authors speculate that this was the cause of death (L. van 
Waeyenberghe 2014 pers. comm.). Serum AST levels were raised in four out of seven of 
these animals, however haemogram, bile acids and creatine kinase measurement were 
not undertaken in this study to help differentiate between hepatic and non-hepatic 
causes of AST elevation. A bearded dragon in a study conducted by Bowman et al. (2007) 
was given itraconazole at 10 mg/kg once daily for 21 days and showed a small decrease 
in appetite, but normal biochemistry. In the same study a different bearded dragon on 
the same dosing regime showed severe anorexia and weight loss, however on post-
mortem there was no evidence of toxicity (Bowman et al. 2007). These results clinically 
illustrate the significant inter-individual variability noted in other studies of itraconazole 
pharmacokinetics. In other cases of infection caused by the CANV complex, itraconazole 
was linked to decreased appetite and condition loss, an unexplained increase in CK and 
AST activity, and a decreased PCV (Section 1.2.5).  
 
In rats, itraconazole has been reported to cause hepatotoxicity, with dose-dependent 
hepatocellular necrosis, bile duct hyperplasia and biliary cirrhosis (Somchit et al. 2004). 
An analysis of toxicity data in humans has shown that plasma itraconazole 
concentrations above 17.1 mg/L have a high probability of toxicity (Lestner et al. 2009), 
however this was measured using bioassay rather than conventional high-performance 
liquid chromatography (HPLC) techniques. The authors suggest that this concentration 




As a result of studies suggestive of itraconazole toxicity in reptiles, pulse dosing has been 
recommended (Bowman et al. 2007). A bearded dragon with a chronic infection caused 
by a member of the CANV complex was treated with itraconazole in a pulse fashion, and 
this failed to completely resolve the lesions (Edgerton and Griffin 2009). This may be 
because pulse therapy is ineffective, or because the authors used compounded 
itraconazole, which studies in birds show is poorly absorbed (Smith et al. 2010). 
Although pulse therapy has been shown to be successful in other animals and humans 
(De Doncker et al. 1997), particularly for onychomycosis, the mechanism of diffusion of 
itraconazole into reptile skin may be sufficiently different as to make such dosing 
regimens unsuccessful. Ideally studies that describe the concentration of itraconazole in 
reptile skin would first be conducted to determine how long and at what concentrations 
it persists there following oral dosing. 
It may be prudent to monitor or decrease concentrations of certain drugs when given 
concurrently with itraconazole, as administration with itraconazole has been shown to 
modify plasma concentrations of drugs metabolised by cytochrome P450. (Manire et al. 
2003, Vantrubova et al. 2010). There is a long list of drugs that fall into this category, 
some of the more commonly used ones include ivermectin, corticosteroids, 
benzodiazepines, rifampin and amphotericin B (Plumb 2011). In a study on itraconazole 
pharmacokinetics in Kemp’s ridley sea turtles (Manire et al. 2003), rifampin was 
administered concurrently with itraconazole in two subjects, and it is possible this 
resulted in lower serum itraconazole concentrations than would otherwise have been 








1.5.1 Indications in humans and other species 
 
Voriconazole is a second-generation triazole antifungal and is synthetically derived from 
fluconazole by modification of its chemical structure (Roffey et al. 2003, Theuretzbacher 
et al. 2006, Beernaert et al. 2009). It has the chemical formula C16H14F3N5O, and the 
structure is illustrated below (Figure 1.6). 
 
Voriconazole has potent activity against a broad range of clinically significant fungi 
including Aspergillus, Candida, Cryptococcus and, importantly, has been shown to be 
effective in treating infections caused by members of the CANV complex (Roffey et al. 
2003, Scope et al. 2005, Theuretzbacher et al. 2006, Van Waeyenberghe et al. 2010). It 
is commonly used in humans to treat invasive aspergillosis and Candida infections in 
immunocompromised hosts. 
 
Figure 1.6 Chemical structure of voriconazole (Roerig 2008). 
 
 
There have been only three published studies of voriconazole use in reptiles. Those are 
in bearded dragons (Van Waeyenberghe et al. 2010), girdled lizards (Hellebuyck et al. 
2010), and red-eared sliders (Innis et al. 2008). This review includes data from studies in 
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humans and other animals in an attempt to provide a comprehensive overview of 
voriconazole characteristics and pharmacokinetics, the assumptions made in these 
studies and how the data is of relevance to developing a treatment protocol in tuatara. 
 
1.5.2 Mechanism of action 
 
Voriconazole acts by inhibiting cytochrome P450-dependent 14-α-lanosterol 
demethylase, an enzyme required for the synthesis of ergosterol. This results in the 
replacement of ergosterols in fungal cell membranes by 14-α-methylated sterols, 
causing disruption of membrane structure and function and inhibiting fungal growth 
(Beernaert et al. 2009). Compared to ketoconazole and itraconazole, voriconazole has a 
greater selectivity for fungal than rat cytochrome P450 liver enzymes (Roffey et al. 
2003). Antimycotics do not eliminate infection completely as they are very rarely 
fungicidal, but the inhibition of fungal growth creates conditions allowing recovery from 
infection with the aid of the animals’ immune system (Vantrubova et al.2010). It is 
reported that the in vitro activity of voriconazole against filamentous fungi exceeds that 
of itraconazole (Diekema et al. 2003). 
 
1.5.3 Formulation and absorption 
 
Voriconazole is available in tablet, oral solution and injectable intravenous formulations 
and is commercially known as VFEND® (Pfizer, Auckland, New Zealand). The majority of 
animal studies have used oral formulations, as intravenous use is often impractical over 
long periods. A study in red-eared sliders used the intravenous formulation 
subcutaneously at a dose rate of 5 mg/kg and reported that serum concentrations only 
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exceeded the target concentration of 1µg/mL for the first two hours, making this dosage 
and route unsuitable for use in these animals (Innis et al. 2008). 
 
Several studies have used tablets crushed and suspended in water, orange juice and 
dilute hydrochloric acid, or a commercial suspending agent in an attempt to provide 
precise dosing and enhance drug absorption from the gastrointestinal tract (Burhenne 
et al. 2008, Flammer et al. 2008, Sanchez-Migallon Guzman 2010). One study in African 
Grey parrots found significant differences in the maximal plasma concentration and area 
under the curve when the same dosage was given with water versus a commercial 
suspending agent (Flammer et al. 2008). The commercial suspending agent may have 
provided a more uniform suspension, altered gastrointestinal transit time or increased 
drug solubility (Flammer et al. 2008). The studies reported in this thesis used the oral 
suspension of voriconazole that comes as a powder to be reconstituted, as this provided 
more consistent and accurate dosing than crushing and suspending tablets prior to 
administration. 
 
Following oral dosing using tablets in humans, voriconazole is rapidly absorbed within 
two hours, and has a bioavailability exceeding 90% that is not affected by gastric pH. The 
presence of food in the stomach significantly delays its absorption and decreases 
bioavailability, but does not affect trough voriconazole concentrations (Purkins et al. 
2003, Theuretzbacher et al. 2006). In humans it is recommended that voriconazole be 
administered more than one hour before or one hour after a meal (Purkins et al. 2003). 
In chickens, bioavailability was less than 20% following oral administration to non-fasted 
animals at a dose rate of 10 mg/kg. In this study on chickens the drug was administered 
by crushing tablets and suspending them in water (Burhenne et al. 2008). Administering 
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the same dosage and formulation to fasted racing pigeons showed a voriconazole 
bioavailability of 43.7%. It is possible the presence of food in the gastrointestinal tract 
of the chickens may have slowed absorption and decreased bioavailability of 
voriconazole, as in humans. When laboratory-synthesised voriconazole of 98% purity 
was suspended in two different solutions and administered orally, bioavailability was in 
excess of 75% in mice, rats, rabbits, guinea pigs and dogs (Roffey et al. 2003). These 
animals had ad-lib access to food throughout the studies, so the effect of food in the 




Voriconazole is eliminated predominantly after biotransformation, and undergoes 
extensive hepatic metabolism by cytochrome P450 enzymes in the liver in all species 
investigated (Roffey et al. 2003, Theuretzbacher et al. 2006, Beernaert et al. 2009). In 
humans it is the CYP2C19 enzyme that is predominantly involved in voriconazole’s 
metabolism, with a lesser contribution from CYP3A4 (Roffey et al. 2003). Levels of 
CYP2C19 can vary significantly between individuals, thus there is significant inter-
individual variation in plasma concentrations of voriconazole even when given at the 
same dosage. This high level of variation in plasma concentration has also been reported 
in other animals including chickens, Amazon parrots and bearded dragons (Burhenne et 
al. 2008, Sanchez-Migallon Guzman et al. 2010, Van Waeyenberghe et al. 2010). This 
variability suggests that higher-end doses may be required to ensure voriconazole 
trough concentrations do not fall below the concentration required to inhibit growth of 




Several animal studies have reported a decline in maximal concentration, minimum 
concentration and elimination half-life over time when giving the same amount of 
voriconazole (Roffey et al. 2003, Beernaert et al. 2009). This effect has been noted in 
mice, rats, dogs, bearded dragons and African Grey parrots but not in humans, girdled 
lizards, guinea pigs, rabbits or chickens (Roffey et al. 2003, Burhenne et al. 2008, 
Beernaert et al. 2009, Van Waeyenberghe et al. 2010). This is thought to be due to 
voriconazole inducing its own metabolism, a hypothesis supported by the findings of 
dose-related increases in hepatic cytochrome P450 content and relative liver weight in 
both rats and dogs (Roffey et al. 2003).  
 
This autoinduction indicates that while an administered dosage may stay above 
minimum inhibitory concentration (MIC) at the start of the study, at the end of a six 
week course this may not be the case. This may require the use of higher doses 
throughout treatment, or increasing dosage in line with monitored voriconazole 
concentrations in the plasma (Flammer et al. 2008). Autoinduction is not seen in 
humans; this may be because of a species-specific difference or because lower dosages 
are used in people (Roffey et al. 2003). It should be noted that the study in girdled lizards 
only sampled plasma drug concentrations for the first three days of treatment, which 
may not have been sufficient for autoinduction to occur (Hellebuyck et al. 2010). 
 
Both liver weight and cytochrome P450 levels returned to normal in rats one month 
after cessation of treatment (Roffey et al. 2003). If tuatara are similar to rats, this would 
indicate that the time between multiple dose voriconazole studies at different 
temperatures would need to be at least one month to ensure liver enzyme levels have 




In humans, voriconazole is eliminated mainly by hepatic metabolism; very little is 
excreted unchanged in urine and faeces (Theuretzbacher et al. 2006). Voriconazole’s 
major metabolite is N-oxide UK-121,265 and shows no significant antifungal activity 
(Flammer et al. 2008, Roffey et al. 2003).  
 
1.5.5 Pharmacokinetic profile in humans and selected other species 
 
In most cases, voriconazole exhibits nonlinear pharmacokinetics, meaning that the 
steady-state concentration of drug in the blood does not increase proportionally with 
dose, so if the amount of drug administered is doubled, the steady state concentration 
in plasma increases by a factor of more than two (Roffey et al. 2003, Theuretzbacher et 
al. 2006, Burhenne et al. 2008, Beernaert et al. 2009). In voriconazole this is thought to 
be a result of capacity-limited metabolism due to saturation of the enzymes required to 
metabolise the drug (Beernaert et al. 2009). This means pharmacokinetic data cannot 
be extrapolated from one dosage to another (Flammer et al. 2008), so it is not possible 
to make an assumption that decreasing the oral dose by a particular amount will result 
in plasma concentration staying above a certain level.  
 
In children under twelve years of age voriconazole has been shown to have linear 
pharmacokinetics (Theuretzbacher et al. 2006), and this has also been shown to occur 
in Amazon parrots, with a doubling of dose from 12 to 24 mg/kg resulting in a doubling 
of maximal plasma concentration and area under the curve (Sanchez-Migallon Guzman 
et al. 2010). It is possible non-linear pharmacokinetics may exist in Amazon parrots at 
different doses; however this has not been investigated. There do not appear to be any 
studies in the scientific literature on the pharmacokinetic behaviour of voriconazole in 
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juvenile animals. This was a contributing factor in the decision to limit the animals in my 
study to those that were considered to be in the adult weight range, in an effort to 
reduce potential age-related variability in drug metabolism. 
 
Studies by Hellebuyck et al. (2010) and Van Waeyenberghe et al. (2010) have described 
the pharmacokinetics of voriconazole in bearded dragons and girdled lizards 
respectively. The administered dosages of 10 mg/kg resulted in trough concentrations 
at least ten times greater than the minimum inhibitory concentrations for the isolates 
of the CANV complex fungi in question. However due to voriconazole’s nonlinear 
pharmacokinetics it is not possible to predict that one tenth or even one fifth of the dose 
would result in trough concentrations still above the required MIC of the fungal isolates, 
and it is not possible to predict pharmacokinetic parameters across species (Beernaert 
et al. 2009). Pharmacokinetics in the rat were gender-dependent with males having 
lower serum voriconazole concentrations than females, however this is a phenomenon 
often observed in rats but not in other species (Roffey et al. 2003). 
In humans steady-state plasma concentrations were achieved after five to seven days of 
oral dosing (Theuretzbacher et al. 2006). 
 
Disposition in skin 
There is limited pharmacokinetic data available on the disposition of voriconazole in 
skin. Clinically, voriconazole has been used successfully in humans with severe, invasive 
fungal dermatitis (Troke et al. 2008). Voriconazole has been studied in guinea pigs in an 
experimental model of dermatophytosis, and after 12 days of administration of 20 
mg/kg orally once daily, maximal plasma concentration was 6.3 mg/L, total skin 
concentration was 18.3 µg/g, and unbound skin concentration was 1.4 µg/mL (Saunte 
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et al. 2007). The authors concluded that there was accumulation of the drug in skin that 
could not solely be explained by protein binding.  
 
Plasma protein binding 
Binding of voriconazole to plasma proteins was reported to be 58% in humans (Roffey 
et al. 2003), in African Grey parrots it varied between 38 and 67% (Flammer et al. 2008), 
and was 67% in mice, 66% in rats, 60% in rabbits, 45% in guinea pigs and 51% in dogs 
(Roffey et al. 2003). Unbound drug concentration in the plasma is shown to have a better 
correlation with clinical outcome than total concentration, however unbound drug 
concentration is rarely measured (Theuretzbacher et al. 2006). 
 
Half-life 
Elimination half-life of voriconazole in humans is approximately six hours, however due 
to the drug’s non-linear pharmacokinetics this is dose-dependent (Theuretzbacher et al. 
2006, Flammer et al. 2008). In racing pigeons dosed at 10 mg/kg using crushed tablets 
suspended in water the elimination half-life was ten hours (Beernaert et al. 2009), 
however in chickens dosed using the same method and dose rate, half-life was less than 
two hours (Burhenne et al. 2008, Beernaert et al. 2009). The racing pigeons were fasted 
and the chickens were not; this would be expected to cause variation in drug absorption 
and time to maximal concentration, but not in drug metabolism and elimination. In 
horses, voriconazole half-life after a 10 mg/kg oral dose was 7.8-12.9 hours (Colitz et al 
2007). It is likely that significant species differences in metabolism, possibly in CYP2C19 
enzymes levels, are the cause of such different half-lives. In African Grey parrots the 
half-life of voriconazole was 1.1 hours at 6 mg/kg, and 1.6 hours at 12 mg/kg, again 
demonstrating that pharmacokinetics of voriconazole change with dose rate, making 
102 
 
extrapolation of pharmacokinetic parameters difficult or impossible at different 
dosages, even within the same species (Flammer et al. 2008, Roffey et al. 2003). 
 
Time to maximal plasma concentration 
The time to peak plasma concentration (Tmax) is influenced by bioavailability, rate of 
absorption and sometimes dosage of the drug. In humans, voriconazole’s Tmax was less 
than two hours following oral dosing (Theuretzbacher et al. 2006). In Amazon parrots it 
was one hour at 12 mg/kg and two hours at 24 mg/kg voriconazole (Sanchez-Migallon 
Guzman et al. 2010), in racing pigeons it was just over two hours at 10 mg/kg 
voriconazole (Beernaert et al. 2009), and in African Grey parrots it was two and four 
hours for 6 and 12 mg/kg respectively (Flammer et al. 2008). Voriconazole Tmax varies 
greatly between mammal species and is reported as two hours in mice (10 mg/kg), six 
hours in male rats (30 mg/kg), one hour in female rats (30 mg/kg), one hour in rabbits 
(10 mg/kg), eight hours in guinea pigs (10 mg/kg), 7.8-12.9 hours in horses (10 mg/kg) 
and three hours in dogs (6 mg/kg), where the numbers in parentheses indicate the oral 
dosages administered (Roffey et al. 2003, Colitz et al. 2007). Tmax is important in 
determining the number of time points used in sampling, as it may affect calculation of 
half-life and determination of dosing interval for multiple dose studies. 
 
The two studies conducted in reptiles by Hellebuyck et al. (2010) and Van 
Waeyenberghe et al. (2010) did not measure voriconazole Tmax. Van Waeyenberghe et 
al. (2010) assumed it to be two hours, presumably extrapolated from the human Tmax, 
and Hellebuyck et al. (2010) assumed a Tmax of three hours. Given the observed species 
differences in other studies it is possible that samples taken at these times do not 
represent the true maximal drug concentrations of voriconazole. These measurements 
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may have led to incorrect calculation of other pharmacokinetic parameters; however 
the two studies in question described treatment of clinical cases and did not include the 
calculation of other values such as half-life and area under the curve. 
 
Maximal drug concentrations in humans were 83% higher in young females than young 
males, however no dosage adjustment is currently recommended to compensate for 
this (Theuretzbacher et al. 2006).  
 
Volume of distribution 
The volume of distribution of voriconazole in humans is high, at 2.0-4.6L/kg 
(Theuretzbacher et al. 2006). In chickens this was lower at 1.68L/kg (Burhenne et al. 
2008), and in horses was 1.6L/kg (Colitz et al. 2007). The lower tissue distribution of 
voriconazole in chickens would contribute to the shorter half-life observed in this 
species 
 
1.5.6 Adverse effects 
 
Approximately 30% of humans experience transient visual disturbances such as 
hallucinations during voriconazole therapy that resolve with cessation of treatment. 
Other side effects include liver function test abnormalities (13%) and dermatological 
reactions such as rashes and photosensitivity (6%) (Theuretzbacher et al. 2006). Some 
studies suggest that visual adverse events and elevations in aspartate aminotransferase 
(AST), alkaline phosphatase (ALP) and bilirubin (but not alanine aminotransferase (ALT)) 
are more likely to occur with higher plasma voriconazole concentrations, but there is no 
statistically significant association between voriconazole trough concentrations and 
hepatotoxicity (Pascual et al. 2008, Tan et al. 2006). Trough plasma voriconazole 
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concentrations above 5.5 mg/L were associated with toxic encephalopathy in 31% of 
patients, and trough concentrations above 8 mg/L had an estimated 90% probability of 
resulting in neurotoxicity (Pascual et al. 2008). Co-medication with omeprazole, which 
is metabolised by the same hepatic enzymes as voriconazole, resulted in higher drug 
concentrations and increased probability of neurotoxicity (Pascual et al. 2008, Shirasaka 
et al. 2013). Symptoms of toxicity resolved with cessation of voriconazole treatment.  
 
In racing pigeons, 20 mg/kg of crushed and suspended tablets administered twice daily 
caused clinically relevant hepatotoxicity, as evidenced by behavioural indicators of 
illness, increased serum AST activity and histological changes including hepatocellular 
vacuolisation, and portal heterophilic and lymphocytic infiltration. Pigeons in this study 
had voriconazole plasma concentrations ranging from 5.85 (± 3.12) to 15.88 (± 7.99) 
mg/L throughout the study (Beernaert et al. 2009). There were no adverse effects 
reported in chickens administered 10 mg/kg of voriconazole suspension of crushed 
tablets once daily (Burhenne et al. 2008), however low oral bioavailability and low 
plasma concentrations were reported in this study. It is possible the same dose rate in 
other animals under fasting conditions or with different capacities to metabolise 
voriconazole could potentially result in higher plasma concentrations that may cause 
side effects. It is also difficult to assess visual disturbances in animals, so it is possible 
side effects may be occurring but are unrecognised. In a retrospective study of 
voriconazole toxicity in multiple penguin species, clinical signs of toxicity included 
anorexia, lethargy, ataxia, paresis, apparent vision changes, seizure-like activity and 
generalised seizures (Hyatt et al. 2015). All penguins showing signs of toxicity had trough 
plasma voriconazole concentrations above 5.5 mg/L, and those with plasma 
concentrations above 30 mg/L had moderate to severe neurological signs. There was no 
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evidence of voriconazole-induced hepatotoxicity in any of the penguins in this study 
(Hyatt et al. 2015). 
 
A study by Van Waeyenberghe et al. (2010) in bearded dragons administered 10 mg/kg 
of voriconazole orally every 24 hours showed significant elevations in serum AST activity 
in three out of seven animals. This was thought to be an indication of liver damage; 
however it was not determined if this was caused by fungal invasion into the liver or by 
voriconazole-related toxicity (Van Waeyenberghe et al. 2010). The study did not 
measure creatine kinase (CK), and it is also possible for muscle damage to cause 
elevations in AST. One animal in this study died during voriconazole treatment with 
fungal hyphae found in the liver and lungs, and again it was not clear on histopathology 
if the mortality was caused by drug hepatotoxicity or consequences of fungal invasion 
(L. Van Waeyenberghe 2014, pers. comm.). 
 
Due to the nonlinearity and high inter-individual variability in voriconazole metabolism, 
it is recommended that both single and multiple dose studies be conducted for each 
species in question when designing a treatment protocol (Beernaert et al. 2009), 
however this is rarely practical in zoo medicine. 
 




The discovery of fungal dermatitis in Auckland Zoo’s tuatara has halted plans to release 
some of these animals back into the wild, and threatens the health of these tuatara. The 
basis for this study was the findings of a Disease Risk Analysis (DRA) for P. australasiensis 
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in Auckland Zoo’s tuatara, which recommended a risk management strategy of treating 
all tuatara with an antifungal for a minimum of six weeks within a quarantine setting 
prior to transfer to another site (Auckland Zoo 2013, unpublished). In addition, it was 
recommended if there was no significant difference in antifungal pharmacokinetics at 
different temperatures, it would be preferable from a logistical, husbandry and welfare 
perspective for the animals to be treated in their normal enclosures at ambient 
temperatures. 
 
Prior to initiating pharmacokinetic studies, it is critical to determine what dose of 
medication is required in vitro to inhibit growth of the target organism. This allows 
determination of a target concentration for in vivo pharmacokinetic studies. 
Characterising fungal growth at different temperatures provides information that may 
be used in the medical and husbandry management of affected animals. 
 
While treatment of tuatara with oral itraconazole has been clinically successful, there 
are no pharmacokinetic studies to support the dose rates and intervals used. Tuatara 
inhabit cold climates unsuitable for most reptiles, and consequently have very low 
metabolic rates. This low metabolic rate can be expected to affect drug 
pharmacokinetics, potentially necessitating the use of different drug dosing protocols 
than those designed for other reptile species. Several studies in other reptiles have 
shown that ambient temperature may affect drug pharmacokinetics (Hodge 1978, 
Mader et al. 1985), however this has not been evaluated using antifungals. There have 
been few studies on the effectiveness and dosages required for use of antifungals in 
reptiles, with treatment recommendations often based on data from mammals or birds. 
Voriconazole is only just starting to be used in veterinary medicine, and it will be useful 
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to determine if it is an effective and safer alternative to itraconazole for antifungal 
treatment in reptiles. This study will also provide evidence of in vitro efficacy of 
itraconazole and voriconazole against P. australasiensis. 
 
Establishing a safe, effective treatment protocol for P. australasiensis infections is 
critical to the future management of captive tuatara held by Auckland Zoo. The results 
of this study have broader application to the treatment of reptiles with antifungals 
within the range of their POTZ, and add to the growing body of knowledge on CANV 
complex-associated infections. There have been few published antifungal 
pharmacokinetic studies in reptiles. This study will provide evidence of in vitro efficacy 
of itraconazole and voriconazole against P. australasiensis, and facilitate the 
development of evidence-based treatment protocols which may be able to be applied 
to other cold-adapted reptiles. Establishing an effective treatment protocol using 
voriconazole is of particular benefit, as voriconazole shows potential to be a safer 
alternative to itraconazole in the treatment of mycoses in reptiles. 
 
1.6.2 Study aims 
 
The aims of this study are: 
• To characterise the in vitro growth of P. australasiensis at different 
temperatures. 
• To determine the MICs of itraconazole and voriconazole for P. australasiensis 
isolates sourced from Auckland Zoo’s animals.  
• To determine single and multiple dose pharmacokinetics of itraconazole and 
voriconazole in tuatara at the high and low end of the POTZ of tuatara.  
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• To develop appropriate dosing regimens for itraconazole and voriconazole for 
the treatment of P. australasiensis in tuatara.  
• To establish haematological and biochemical reference ranges for captive 
tuatara, as a basis for monitoring and evaluating the health of these animals 
throughout the study and into the future. 
 
This study is novel and addresses an issue of significant practical relevance to captive 
wildlife institutions in New Zealand.  It also has broader application to the captive 
management of reptiles and the growing concern regarding emerging fungal disease in 











2. Chapter 2: General methods  
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2.1 Overview of study design 
 
The first step in this study was to determine optimal fungal growth temperatures and 
Mean Inhibitory Concentrations (MICs) of itraconazole and voriconazole for P. 
australasiensis. Following this, a pharmacokinetic study was conducted to investigate 
single dose pharmacokinetics of itraconazole and voriconazole in healthy tuatara at 12oC 
and 20oC, reflecting the lower and upper limits of the tuatara’s Preferred Optimal 
Temperature Zone (POTZ). Healthy animals were divided into itraconazole and 
voriconazole treatment groups, and these did not change throughout the study. Health 
screening of the tuatara, including haematology, biochemistry, radiographs and physical 
examination, was performed prior to the commencement of the single dose studies. The 
itraconazole group completed the single dose study at 12oC and then at 20oC, while the 
voriconazole group completed the study at 20oC and then at 12oC. This meant that each 
animal served as its own control, in a crossover study design. There was a five-week 
washout period between studies at the two temperatures. Blood samples were taken at 
predetermined intervals following the drug administration to determine antifungal 
concentrations, and characterise individual pharmacokinetic profiles for each drug. 
Following this, pharmacokinetic modelling was performed to estimate pharmacokinetic 
parameters and simulations were undertaken to explore appropriate dose regimen 
(dose rate and dosing intervals) for multiple dose studies. 
 
Multiple dose studies were each planned to be conducted over an eight week period, 
with six weeks of medication administration and two weeks to measure drug 
elimination. The clinical study used a fixed sequence design with the investigation at 
12oC first, and after a fifteen-week washout period, repeated at 20oC. Blood samples 
were collected at predetermined intervals to determine antifungal concentrations, and 
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pharmacokinetic modelling was used to analyse the data. This led to alterations in the 
dosing regimens for the 20oC studies. Health screening was performed for each animal 
before each multiple dose study commenced, and regularly during the studies to 
monitor haematologic and biochemical values. These health screening data were used 
to develop haematologic and plasma biochemical reference ranges for tuatara (see 
Chapter 6). 
 
2.2 Permits and ethics approval 
 
This research was conducted with approval from Murdoch University’s Animal Ethics 
Committee (permit RW2627/14). Ethics approval was also granted by Auckland Zoo’s 
Animal Ethics Committee. A Wildlife Act Authority application to use tuatara in research 
was granted from New Zealand’s Department of Conservation (permit 38610-FAU), in 
consultation with iwi. 
 
2.3 Animal selection and health screening 
 
2.3.1 Animal selection and grouping 
 
Healthy tuatara used in the study were adults (>20 years of age), with a minimum weight 
of 400 g. Ages ranged from 21 years to unknown-aged adult, as many were adults when 
acquired from wild populations up to 25 years ago. At the time of this study Auckland 
Zoo held 12 adult tuatara: 4 males and 8 females above 400 g. Three of these animals 
(one male and two females) were unavailable for the single dose study as they were in 
a display enclosure in the zoo, while the remaining nine were housed off-show. All nine 
of these animals underwent health screening, though only eight animals were required 
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for this part of the study. Health screens comprised a physical exam, dorso-vental 
radiograph, and haematological and biochemical testing. All health screening results 
were within normal limits for this species (see Section 2.3.2 and Chapter 6), but, to retain 
equal sex ratios for each group, only two of the three males were used for this study. 
The heaviest male was excluded, as the other two males were of similar body weight, 
making the groups roughly equal in terms of weight distribution. The eight selected 
tuatara were divided into two treatment groups: an itraconazole and a voriconazole 
group, which remained unchanged throughout the study. Each group comprised one 
male and three females, of comparable size and age.  
 
For the multiple dose studies, all twelve tuatara participated. The four animals that did 
not participate in the single dose studies were allocated to the itraconazole or 
voriconazole groups in a way that maintained similar age, sex and weight ratios, so that 
there were four females and two males in each group. Several animals were unknown-
aged adults, and these animals have their ages listed as a ‘greater than’ value. 
Population demographics and drug allocation for the study population are displayed in 
Table 2.1. 
 
There was a four month washout period between multiple dose studies to ensure all 
previously administered drugs had been eliminated and to allow tuatara time to recover 
from any physiologic changes related to the study, including blood sampling. One month 
before commencement of the second multiple dose study, blood samples were taken to 
confirm the absence of antifungal drug concentrations, including itraconazole’s active 
metabolite hydroxy-itraconazole (OH-itraconazole), in the plasma of all tuatara. No 
tuatara had detectable antifungal concentrations. 
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Table 2.1 Population demographics for tuatara studies. Weight and age was at the time 
of animal allocation, one month prior to the first single dose studies commencing. Minor 
weight changes occurred throughout the study. 
Animal ID Medication group Sex Age (years) Weight (kg) 
101 Itraconazole F 20 0.486 
104 Itraconazole M >44 0.789 
105 Itraconazole F >43 0.472 
107 Itraconazole F >44 0.542 
109 Itraconazole F 22 0.489 
112 Itraconazole M >44 1.030 
202 Voriconazole F 20 0.479 
203 Voriconazole M >44 0.952 
206 Voriconazole F >44 0.517 
208 Voriconazole F >44 0.556 
210 Voriconazole M 22 0.912 
211 Voriconazole F 22 0.432 
 
 
2.3.2 Health screening 
 
All samples were stored refrigerated at 4oC and analysed within 2 hours of collection. 
 
Haematology 
Blood was collected from the caudal vein for measurement of haematologic and 
biochemical values. Blood was collected into lithium heparin tubes, and fresh blood 
smears were prepared using the wedge technique. Haematology was performed by a 
single technician at a commercial laboratory (New Zealand Veterinary Pathology, 
Auckland, NZ), and reported values for haematocrit, haemoglobin, mean corpuscular 
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haemoglobin concentration, white blood cell count, fibrinogen, and a white blood cell 
differential count. White blood cell numbers were determined using the chamber count 
method, except when there was insufficient blood volume, in which case an estimate 
based on blood smear examination was reported. Haemoglobin (Hb) was measured 
using an automated optical method (HemoCue Hb 201+, Radiometer Pacific, NZ). Packed 
cell volume (PCV) was measured by loading capillary tubes with whole blood and 
centrifuging them at 10,000RPM for 5 minutes, then reading the results from a standard 
chart. Mean corpuscular haemoglobin concentration (MCHC) was determined using the 
equation MCHC = Hb/PCV. Fibrinogen was determined using the heat precipitation 
method (Millar et al. 1971).  
 
Total white blood cell counts were performed manually, using a haemocytometer and 
1% ammonium oxalate solution (Samour 2000). Smears for estimated white cell counts 
and differential counts were stained using Romanowsky stains (Leishman’s and May 
Grunwald stains, Amber Scientific, Australia), and read using published methods (Dacie 
and Lewis 1995, Samour 2000). For some samples, insufficient blood was available for a 
white cell count using the haemocytometer, and an estimated count from a smear was 
performed (see Chapter 7 for haemocytometer and estimated white cell count 
comparisons). All haematology at NZVP was read and reported by the same operator 
throughout the study. 
 
Results were evaluated using reference intervals compiled from several sources, 
including previous testing of healthy zoo animals, and unpublished data from healthy 
wild tuatara from the Department of Conservation (Jakob-Hoff 1996, Boardman & 
Blanchard 2006, Gartrell et al 2006). All animals were determined to have blood values 
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within the reference ranges and less than three standard deviations from the mean, so 
on this basis and the absence of clinical signs of disease were considered clinically 
normal and suitable for participation in the study. The same haematology and 
biochemistry testing was repeated 4-6 weeks prior to each phase of drug administration, 
to allow for regeneration of any lost blood volume. 
 
Biochemistry 
Whole blood (0.1 ml) was used to conduct biochemical assays using the Avian/Reptilian 
Profile Plus rotors in the Abaxis Vetscan classic chemistry analyser (Abaxis, USA). 100µL 
of lithium heparin-preserved whole blood was pipetted into the rotor, and samples were 
run immediately. The following parameters were measured for each animal: aspartate 
aminotransferase (AST), bile acids (BA), creatine kinase (CK), uric acid (UA), glucose 
(Glu), calcium (Ca2+), phosphorous (Phos), total plasma protein (TP), albumin (Alb), 




A dorso-ventral radiograph was taken of each animal while conscious prior to entry into 
the study using a DR digital radiography system (Sound-Eklin, USA). This allowed 
evaluation of bone density, organ size, and whether the females were gravid. On 
radiographs it was possible to detect the presence of large developing ovarian follicles 
or calcified eggs in a gravid animal, depending on the time of year. All animals had 






Physical examination and faecal screening 
Each animal was given a thorough physical examination, including oral exam, 
ophthalmologic exam, coelomic auscultation, and visual examination of the whole body 
and cloaca. Several animals had regenerated tails or scarring from injuries sustained 
over ten years prior to this study. Physical examination findings were considered normal 
in all animals. There was no evidence of ocular, nasal, oral or aural discharge. Heart rate 
and respiratory rate and quality were normal, swelling of the coelom was not palpated, 
and cloacal appearance was normal. There were no skin lesions, and demeanour and 
locomotion were assessed as normal. Routine faecal examinations using ZnSO4 
floatation were conducted twice yearly for the previous 5 years, and did not detect any 
faecal parasites. 
 
2.4 Animal housing and care during study 
 
2.4.1 Enclosure design and environmental maintenance 
 
Enclosure design 
Animals were housed individually during the study. Tuatara are territorial and do not 
cohabit in small spaces, so individual housing eliminated the possibility of fighting and 
unequal food or environmental access. Study enclosures were constructed of untreated 
pine plywood, and had internal dimensions of 1500 x 800mm, with a height of 600mm. 
Enclosure floors were lined with corrugated cardboard to provide an easily maintained 
surface that provided adequate grip for the animals. Substrate such as mulch was not 




Animals were provided with a shallow plastic water dish of 300mm diameter, in which 
they could bathe and pass urates and faeces. This was cleaned and replaced when 
necessary, at a minimum once weekly. Each tuatara was provided with a hide tunnel 
constructed of double-walled corrugated high density polyethylene culvert pipe of 
225mm diameter, cut into semicylindrical lengths of 600mm (Figure 2.1). Flaps of plastic 
cut from black garbage bags were taped at one end to provide an entry and exit point 
while maintaining darkness, the other end was positioned against a wall of the 




Studies were conducted at 12oC and 20oC.  Reverse-cycle air conditioning units were 
used to maintain temperature, and dataloggers (Thermochron iButtons, Maxim, USA) 
were placed at two points in each room to ensure temperatures remained within an 
acceptable range. These were set to record temperatures every 30 minutes throughout 
the study period. Temperatures in the 12oC room ranged from 10.5-13.0oC, and in the 
20oC room from 19.5-21oC. A thermal imaging camera (Trotec IC080LV infrared camera) 




Photoperiod was maintained at 12 hours by use of an automatic timer. The same 
photoperiod was applied in all parts of the study to minimise variation in metabolic rate 
associated with season or circadian rhythms. Ultraviolet (UV) lighting was provided using 
two 39-watt tubes (Reptisun T5 High Output 10.0 UVB lamp, ZooMed, USA) above each 
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enclosure. These were positioned at one end of the enclosure 600mm above the floor, 
and set to come on for two three-hour intervals each day. Temperature below the lights 
was monitored using dataloggers to ensure it was not significantly different from the 
desired study temperature.  
 









Animals had an acclimatisation period of one week in the study environment prior to 
experiments beginning. Tuatara have been shown to reflect their environmental 
temperature 15 minutes after moving into a new environment (Wells et al. 1990), and 
other temperature-related pharmacokinetic studies in reptiles have used an 
acclimatisation period of one week (Caligiuri et al. 1990, Johnson et al. 1997) and one 
month (Mader et al. 1985). The acclimatisation process was designed to ensure tuatara 
adapted to the experimental environment, and that their internal temperature and 
metabolic rate had stabilised at the new ambient temperature. Cloacal temperature was 
measured using a digital thermometer the day prior to medication administration, and 
was found to reflect that of the environment. 
 
2.4.2 Diet  
 
Animals were fed their usual diet, which is 2-3 locusts (Locusta migratoria) or 3-4 field 
crickets (Gryllus bimaculatus) per feed, dusted with a calcium powder (Calcium Plus, 
Repashy Superfoods, UK). This was supplemented with kawakawa (Macropiper 
excselsum) berries, when in season. Animals held at 20oC were fed twice weekly, and 
animals at 12oC were fed once every two weeks based on recommendations from 








2.5 Blood sampling and medication administration 
 
2.5.1 Sampling method 
 
Restraint 
For blood collection, tuatara had a head bandage applied prior to sample collection 
(Figure 2.3). Head bandaging involves placing two cotton wool balls over the eyes and 
securing them with a moderately tight elastic bandage (Vetrap, 3M, USA). This produces 
a vaso-vagal response which lowers heart rate and blood pressure, producing a 'trance-
like' state (Hernandez-Divers 2006). This reduces animal movement and stress during 
minor procedures such as blood sampling. The tuatara was initially restrained 
horizontally, with one hand behind the angle of the jaw and the other over the lumbar 
area, restricting movement to reduce the risk of the animal moving and injuring itself or 
the handler. The animal was then moved into an upright position, with the head towards 
the ceiling, tail towards the floor and the ventrum pointed towards the operator 
collecting blood. Following sampling, the head bandage was removed and the animal 
returned to its enclosure. 
 
Volume 
A volume of 0.2 mL of blood was required for antifungal testing per sample, to provide 
an adequate plasma volume for repeat testing if required. An additional 0.2 mL of blood 
was required for health screening at set intervals during the study. The total blood 
volume required was 1.2 mL per animal over a period of two days for single dose studies, 
and 3.4 mL over a period of up to eight weeks for multiple dose studies. This is less than 
the recommended 1% of body weight that can be taken from a healthy reptile on a single 
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occasion (Douglas Mader, pers comm January 2014), which would equate to 4 mL in a 
400 g animal. 
 
Figure 2.3 Tuatara restrained in horizontal recumbency with head bandage applied. 
 
      
Location and technique 
Blood was taken from the ventral coccygeal vein, approximately 20-30% of the way 
down the tail. Tuatara do not possess hemipenes (Boardman and Blanchard 2006), so 
there was no need to sample more distally to avoid these, as would be necessary in 
lizards. Jugular and cephalic venepuncture sites were investigated on a deceased 
specimen, and these were found not to be practical options. Placing of a jugular catheter 
to allow repeat atraumatic sampling would require general anaesthesia, which could 
alter the metabolism of the animal and potentially influence the pharmacokinetics of 
the antifungal agents. It was also considered that placement of a jugular catheter would 
be awkward due to the tuatara’s head and neck conformation, and the cranial position 
of the heart in the thoracic cavity. Use of an indwelling catheter would also necessitate 
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the removal of additional blood volumes, to ensure circulating venous blood was being 
sampled, rather than blood or saline sitting in the catheter. The ventral coccygeal vein 
is the standard site used by researchers and clinicians for obtaining blood samples from 
tuatara (Boardman and Blanchard 2006) and was selected as the most appropriate for 
this study. 
 
The ventral coccygeal vein is not visible superficially and is located using anatomical 
landmarks. The animal was restrained as described above, and the skin overlying the 
venepuncture site prepared with an alcohol swab. A 25 gauge 1.5” needle (BD 
PrecisionGlide Needle 0.5 x 38 mm, BD, Singapore) attached to a 1 mL syringe (BD 1 mL 
tuberculin syringe, BD, Singapore) was inserted on a 45-degree angle between scales on 
the ventral midline of the tail. Blood was most reliably obtained just before the needle 
hit the ventral surface of the coccygeal vertebrae though, at times, repositioning was 
required. No lymph contamination was observed. No more than three attempts to draw 
blood were made, after which the animal was returned to its enclosure even if a sample 
was not obtained.  
 
Blood for antifungal plasma concentration measurement was immediately transferred 
into a small potassium EDTA tube (K2EDTA Microtainer, Beckton, Dickson and Company, 
USA), and inverted several times to ensure adequate mixing. Use of serum tubes was 
investigated, but this resulted in loss of a significant amount of plasma in the clot, so use 
of tubes containing an anticoagulant were preferred. Potassium EDTA was requested by 
the testing laboratory in preference to lithium heparin due to their familiarity with the 
product. In blood collection for health screening, blood was dispensed into lithium 
heparin gel tubes (Lithium heparin and plasma separator Microtainer, BD, USA), as this 
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was the preferred anticoagulant for haematologic and biochemical analysis in reptiles 
(Mader 1999). 
 
2.5.2 Sample processing, storage and transport 
 
Samples for plasma drug concentration 
Following blood collection, samples were centrifuged for 10 minutes at approximately 
1200 g in a LW Scientific ZipSpin (LW Scientific, USA). Plasma was then harvested using 
a 100 µL pipette (Piccolo 100 µL Minipette, Abaxis, USA) and transferred to plastic 0.5 
mL tubes (Free Standing Screw Tubes 0.5 mL, Scientific Specialties Inc, USA), labelled 
and frozen at -20oC until transport. Samples were couriered in batches on ice to 
Canterbury Health Laboratories (CHL) for analysis, and were confirmed as frozen when 
they arrived. Following receipt, samples were kept frozen by the laboratory at -80oC 
prior to analysis. 
 
2.5.3 Medication administration 
 
Medication was administered using a 0.3 mL insulin syringe (BD 0.3 mL Ultra-Fine Insulin 
syringe, Beckton, Dickinson and Company, USA) with the needle and hub removed. This 
allowed for more accurate dosing than using a 1 mL syringe. The animal was held 
horizontally on a flat surface by a handler, and the jaws opened using a wooden tongue 
depressor or the syringe itself. Medication was administered into the caudal oral cavity, 
the animal was then returned to its study enclosure and observed for 5 minutes 





2.6 Itraconazole and voriconazole drug assays 
 
2.6.1 Liquid Chromatography Mass Spectrometry-Mass Spectrometry assays 
 
Antifungal drug concentrations were measured using aLiquid Chromatography Mass 
Spectrometry-Mass Spectrometry (LCMS/MS) assay. This is a combination of two 
laboratory techniques: High Performance Liquid Chromatography (HPLC) and tandem 
Mass Spectrometry (MS/MS). HPLC separates different compounds within a mixture 
based on their chemical and physical properties such as size, charge and affinity to other 
molecules. The mixture is known as the mobile phase, and the mobile phase travels 
through the stationary phase, or column, where analytes are separated. The mobile 
phase then enters the mass spectrometer. 
The mass spectrometer conditions and settings were previously optimised for the 
compounds of interest and precursor-to-product ion transitions were selected. Data 
acquisition was performed via selected reaction monitoring (SRM).   
 
Analytes then interact with the electrospray ioniser in the mass spectrometer (Q0), 
which uses a nebulising gas (usually nitrogen) to create a fine mist of molecules, which 
are then exposed to an electrical field that ionises them. These ions then enter the first 
quadrupole (Q1), where the ions of interest are allowed to pass through using selective 
electron fields. The selected ions from Q1 are then passed through the second 
quadrupole (Q2), where they are fragmented. Selected fragments then pass through the 
third quadrupole (Q3) and are detected at the Channel Electron Multiplier (CEM). This 





Quantitation of analytes was done using peak area ratios and assessing these against 
calibration curves of known standard concentrations.  
 
2.6.2 Drug assay procedure 
 
Plasma (30 µL) was mixed with deuterated internal standards of 98-99.4% purity 
(Toronto Research Chemicals Inc, Canada) in acetonitrile (30 µL) to precipitate protein. 
After centrifugation, the supernatant was diluted and injected onto the reverse-phase 
HPLC system. Antifungals and internal standard were detected by LCMS/MS and 
quantitated. The process for preparing samples and standards, and the drug assay 
procedure, are detailed in Appendix 3.  
 
Samples were prepared and analysed as duplicates, and the mean of these duplicates 
provided the final result for each sample. All duplicate samples were within 20% of each 
other, or were re-run until this acceptable level of agreement was achieved. 
 
2.6.3 LCMS/MS conditions 
 
This assay used a 3200 QTRAP LC/MS/MS system, with hybrid triple quadrupole/ion trap 
capabilities. The column used was a Kinetex XB-C18 100A reverse-phase silica-based 
column (50 x 2.1 mm) and particle size of 2.6 µm. LCMS/MS conditions are displayed in 





Table 2.2 Retention time of analytes (minutes). Q1 = precursor ion mass (analyte mass 
+ 1) of antifungal being measured. Q3 = product ion mass of the two most common 
fragments of the antifungal being measured. 



















































Table 2.3 Solvent gradient for LCMS/MS. 
Time (min) Flow rate (µL/min) % eluent A % eluent B 
0 600 95 5 
1.0 600 95 5 
2.0 600 90 10 
3.0 600 10 90 
5.0 600 10 90 
7.0 600 95 5 





2.6.4 Development of calibration curves 
 
Standards of voriconazole, itraconazole and hydroxy-itraconazole were prepared as 
described in Appendix 3. Calibration curves were produced by using standards over the 
concentration range 0-10 mg/L in drug-free tuatara plasma. Results were plotted 
graphically, and a line of best fit calculated for the results, plotting analyte concentration 
against analyte peak area ratios. The equation of this line was then used in determining 
antifungal concentrations.   
 
2.6.5 Assay validation: precision, accuracy and matrix effects 
 
Inter- and intra-run precision was estimated at three concentrations. For the inter-run 
statistics, measurements were conducted on a six point calibration, over two weeks, 
with a total of six replicates at each concentration. The intra-run statistics were 
calculated from six replicates at each concentration on a single day. The inter- and intra-
run statistics are recorded in Appendix 4. 
 
The following results were produced by the assay validation process: 
Carryover: This was determined by three consecutive injections of the top standard 
followed by three blank injections. There was no detectable carryover. 
Limit of detection: This is the concentration where the signal to noise ratio is <3:1 
Limit of quantitation: This is the concentration where the signal to noise ratio is <10:1 
Linearity: the method is linear to 10 mg/L 
Matrix effects: Matrix effects for all four analytes had a % CV <10. European Medicines 




Recovery: Recovery of hydroxy-itraconazole was 100%. Voriconazole (101%) and 
itraconazole (103%) appear to have enhanced recovery in plasma, due to their reduced 
solubility in aqueous media. All standards and QC samples were prepared in drug free 
human plasma to eliminate this effect. Recovery was calculated at 3 concentrations, 
using the methods described in Bansal and DeStefano (2007). 
 
2.6.6 Tuatara plasma matrix effects 
 
The antifungal standards prepared in plasma were, by necessity, prepared using human 
drug-free plasma (DFP). It was not possible to collect sufficient drug-free plasma from 
tuatara for the purposes of this research, but enough was available to test for matrix 
effects, and ensure human DFP was comparable to tuatara DFP for the experimental 
conditions and analytical method. A chromatogram of drug-free tuatara plasma, and a 
chromatogram of tuatara plasma plus all four deuterated internal standards, did not 
show any peaks in the tuatara plasma that would interfere with drug assays (Appendix 
5).  
 
2.7 Non-compartmental pharmacokinetic analysis 
 
Definitions and equations were derived from Concepts in Clinical Pharmacokinetics 4th Edition 
(DiPiro et al. 2005) 
 
Elimination rate constant and half-life of antifungal drugs 
The terminal elimination rate constant (kel) describes the rate of elimination of the drug 
from the body. It was determined by calculating the slope of elimination from 
sequentially decreasing drug concentrations in the body. The points to be included in 
the equation are those drug concentrations in the terminal portion of the log-
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concentration-time curve, or those after the peak concentration has occurred, and 
where there is a consistent decline in concentration. Determining which data pairs are 
suitable for inclusion is aided by plotting the points on a natural log graph and observing 
the slope to ensure the overall trend is one of declining drug concentrations. The 
terminal elimination rate constant is used in calculating elimination half-life and volume 
of distribution. 
 
The terminal elimination rate constant was calculated using the SLOPE function in 
Microsoft Excel, and expressed in h-1. 
 
The half-life (t½) of a drug is the amount of time it takes for the concentration of the drug 
in the body to halve during the elimination phase. It is expressed in hours, and calculated 
using the formula: 
t½ = ln(2)/kel 
 
Area under the curve 
Area under the concentration-time curve (AUC) is the area under the plot of drug 
concentration against time, and represents total exposure to the drug over time. It is 
calculated using the trapezoidal rule to the last point that drug concentration was 
measured (AUC0-t) and extrapolated to give AUC to infinity (AUC0-∞) using the following 
equation, and is expressed in mg/L*h:  
AUC0-∞ = AUC0-t + (Clast/kel) 







Clearance (CL) is the volume of plasma which is completely cleared of drug per unit time. 
Clearance is typically hepatic metabolism or excretion, renal excretion, or a combination 
of these pathways. Clearance is most accurately calculated after an intravenous dose; 
after an oral dose and without knowledge of the oral bioavailability data it is termed 
“apparent clearance” (CL/F). Apparent clearance is generally reported L/h/kg, and 
calculated using the equation: 
CL/F = (dose (mg)/AUC0-∞ (mg/L*h)) / weight (kg)  
 
Volume of distribution 
Volume of distribution (V) is the theoretical volume of plasma that would be necessary 
to account for the total amount of drug in an animal’s body, if that drug was present 
throughout the body at the same concentration as found in the plasma. Volume of 
distribution is most accurately calculated after an intravenous dose; after an oral dose 
this is termed “apparent volume of distribution” (V/F). It is usually expressed in L/kg, 
and is calculated using the equation: 
V/F = (CL/kel) / weight (kg) 
 
Loading dose 
Where appropriate, use of a loading dose shortens the time taken for a drug to reach 
the target plasma concentration. The loading dose is expressed in mg, and is calculated 
using the equation: 





Coefficient of variation 
The coefficient of variation (CV) is a measure of the ratio of the standard deviation to 
the mean. It provides a measure of the variability within a dataset. In pharmacokinetics 
it is often expressed as a percentage, and is calculated using the following equation: 
CV = (standard deviation / mean) * 100 
 
Statistical analysis of pharmacokinetic variation with temperature 
Statistical analysis to compare pharmacokinetic parameters was conducted using the 
paired t-test in GraphPad Prism version 6.07 (GraphPad Software, USA). Data were 
analysed for normality using the Shapiro-Wilk normality test. Where necessary, data 
underwent log transformation to produce a Gaussian distribution, allowing the 
parametric paired t-test to be used on transformed data. Non-parametric tests such as 
the Wilcoxon matched pairs test were not suitable for use due to the small sample sizes 
in this study. Significance was assessed at a level of p<0.05. 
 
2.8 Model-based pharmacokinetic analysis 
 
Pharmacokinetic modelling enables the prediction of appropriate dosing and dosing 
intervals for administering multiple doses of a drug to a large population, based on single 
and/or multiple dose data, and a target drug concentration. Population pharmacokinetic 
modelling was conducted by Professor Nick Holford (Professor of Clinical Pharmacology, 
University of Auckland). 
 
A pharmacokinetic (PK) model assuming one compartment distribution, first-order 
elimination and first-order absorption was used to describe the time course of 
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concentrations. The model was parameterised in terms of clearance, volume of 
distribution and absorption half-life.  
 
The effect of lower temperature (12oC) compared with the reference at 20oC was 
modelled by a factor reflecting the fold decrease in Vmax or clearance at 12oC compared 
with 20oC. A mixed effects model was used to estimate population parameters assuming 
log-normal between and within subject variability of PK parameters.  
 
The same structural and random effects model was used for both antifungals, with 
different parameters estimated for each drug. Because of limited sampling and large 
between animal variability it was decided to make plausible assumptions about the 
residual error in the single dose studies rather than attempt to estimate it. Residual error 
was assumed to be a combination of 10% proportional (coefficient of variation) and 0.3 
mg/L additive (standard deviation) components. The residual error parameters were 
assumed to be the same for both drugs. 
 
Mixed effects modelling was performed using NONMEM v7.3.0 with the Intel Fortran 





The facility where MIC testing was conducted was not able to monitor overnight room 
temperature, meaning the results for this part of the experiment could not be linked 
with a set temperature. It would also have been ideal to conduct MIC testing at lower 




The plasma protein binding of the antifungal drugs in tuatara plasma was not 
investigated, as it was not possible to collect enough drug-free plasma from tuatara for 
this process. Protein binding of itraconazole is discussed in Section 1.5.5 and 
voriconazole in Section 1.6.5. Protein binding may reasonably be expected to vary with 
temperature, and these data would have provided more information to base target 
concentration and dosage recommendations on. 
 
As intravenous data on itraconazole and voriconazole in tuatara was not available, oral 
bioavailability could not be calculated. Oral bioavailability of itraconazole in other 
species is discussed in Section 1.5.3, and voriconazole in Section 1.6.3. Oral 
bioavailability data is used to more accurately calculate volume of distribution and 
clearance, so would be used in recommended dosage calculations. 
 
The small sample sizes in this study limited the utility of statistical tests. Larger sample 
sizes providing more data would allow more accurate statistical comparisons between 
datasets, however the sample sizes were limited by animal welfare concerns and the 
availability of suitable subjects. Population pharmacokinetic modelling is specifically 
designed for use in cases of limited sampling, and the results derived from modelling 
facilitate interpretation of differences when sample sizes are small.  
 
Haematology and biochemistry reference ranges for a population of healthy tuatara 
were also established in this study (Chapter 6). Reference ranges were divided based on 
sex and season where significant differences in parameter values were noted. However, 
as there were only four male tuatara in the population, sex-based differences in 















3.1.1 MIC testing of filamentous fungi 
 
Antifungal susceptibility testing is not widely used in veterinary practice, but has been a 
recognised diagnostic tool in human medicine for over 20 years (Fothergill 2012). In vitro 
susceptibility testing should (1) provide a reliable measure of the relative activities of 
two or more antifungal agents; (2) correlate with in vivo activity and predict the likely 
outcome of therapy; (3) monitor the development of resistance among a normally 
susceptible population of organisms; and (4) predict the therapeutic potential of newly 
discovered agents (Espinell-Ingroff et al. 2009). 
 
3.1.2 Clinical and Laboratory Standards Institute guidelines 
 
The Clinical and Laboratory Standards Institute (CLSI) is a collaborative organisation that 
develops and implements clinical laboratory standards for microbiological testing. The 
CLSI has published standard methods for antifungal susceptibility testing for both yeasts 
and moulds. P. australasiensis is a mould, and the relevant CLSI reference for 
determining the antifungal MIC to inhibit the growth of yeasts and moulds is document 
M38-A2 (CLSI 2008). This document details the recommended broth microdilution 
method for determining the antifungal MIC testing of moulds, which stipulates the 
concentration of fungal conidia, antifungals and other reagents to determine antifungal 
MICs. 
 
P. australasiensis and related fungi are not specifically discussed in the M38-A2 
document, and it has been stated that different assay conditions, often determined 
through trial and error, may be required to determine the antifungal MICs for unlisted 
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species of fungi (Fothergill 2012). Moulds are slow growing fungi and can be difficult to 
test using microtiter methods. This is due to dehydration of the inoculum, and that it 
may take up to 6 days before fungal growth is detected in the drug-free control well 
(Espinel-Ingroff et al. 2009, Fothergill 2012). The MIC endpoint for moulds is determined 
as the lowest concentration that prevents discernible fungal growth, seen as the first 
optically clear well (CLSI 2008). Fungal isolates are considered susceptible to the 
antifungals amphotericin B, itraconazole, voriconazole, posaconazole, and caspofungin 
when the MIC is <1.0 µg/mL, are considered to have intermediate susceptibility with an 
MIC of 2.0 µg/mL, and are considered resistant with an MIC >4.0 µg/mL (Fothergill 
2012). 
 
3.1.3 Colorimetric plates for antifungal susceptibility testing 
 
Colorimetric testing is not covered in the CLSI documents, but is a frequently-used, user-
friendly method of determining antifungal MICs. The availability of commercial plates 
means that the tester does not have to design their own plates, which can be labour and 
cost-intensive and have quality-control and replication limitations (Wanger 2012). 
Several studies have established Sensititre YeastOne (TREK Diagnostic Systems, 
Cleveland, OH) colorimetric testing to be comparable with results obtained using the 
CLSI guidelines, when comparing MICs of itraconazole and voriconazole for Aspergillus 
species moulds (Martin-Manzuelos et al. 2003, Castro et al. 2004). 
 
Sensititre YeastOne colorimetric testing uses the addition of the colour indicator Alamar 
Blue to each well (Espinell-Ingroff et al. 1999). This agent changes colour from blue to 
purple to red through an oxidation-reduction reaction. Fungal growth causes a colour 
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change, thus the first blue well indicates the minimum concentration of antifungal 
required to inhibit growth of the organism. 
 
No published accounts on the use of Sensititre plates to determine MICs of CANV 
organisms could be found, however correspondence with Dr Jean Paré (pers comm) has 
indicated that Sensititre plates can be used successfully for this purpose, with the use of 





3.2.1 Isolate recovery from affected animals 
 
Animals with lesions grossly suspicious for P. australasiensis infection underwent biopsy 
under general anaesthesia. Animals were anaesthetised with isoflurane in 100% oxygen 
via mask, or with intravenous (IV) alfaxan at 5 mg/kg via the caudal vein. When 
sufficiently sedated they were intubated and maintained on 2-4% isoflurane in 100% 
oxygen as required, using a ventilator delivering 3-6 breaths per minute. Gross debris 
was removed from skin with gentle saline flushing, but no other skin preparation was 
performed. Lesions were biopsied using a biopsy punch (3-5 mm diameter), and were 
divided in two using a sterile scalpel blade. Wounds were sutured using 3/0 absorbable 
braided suture material (Polysyn, Surgical Specialties Corp, USA). All animals received a 
single meloxicam (Metacam, Boehringer Ingelheim, Germany) injection at 0.2 mg/kg 




Half of the lesion was preserved in phosphate-buffered formaldehyde and submitted to 
a pathology service, New Zealand Veterinary Pathology, Auckland (NZVP), for 
histopathological examination. The other half of the lesion was placed in a sterile urine 
collection jar and sent at room temperature for culture at the Ministry of Primary 
Industries (MPI) laboratory.  
 
3.2.2 Culture of isolates 
 
Culture was performed by staff at the MPI’s Investigation and Diagnostic Centre, with 
methods adapted from information provided by Dr. Lynne Sigler (University of Alberta 
Microfungus collection and Herbarium, Canada). The method used is detailed in 
Appendix 1.  
 
Large populations of contaminant fungi and bacteria were associated with some skin 
samples and overgrew quickly on the Sabourauds Dextrose Agar (SDA) plates without 
antibiotics (SDA-). The SDA plates with antibiotics (SDA+) and the Mycosel plates grew 
P. australasiensis -suspicious colonies within 2 weeks, and these were then subcultured 
onto new SDA+ plates.  
 
After 7-10 days lactophenol cotton blue preparations were made, allowing microscopic 
examination of fungal morphology (Figure 3.5). At this time, fungi were subcultured 
onto a SDA slope with cycloheximide to allow them to be sent to other institutions. SDA 
slopes sent to CHL were stored in a -80oC freezer prior to use for MIC testing.  
 
Further growth studies were subsequently conducted at MPI at 12, 15, 20, 22, 30 and 
37oC on Potato Dextrose Agar (PDA) when resources became available. Photographs 
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were taken after 18 days of incubation to compare growth at these temperatures. It was 
not possible to conduct MIC testing at MPI due to staff and resource constraints. 
 
3.2.3 Preparation of inoculum 
 
Fungal samples sent to CHL were retrieved from the -80oC freezer one week prior to 
conducting MIC testing. This allowed time to subculture the isolates onto SDA slopes to 
ensure they were still viable. A total of three samples were available and suitable for 
testing. Cultures were incubated at 30oC or at room temperature (approximately 23oC), 
and this allowed assessment of growth at these temperatures. 
 
A working inoculum was prepared from each of these samples. The procedure for this is 
detailed in Appendix 2.  The process was performed in duplicate for each fungal isolate, 
so that each isolate could be incubated and undergo MIC testing at both 30oC and 23oC. 
This allowed assessment of any differences in MICs at the two temperatures. 
 
3.2.4 Sensititre plates 
 
Sensititre YeastOne YO2IVD plates contain ascending concentrations of voriconazole, 
itraconazole, 5-flucytosine, fluconazole and caspofungin. Each plate has two sets of 
these concentrations, to allow replication if desired. The plate format is illustrated below 
(Figure 3.1), where the numbers indicate concentration in mg/L. 
 
3.2.5 Reading results 
 
Results were read on the day the control well showed growth, as indicated by a colour 
change from blue to red. P. australasiensis is slow-growing, and results were read after 
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7 days for the plates incubated at 30oC, and after 13 days at 23oC. Results were read by 
the same operator for each sample and checked again one day later to ensure there 
were no further colour changes. The MIC is read as the lowest antifungal concentration 
that inhibits growth, indicated by a lack of colour change. 
 




3.3.1 Culture temperatures 
 
Subjectively, fungal growth was faster and more profuse at 30oC than at room 
temperature (Figure 3.2). Subsequent growth studies at MPI showed minimal growth at 
12oC, moderate growth at 15oC, and good growth at 20, 22 and 30oC, with absence of 




P. australasiensis cultured using this method was creamy-to-yellow, slightly powdery 
and had a noticeable strong, sweet odour (Figure 3.3). The microscopic appearance was 
as described by Sigler et al. (2013) (Figure 3.4). 
 
Figure 3.2 Growth of three P. australasiensis isolates at 23oC (left) and 30oC (right) after 
7 days at CHL on SDA+ slants.        
 
 
Figure 3.3 Growth of three P. australasiensis isolates at 12oC to 37oC after 18 days at 




Figure 3.4 Lactophenol Cotton Blue preparation of P. australasiensis, 400x magnification 
(courtesy MPI). 
   
 
3.3.2 Itraconazole MIC results 
 
Minimum Inhibitory Concentration results were read on the first day that distinct colour 
change from blue to red was detected in the control well (Table 3.1, Figure 3.5). This was 
7 days at 30oC, and 13 days at room temperature. 
 
Table 3.1 Itraconazole MIC results. 
Temperature Isolate 1 MIC 
(mg/L) 
Isolate 2 MIC 
(mg/L) 
Isolate 3 MIC 
(mg/L) 
Read time 
Room temp 0.12 0.12 0.12 Day 13 
30oC <0.03 0.12 0.06 Day 7 
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Figure 3.5 Sensititre YO2IVD plate showing MIC results for five antifungals. 
 
 
3.3.3 Voriconazole MIC results 
 
Minimum Inhibitory Concentration results were read as for itraconazole results (Section 
3.3.2) and are described below (Table 3.2).  
 
Table 3.2 Voriconazole MIC results. 
Temperature Isolate 1 MIC 
(mg/L) 
Isolate 2 MIC 
(mg/L) 
Isolate 3 MIC 
(mg/L) 
Read time 
Room temp 0.008 0.015 0.015 Day 13 
30oC <0.008 <0.008 <0.008 Day 7 
 
3.3.4 Other antifungal agent MIC results 
 
Sensititre YO2IVD plates also determine MICs for the antifungals flucytosine, fluconazole 
and caspofungin. Results are reported here to add to the body of knowledge on P. 
australasiensis, though these antifungals are not part of this pharmacokinetic study. 
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Minimum Inhibitory Concentration results were read as for itraconazole results (Section 
3.3.2) and are described below (Table 3.3).  
 










1 Room temp >32.0 32.0 2.0 13 days 
30oC >32.0 16.0 >8.0 7 days 
2 Room temp >32.0 64.0 >8.0 13 days 
30oC >32.0 16.0 >8.0 7 days 
3 Room temp 16.0 64.0 8.0 13 days 




3.4.1 General discussion 
 
There were differences in fungal growth rates at different temperatures between 
laboratories. At MPI the growth rates were the same for three isolates at 20, 22 and 
30oC, while at CHL growth was slower at room temperature (approximately 23oC) than 
at 30oC. This could be because room temperature may have dropped to below 20oC at 
night at CHL, or because different isolates were used at each laboratory, as it is possible 
that different isolates have different temperature growth profiles. It is unlikely the 
variation was due to different agars being used at each laboratory (SDA at CHL and PDA 
at MPI). CHL were not equipped to monitor overnight room temperature remotely at 




Minimum inhibitory concentrations of voriconazole and itraconazole were similar for all 
three isolates of P. australasiensis. The fact that the MIC endpoints were read almost 
one week later in the room temperature samples indicates that fungal growth was 
slower at room temperature than 30oC. The MICs did not differ significantly at different 
incubation temperatures, however it was recommended to use the MICs obtained at 
30oC, as they were faster to grow and possibly more accurate (Ros Podmore, medical 
laboratory scientist, Canterbury Health Laboratories, pers comm May 2014). These 
suggest that an MIC of 0.12 mg/L is appropriate for itraconazole, and 0.008 mg/L for 
voriconazole to inhibit P. australasiensis. 
 
Flucytosine, fluconazole and caspofungin are commonly used to treat Candida and other 
yeast infections, and are not considered as effective as itraconazole and voriconazole 
against ascomycetes (Cuenca-Estrella et al. 2006, Berger 2015). It is therefore 
unsurprising that the MICs for these antifungals were high compared to those of 
itraconazole and voriconazole. 
 
Few published studies have determined the MICs of CANV isolates, but those available 
reported similarly low MICs for itraconazole and voriconazole (Hellebuyck et al. 2010, 
van Waeyenberghe et al. 2013). A study evaluating the MICs of 32 CANV isolates 
reported a MIC50 of 0.0313 mg/L for both itraconazole and voriconazole, and an MIC90 
of 0.25 mg/L for itraconazole and 0.0625 mg/L for voriconazole. This study conducted 
MIC testing at 30oC using the CLSI guidelines published in document M38-A2 (van 
Waeyenberghe et al. 2013). These MICs were similar to our results reported above. 
 
MICs, in combination with pharmacokinetic data including protein binding and area 
under the curve, can be used to develop a target concentration for plasma antifungal 
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drugs. The data obtained here were used to assist in determine dosing rates and 
intervals for the multiple-dose pharmacokinetic studies. 
 
3.4.2 Target concentrations for multiple dose studies 
3.4.2.1 Itraconazole 
The MIC range of itraconazole for P. australasiensis was <0.03-0.12 mg/L at 30oC. 
Determining a suitable dose for multiple dose studies ideally requires data on 
itraconazole protein binding, which was not available as part of this study (see Section 
2.7.1). A target of 20 times the higher MIC for steady-state concentration was 
considered appropriate, to ensure that sufficient free drug was available for distribution 
and action at target sites. This target was arrived at after extensive consultation with 
Prof. Nick Holford, in an effort to maximise therapeutic efficacy while minimising the 
likelihood of toxicity. This results in a steady-state trough target concentration of 2.4 
mg/L for itraconazole. 
 
3.4.2.2 Voriconazole 
The MIC of voriconazole for P. australasiensis was <0.008 mg/L at 30oC. As with 
itraconazole, data on protein binding was not available, and a target of 20 times the MIC 
for steady-state concentration was considered appropriate. This results in a steady-state 




Growth of P. australasiensis varied significantly with incubation temperature, with 
maximal growth occurring between 20oC and 30oC. It is possible that different isolates 
may have different growth temperature profiles, and this could be investigated with 
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further studies. MICs of itraconazole and voriconazole for P. australasiensis were low, 
and were similar to those reported elsewhere (van Waeyenberghe et al. 2013, J. Paré 
2014 pers. comm.). It would be ideal to also conduct MIC testing at lower temperatures, 
however interpretation of an end-point may be difficult due to slow fungal growth. The 
MICs determined here provide a sound basis for estimation of plasma target 
















Itraconazole is a triazole antifungal that has a broad spectrum of antifungal activity, and 
is commonly used in the treatment of aspergillosis, candidiasis, fungal dermatitis and 
nail bed infections in humans and animals (Vantrubova et al. 2010). Itraconazole has 
been used with variable success in the treatment of fungal dermatitis in reptiles, and 
adverse effects including anorexia and fatal hepatotoxicity have been reported 
(Bowman et al. 2007, Johnson et al. 2011, Paré et al. 1997, van Waeyenberghe et al. 
2013). 
 
Itraconazole undergoes hepatic metabolism, and its main metabolite is hydroxy-
itraconazole (Heykants et al. 1989). Hydroxy-itraconazole has significant antifungal 
activity with a very similar spectrum to the parent compound. In humans, hydroxy-
itraconazole concentrations have been observed to range from zero to ten times the 
concentration of itraconazole, demonstrating significant inter-patient variability 
(Heykants et al. 1989, Manire et al. 2003, Orosz and Frazier 1995, Prentice and 
Glasmacher 2005). 
 
Pharmacokinetic studies on itraconazole in reptiles are sparse, with one study on Kemp’s 
ridley sea turtles (Manire et al. 2003), one study on bearded dragons (van 
Waeyenberghe et al. 2013), and one study on spiny lizards (Gamble et al. 1997). The 
study in Kemp’s ridley sea turtles recommended administration of itraconazole orally 
(as capsules) at 5 mg/kg once daily (SID) or 15 mg/kg every 3 days (Manire et al. 2003), 
while in bearded dragons 5 mg/kg PO SID of an unspecified formulation of itraconazole 
achieved above therapeutic concentrations, but resulted in presumed fatal 
hepatotoxicity (van Waeyenberghe et al. 2013). In spiny lizards, a dose rate of 23.5 
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mg/kg SID of the itraconazole capsules (opened and given with food) achieved 
therapeutic concentrations (Gamble et al. 1997). None of these studies evaluated the 
effects of temperature on pharmacokinetics. 
 
The aim of this study was to investigate the pharmacokinetics of itraconazole and its 
active metabolite, hydroxy-itraconazole, after oral administration of a liquid formulation 
of itraconazole in tuatara. Single and multiple dose studies were conducted at high and 
low ends of the tuatara’s preferred optimal temperature zone (POTZ) to assess 




Single dose studies were conducted first, and the results of these informed the methods 
used in the multiple dose studies. For general methods relating to animal selection, 
environmental conditions, drug assay method and pharmacokinetic analysis, see 
Chapter 2. 
 
Mixed effects pharmacokinetic modelling was performed using NONMEM v7.3.0 with 
the Fortran Compiler v11. Modelling for itraconazole concentration-time data in tuatara 
assumed one compartment pharmacokinetic model, first-order elimination and first-
order absorption (see Chapter 2 and Appendix 6).  
 
Animal ethics approvals were obtained from Murdoch University, Auckland Zoo and the 




Plasma antifungal concentrations were determined using Liquid Chromatography and 
tandem Mass Spectrometry (LCMS/MS). Drug assay methods and HPLC conditions are 
described in Section 2.6 and Appendices 3 and 4. All reported white blood cell counts 
were obtained using a haemocytometer. 
 
4.2.1 Single dose studies 
 
Dose determination 
Oral itraconazole has been used to treat mycotic infections involving fungi of the CANV 
group at 5-10 mg/kg SID PO in various reptile species (Paré et al. 1997, Bowman et al. 
2007, van Waeyenberghe et al. 2010, Johnson et al. 2011, Masters et al. 2016). At 
Auckland Zoo, clinical success has been achieved with itraconazole 3-5 mg/kg PO SID, 
(and in one case, 3 mg/kg PO q48h) in tuatara, with no observable adverse effects. 
Presumptive itraconazole toxicity has been documented at 5 mg/kg SID in bearded 
dragons (van Waeyenberghe et al. 2010), and itraconazole-related anorexia was 
observed in bearded dragons receiving itraconazole at 10 mg/kg PO SID (Bowman et al. 
2010). As the metabolic rate of tuatara is lower at their preferred body temperature 
than that of most other reptiles when in their POTZ, a lower dosage of itraconazole was 
indicated than has been used in other reptile species. The Minimum Inhibitory 
Concentration (MIC) of itraconazole required to inhibit growth of the tuatara P. 
australasiensis isolates tested was also low, at <0.03-0.12 mg/L (see Chapter 3), further 
suggesting that a relatively low dosage of itraconazole would be appropriate. As 
itraconazole dose rates of 3 mg/kg had been clinically effective previously with no 






Drug formulation and administration 
The itraconazole formulation used in this study was an oral 10 mg/mL liquid (Sporanox 
10 mg/mL Oral Solution, Janssen-Cilag, NZ). The liquid formulation allowed ease of 
administration and accurate dosing. Medication was administered orally as described in 
Chapter 2.  
 
Blood sampling intervals 
There is no published data on the absorption or elimination of oral antifungals in 
reptiles. This necessitated the estimation of appropriate sampling intervals based on 
assumptions made from pharmacokinetic data in other animals, and factoring in the 
lower metabolic rate of tuatara compared to these animals. Sampling intervals were 
shorter just after medication administration, in an effort to capture the point of maximal 
concentration, and longer towards the end of sampling, as less data points were likely 
to be required to capture elimination. The number of sampling points was also limited 
by concerns for the potential negative welfare impacts associated with repeat handling 
of the animals, and the amount of blood that could be taken from each animal during 
the short time period of the study. With these factors in mind, it was decided to sample 
at 6 time points during the single dose study. These were at 2, 4, 8, 12, 24 and 48 hours 
following medication administration. Each animal was administered medication 10 
minutes apart, and blood sampling was performed as close to the planned time after 
medication administration as possible. Sampling times were recorded to the nearest 





4.2.2 Multiple dose studies 
 
Dose  determination 
For the purpose of direct comparison, the same dosage was used at both temperatures 
for the multiple dose studies. All animals in the study weighed over 500 grams (range 
501-1016g), so this was the weight that was chosen for which the dosage required to 
achieve the target concentration of 2.4 mg/L would be determined. The predicted 
itraconazole dosage to achieve the target concentration in a 500g animal at 20oC is 2.57 
mg/kg once daily (see Section 4.2.2.4).  
 
A dose rate of 2.5 mg/kg PO SID was selected, for ease of calculation and administration. 
Health screening was conducted every two weeks to monitor tuatara for any signs of 
itraconazole toxicity. This consisted of weighing, physical examination, haematology and 
biochemistry measurements every two weeks until the end of the study. 
 
Drug formulation and administration 
Itraconazole was administered as per the single dose studies, using itraconazole 10 
mg/mL liquid (Sporanox 10 mg/mL Oral Solution, Janssen-Cilag, NZ). This was 
administered once daily as described in Section 4.2.1.2. Itraconazole was to be 
administered at 2.5 mg/kg PO SID for 42 days, however abnormalities detected during 
health screening resulted in cessation of drug administration on day 21 in the 12oC 
study, and on day 13 in the 20oC study (see Section 4.3.2). The medication was given at 
approximately the same time each day for each animal (with up to 5 minutes variation 
between days), between the hours of 7am and 8am. Tuatara were fed once weekly at 
12oC, and twice weekly at 20oC. Tuatara were fed in the afternoon, in an effort to 
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minimise any effect of food on absorption of medication. The gastric pH and gastric 
emptying time of tuatara is unknown. 
 
Blood sampling intervals 
Blood samples were collected just prior to a dose being given, to measure trough 
concentrations. The first day of medication was designated as day zero, and it was 
planned to take samples for trough itraconazole concentrations on days 2, 4, 6, 13, 20, 
27, 24 and 41. This sampling regime altered when antifungal concentration and health 
screening results were received during the study, as described below. 
 
In the 12oC study samples for determination of antifungal concentrations were taken on 
days 2, 4, 6, 13 and 20. Health screening results from day 13 revealed mild elevations in 
bile acids in two animals (possibly within normal variation, see Chapter 6). Blood could 
not be obtained for health screening from one animal, so a sample was obtained one 
week later on day 20, showing marked elevation in bile acids. At this stage all animals 
were re-sampled for health screening, and abnormal results were obtained in four 
animals (Section 4.3.2.4). Results from the first two weeks showed that itraconazole 
concentrations were increasing with no evidence of approaching steady-state 
concentrations and, as a result, the decision was made to cease itraconazole 
administration. The last dose of itraconazole was given on day 21, and samples were 
taken to measure drug elimination on days 28, 34, 41 and 55.  
 
Blood samples were taken for health screening at 6-14 day intervals for each animal, 
until all values had returned to normal. Normal haematology and biochemistry ranges 
for tuatara were developed as part of this research (Chapter 6). Reference ranges were 
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obtained from a small population, so a result was only considered to be definitively 
abnormal if it was more than three standard deviations from the mean.  
 
In the 20oC study, elevated bile acids were detected on health screening at day 13. The 
last dose of itraconazole was given on day 13, with the last sample for trough 
concentration taken on day 14. Samples during drug elimination were taken on days 17, 
20, 23 and 27. Blood samples were taken for health screening on days 13 and 20 for each 
animal, and on days 27, 41 and 89 for animals with abnormal results requiring further 
monitoring. 
 
There was a fifteen-week washout period between multiple dose studies at the two 
ambient temperatures. Blood samples collected one week before the commencement 
of the 20oC study confirmed there was no detectable itraconazole or hydroxy-




4.3.1 Results for single dose studies 
 
4.3.1.1 Single dose studies conducted at 12oC ambient temperature  
Plasma antifungal concentrations 
Itraconazole was administered to four tuatara at a dose rate of 3 mg/kg PO, at time zero. 
Plasma samples were analysed using LCMS/MS and were run in duplicate to ensure 





Table 4.1 Itraconazole (Itra) and hydroxy-itraconazole (OH-itra) plasma concentrations 
(mg/L) in four tuatara at time from itraconazole administration (hours) at 12oC. 
Animal ID Sex Drug 2h 4h 8h 12h 24h 48h 
101 F Itra 0.317 0.769 0.632 0.707 0.799 1.025 
OH-itra 0 0 0.034 0.041 0.152 0.113 
104 M Itra 0.206 0.405 0.675 0.877 1.445 1.785 
OH-itra 0 0 0.030 0.050 0.115 0.216 
105 F Itra 0.173 0.318 0.565 0.570 0.803 0.799 
OH-itra 0 0 0 0 0.080 0.172 
107 F Itra 0.0860 0.160 0.212 0.187 0.862 0.910 
OH-itra 0 0 0 0 0.039 0.089 
 
Figure 4.1 Itraconazole ( ) and hydroxy-itraconazole ( ) plasma concentration (mg/L) 




Figure 4.2 Itraconazole (itra) and hydroxy-itraconazole (OH-itra) plasma concentrations 
(mg/L) at time from itraconazole administration (hours) from all animals at 12oC. 
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Pharmacokinetic data and analysis 
No animals were observed to have a concentration-time profile in the terminal 
elimination phase for itraconazole or hydroxy-itraconazole during the 48 hour period of 
the study, though this may be at least partially due to the sparse sampling towards the 
end of the study period. Only one of the four subjects (105) had an itraconazole 
concentration that was lower at 48 hours than at the previous sampling timepoint at 24 
hours. Thus it was not possible to calculate the elimination constant (kel), area under the 
concentration versus time curve from 0h to infinity (AUC0-∞), elimination half-life (t1/2), 
clearance (CL), or volume of distribution (V) at 12oC. The only parameter able to be 
calculated was, for both drugs, AUC0-48 (Table 4.2)  
 
Approximate maximal plasma concentration (Cmax) and time to maximal plasma 
concentration (Tmax) were not able to be determined, as the majority of subjects were 
not in the terminal elimination phase at the last time point. 
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Table 4.2 AUC for itraconazole and hydroxy-itraconazole at 12oC.  
Animal ID Itraconazole AUC0-48 (mg/L*h) OH-itraconazole AUC0-48 (mg/L*h) 
101 21.93 4.56 
104 58.78 5.18 
105 32.18 3.50 
107 29.44 3.52 
   
Mean ± SD 35.58 ± 13.9 4.19 ± 0.7 
      
Pharmacokinetic modelling results 
Using mixed effects modelling (see Section 2.11), it was possible to estimate the 
pharmacokinetic parameters and itraconazole dosages required to reach the plasma 
target concentration of 2.4 mg/L at 12oC for tuatara of different weights (Table 4.3). Due 
to the lack of good elimination data, the modelling findings may not be as accurate as 
desired. 
 
Plasma antifungal concentrations 
Itraconazole was administered to the same four tuatara as described in Section 4.2.1. 









Table 4.3 Pharmacokinetic modelling results for attaining steady-state plasma 
concentrations of 2.4 mg/L of itraconazole at 12oC. 
Weight (kg) Volume (L) Clearance (L/h/kg) Dose rate (mg/kg/day) 
0.1 0.29 0.0099 0.571 
0.2 0.58 0.0083 0.480 
0.3 0.87 0.0075 0.434 
0.4 1.15 0.0070 0.404 
0.5 1.44 0.0066 0.382 
0.6 1.73 0.0063 0.365 
0.7 2.02 0.0061 0.351 
0.8 2.31 0.0059 0.340 
0.9 2.60 0.0057 0.330 
1 2.89 0.0056 0.321 
 
4.3.1.2 Single dose studies conducted at 20oC ambient temperature 
 
Table 4.4 Itraconazole (Itra) and hydroxy-itraconazole (OH-itra) plasma concentrations 
(mg/L) at time from itraconazole administration (hours). NS = no sample. 
   Time after dose (hours) 
Animal ID Sex Drug 2 4 8 12 24 48 
101 F Itra 0.375 1.465 0.997 0.737 0.853 0.693 
OH-itra 0.018 0.067 0.242 0.245 0.315 0.395 
104 M Itra NS 0.552 1.405 1.290 1.405 0.605 
OH-itra NS 0.048 0.342 0.326 0.593 0.504 
105 F Itra 0.208 0.632 0.629 0.546 0.535 0.278 
OH-itra 0 0 0.095 0.127 0.279 0.219 
107 F Itra 0.164 0.436 0.839 NS 0.386 0.347 




Figure 4.3 Itraconazole ( ) and hydroxy-itraconazole ( ) plasma concentration (mg/L) 
at time from itraconazole administration (hours) for each animal at 20oC. 
 
 
Figure 4.4 Itraconazole (itra) and hydroxy-itraconazole (OH-itra) plasma concentrations 
(mg/L) at time from itraconazole administration (hours) from all animals at 20oC. 







































1 0 5  i t r a
1 0 7  i t r a
1 0 1  O H - i t r a
1 0 4  O H - i t r a
1 0 5  O H - i t r a
1 0 7  O H - i t r a
1 0 1  i t r a




Pharmacokinetic data and analysis 
All four subjects had passed the peak of itraconazole concentrations by the last time 
point. The extrapolated percentage of AUC0-∞ was higher than 20%, precluding the 
accurate calculation of the elimination constant, elimination half-life, clearance and 
volume of distribution. Three of the subjects had passed the peak of hydroxy-
itraconazole concentrations. Because only two time points were measured after the 
peak concentration, it was not possible to accurately calculate pharmacokinetic 
parameters and indices other than AUC0-48 (Table 4.5). 
 
Table 4.5 Selected pharmacokinetic parameters for itraconazole and hydroxy-
itraconazole at 20oC.  








101 38.70 84.40 54.1 13.58 
104 50.71 77.01 35.1 21.19 
105 22.18 32.35 31.4 9.06 
107 21.93 38.69 43.3 6.59 
     
Mean ± SD 33.38 ± 12.1 58.11 ± 22.9 40.98 ± 8.7 12.60 ± 5.6 
 
Approximate time to maximal plasma concentration (Tmax), and approximate maximal 
plasma concentration (Cmax) of itraconazole were variable. Tmax appears to occur 4-8 
hours following oral administration of itraconazole, and Cmax appears to be between 
0.632 and 1.450 mg/L. It is not appropriate to estimate Tmax and Cmax for hydroxy-





Pharmacokinetic modelling results 
Using mixed effects modelling (see Section 2.11), it was possible to estimate the drug 
dosages required to reach the itraconazole target concentration of 2.4 mg/L at 20oC for 
tuatara of different weights. It was also possible to estimate pharmacokinetic 
parameters of itraconazole for different animal weights at these temperatures (Table 
4.6). Due to the lack of good elimination data at both temperatures, but particularly at 
12oC, the modelling findings may not be as accurate as desired. 
 
Table 4.6 Pharmacokinetic modelling results for attaining steady-state plasma 
concentrations of 2.4 mg/L of itraconazole at 20oC. 
Weight kg Volume (L) Clearance (L/h/kg) Dose rate (mg/kg/day) 
0.1 0.29 0.067 3.84 
0.2 0.58 0.056 3.23 
0.3 0.87 0.051 2.92 
0.4 1.15 0.047 2.72 
0.5 1.44 0.045 2.57 
0.6 1.73 0.043 2.46 
0.7 2.02 0.041 2.36 
0.8 2.31 0.040 2.29 
0.9 2.60 0.039 2.22 
1 2.89 0.038 2.16 
 
4.3.1.3 Statistical comparisons 
Itraconazole 
The only value suitable for statistical comparison between temperatures for 





The only value suitable for statistical comparison between temperatures for hydroxy-
itraconazole was AUC0-48, and this was not significantly different (p = 0.058). 
 
4.3.1.4 Combined pharmacokinetic modelling results 
Combined pharmacokinetic parameters derived from the single dose studies are 
provided in Table 4.7. Although not practically applicable to tuatara, data for a 70kg 
animal is included in the results as this is the standard employed in human medicine to 
allow comparisons between medications, as generally speaking, pharmacokinetic 
parameters differ on an allometrically scalable basis (Huang and Riviere 2014). 
 
Table 4.7 Estimates of modelling-derived itraconazole PK parameters from single dose 
studies. 
Parameter Estimate 
Clearance at 20oC (L/h/70kg)  1.26 
Km (mg/L)  0.01 
Volume of distribution (L/70kg) 150 
Absorption half-life (hours) 7.95 
Fold decrease in CL relative to 20oC 15 
 
4.3.2 Results for multiple dose studies 
 
4.3.2.1 Multiple dose studies conducted at 12oC ambient temperature 
Plasma antifungal concentrations 
Itraconazole was administered to six tuatara at a dose rate of 2.5 mg/kg PO once daily 
until the last dose on day 21, and blood samples were obtained as described in Section 
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4.2. Samples were analysed using LCMS/MS, and results are displayed below (Table 4.8 
and Figures 4.5 and 4.6). Animal 104 experienced adverse effects from the medication 
and was moved to a warmer ambient temperature to hasten drug elimination on day 
33, so drug concentrations were not measured after this date. 
 
Table 4.8 Trough itraconazole (Itra) and hydroxy-itraconazole (OH-itra) plasma 
concentrations (mg/L) at time from first day of itraconazole administration (days) at 
12oC. * = sample taken on day 33. The final itraconazole dose was administered to all 
animals on day 21. 
 Days after first dose 
Animal ID Sex Drug  2 4 6 13 20 28 34 41 55 
101 F Itra 1.55 3.95 6.85 16.0 14.2 8.21 5.99 4.72 1.38 
OH-itra 0.181 0.565 1.22 2.95 3.17 3.47 3.89 3.36 2.42 
104 M Itra 1.82 5.02 7.44 15.8 22.9 20.7 15.7* NS NS 
OH-itra 0.203 0.587 1.67 3.76 4.76 6.83 8.33 NS NS 
105 F Itra 2.13 3.29 5.62 NS 13.3 10.6 11.7 7.91 7.4 
OH-itra 0.135 0.884 1.25 NS 2.43 3.74 6.17 4.08 4.03 
107 F Itra 1.89 3.20 3.77 6.96 10.9 7.02 4.86 3.38 1.82 
OH-itra 0.172 0.376 0.72 1.87 1.86 2.49 2.98 2.56 2.3 
109 F Itra 1.43 3.76 5.49 9.16 14.0 9.02 7.93 5.43 3.72 
OH-itra 0.445 1.00 1.11 2.85 4.43 4.99 5.51 6.84 7.57 
112 M Itra 2.46 4.61 6.24 15.1 18.7 15.0 13.3 11.7 7.94 








Figure 4.5 Itraconazole ( ) and hydroxy-itraconazole ( ) plasma concentration (mg/L) 








Figure 4.6 Itraconazole (itra) and hydroxy-itraconazole (OH-itra) plasma concentrations 
(mg/L) at time from itraconazole administration (days) from all animals at 12oC. 
 
 
Pharmacokinetic data and analysis 
The only index that could be calculated using traditional PK analysis (Chapter 2) was 
elimination half-life (Table 4.9). The mean ± SD half-life of itraconazole was 22.0 ± 9.4 
hours. The mean ± SD half-life of hydroxy-itraconazole was 34.7 ± 11.9 hours. 
 
Table 4.9 t1/2 of itraconazole and hydroxy-itraconazole at 12oC. NC = not calculated. 
Animal ID Itraconazole t1/2 (hours) Hydroxy-itraconazole t1/2 (hours) 
101 10.50 30.51 
104 NC NC 
105 35.77 14.18 
107 14.04 39.58 
109 20.37 49.42 
112 29.33 39.58 
   
Mean ± SD 22.00 ± 9.4 34.65 ± 11.9 
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Pharmacokinetic modelling results 
 
The modelling data below (Table 4.10) describe select pharmacokinetic parameters 
(clearance and volume of distribution), half-life and the mg/kg per day dosage of 
itraconazole required to achieve a plasma target concentration of 2.4 mg/L for tuatara 
weighing between 0.1-1.0kg maintained at 12oC. Dose rates range from 0.21-0.38 
mg/kg.  
 
Table 4.10 Model predictions of pharmacokinetic parameters and itraconazole dose rate 
required to attain steady-state target concentration of 2.4 mg/L at 12oC. 
Weight kg Volume (L) Clearance (L/h/kg) Dose rate (mg/kg/day) 
0.1 0.27 0.0065 0.38 
0.2 0.53 0.0055 0.32 
0.3 0.80 0.0050 0.29 
0.4 1.06 0.0046 0.27 
0.5 1.33 0.0044 0.25 
0.6 1.59 0.0042 0.24 
0.7 1.86 0.0040 0.23 
0.8 2.13 0.0039 0.22 
0.9 2.39 0.0038 0.22 
1 2.66 0.0037 0.21 
70 186.00 0.0013 0.07 
 
Health screening results 
Health screening was conducted during the study as described in Section 2.3.2. 






Elevations in white blood cell count were the only haematologic abnormality found. 
Results are summarised below (Table 4.11). The reference range for the tuatara white 
cell count is 0.7-3.1 x 109/L, with some seasonal and sex variation (Section 6.3.1). 
 
Table 4.11 Summary of white cell counts (* 109 cells) for multiple dose studies 
conducted at 12oC. NS = no sample. * = sample obtained on day 33. ~ = sample obtained 
on day 20. The final itraconazole dose was administered to all animals on day 21. Results 
considered definitively abnormal are coloured in red. 
 White cell count (x 109 cells) at number of days after first dose 
Animal ID Sex 13 22 28 34 41 55 
101 F 0.6 1.8 2.6 NS NS NS 
104 M 2.1 5.5 8.6 9.1* 7.9 2.1 
105 F 0.8~ 0.8 0.9 NS NS NS 
107 F 1.6 3.4 2.7 NS NS NS 
109 F 0.7 1.5 1.8 NS NS NS 
112 M 3.1 8.6 8.6 8.2 7.0 2.1 
 
Haematology performed on day 13 was considered within normal limits for all animals 
(Section 6.3.1). Throughout the experiments other haematology values (haematocrit, 
haemoglobin, mean corpuscular haemoglobin concentration, and fibrinogen) remained 
within normal limits. The elevations in white cell counts in animals 104 and 112 are 




Table 4.12 White cell count elevations in animals 104 and 112. Differential results considered definitively abnormal are coloured in red. 
 Heterophils Lymphocytes Monocytes Eosinophils Basophils 
Animal ID Day Total WCC x 109 x 109 % x 109 % x 109 % x 109 % x 109 % 
104 22 5.5 2.4 43 0.7 13 2.3 41 0.1 2 0.1 1 
28 8.6 3.6 42 1.4 16 3.4 39 0.3 3 0 0 
33 9.1 3.2 35 1.0 11 4.6 50 0.3 3 0.1 1 
41 7.9 2.9 37 2.3 29 2.3 29 0.1 1 0.3 4 
112 22 8.6 5.2 60 1.9 22 1.5 17 0.1 1 0 0 
28 8.6 6.3 73 0.5 6 1.7 20 0.1 1 0 0 
34 8.2 5.4 66 1 12 1.6 20 0.1 1 0.1 1 
41 7.0 3.9 55 1.4 20 1.4 20 0.4 5 0 0 
Reference range  0.7-3.1 0.1-1.1 15.2-53.4 0.2-1.0 11.2-53.8 0.1-0.7 5.4-35.4 0-0.5 1.2-21.8 0.0-0.3 0.0-9.8 
 
The elevations in white cell counts were predominantly increases in heterophils and monocytes, indicative of granulocytic inflammation. Subject 112 
had reactive monocytes on day 34, characterised by cytoplasmic vacuolation. In the other samples, white blood cell morphology remained normal 




Of the biochemistry panel, bile acids and uric acid concentrations were elevated in 
several animals. The lower and upper limits of quantitation for bile acids using the Abaxis 
Vetscan were 35 and 200 µmol/L respectively. Due to the limits of quantitation it was 
not possible to definitively determine a bile acids reference range for tuatara (see 
Section 6.3.2). The reference range for uric acid is 51.8-163.6, with some differences 
based on sex (Section 6.3.2). Biochemistry results are summarised below in Table 4.13.  
 
Table 4.13 Summary of bile acids and uric acid concentrations (µmol/L) for multiple dose 
studies conducted at 12oC. - = no sample. * = sample obtained on day 20. The final 
itraconazole dose was administered to all animals on day 21. Results considered 
definitively abnormal are coloured in red. 
  Days after first dose 
Animal ID Sex Biochemical 
analyte 
13 22 28 34 41 55 
101 F Bile acids <35 52 <35 48 - - 
Uric acid 152 486 138 168 - - 
104 M Bile acids 64 <35 <35 - - - 
Uric acid 292 436 540 - - - 
105 F Bile acids 100* 63 - 48 60 62 
Uric acid 245* 195 - 103 79 58 
107 F Bile acids <35 56 <35 <35 - - 
Uric acid 34 139 54 128 - - 
109 F Bile acids <35 <35 <35 - - - 
Uric acid 24 31 29 - - - 
112 M Bile acids 55 >200 151 119 54 <35 





Biochemistry showed mild elevations in bile acids in two animals (104 and 112) on day 
13. Normal bile acids concentrations had not been determined for tuatara at this time, 
however during health screening all tuatara had bile acids ranging from less than 35 (the 
lower limit of quantitation) to 41 µmol/L (see Chapter 6). Animal 104 had bile acids of 
64 µmol/L, and animal 112 a concentration of 55 µmol/L, however at the time these 
increases were considered mild and possibly post-prandial elevations related to food 
intake. It was not possible to obtain blood from one animal (105) at this time, so a 
sample was taken on day 20 from this animal for health screening. This revealed bile 
acids of 100 µmol/L, and this was considered likely to be a pathological increase. 
Following this, all six tuatara underwent repeat health screening on day 22 of the study, 
which detected elevations in bile acids in four animals (101, 104, 105, and 112). While 
three of these elevations were considered mild and possibly within normal limits, one 
animal (112) had a concentration exceeding 200 µmol/L (the upper limit of 
quantitation).   
 
Uric acid 
Uric acid was elevated in three animals (101, 104 and 105) at different periods 
throughout the study. Normal uric acid concentrations had not been determined for 
tuatara at this time, but the reference range has now been established as 51.8-163.6 







4.3.2.2 Multiple dose studies conducted at 20oC ambient temperature 
Plasma antifungal concentrations 
Itraconazole was administered to six tuatara at a dose rate of 2.5 mg/kg PO, once daily 
until the last dose on day 13. Blood samples were obtained as described in Section 4.2.2. 
Samples were analysed using LCMS/MS, and results are displayed below. (Table 4.14 
and Figures 4.7 and 4.8). 
 
Table 4.14 Itraconazole (Itra) and hydroxy-itraconazole (OH-itra) plasma concentrations 
(mg/L) at time from first day of itraconazole administration (days) at 20oC. The final 
itraconazole dose was administered to all animals on day 13. 
   Days after first dose administered 
Animal 
ID 
Sex Drug 6 13 14 17 20 23 27 
101 F Itra 4.696 5.824 5.328 4.559 2.281 1.879 1.250 
OH-itra 2.837 4.031 2.651 1.950 2.448 1.624 2.488 
104 M Itra 6.921 10.621 11.734 8.224 5.393 4.728 2.403 
OH-itra 3.405 6.129 4.595 4.387 5.409 4.66 4.158 
105 F Itra 0.622 7.315 6.121 4.315 5.470 2.977 2.720 
OH-itra 0.266 3.530 3.356 3.254 3.620 2.742 3.691 
107 F Itra 2.842 4.893 3.928 3.010 1.827 1.747 1.310 
OH-itra 1.184 3.651 2.802 2.950 2.055 2.352 2.055 
109 F Itra 3.279 4.921 4.053 3.452 2.436 2.206 0.946 
OH-itra 2.467 3.645 3.630 4.091 4.509 3.059 4.208 
112 M Itra 3.934 6.606 6.164 5.696 3.403 3.397 3.158 




Figure 4.7 Itraconazole ( ) and hydroxy-itraconazole ( ) plasma concentration (mg/L) 









Figure 4.8 Itraconazole (itra) and hydroxy-itraconazole (OH-itra) plasma concentrations 




Pharmacokinetic data and analysis 
The only index that could be calculated using traditional pharmacokinetic analysis was 
half-life. The mean and standard deviation of itraconazole half-life was 7.65 ± 2.2 hours. 
The mean half-life of hydroxy-itraconazole could not be calculated, as it was only 
undergoing elimination in one animal during the sampling period. The half-life in this 










Table 4.15 t1/2 of itraconazole and hydroxy-itraconazole at 20oC. NC = not calculated. 
Animal ID Itraconazole t1/2 (hours) OH-itraconazole t1/2 (hours) 
101 5.88 NC 
104 5.92 19.66 
105 7.25 NC 
107 8.16 NC 
109 6.49 NC 
112 12.20 NC 
   
Mean ± SD 7.65 ± 2.2 NC 
      
Pharmacokinetic modelling results 
The modelling data below (Table 4.16) describe the mg/kg per day dosage of 
itraconazole required to achieve a plasma target concentration of 2.4 mg/L for tuatara 
in a weight range from 0.1-1.0kg maintained at 12oC. Dose rates range from 0.60-1.08 
mg/kg. A loading dose is provided as an optional first dose to facilitate achieving steady 
state concentrations more rapidly. Pharmacokinetic parameters vary with weight, but 
for a 1kg animal to reach an itraconazole target concentration of 2.4 mg/L, volume of 
distribution is estimated at 2.66L and clearance at 0.010 L/h.  
 
Modelling based on both the single and multiple dose data illustrate the predicted and 
observed concentrations of itraconazole at the administered dosage of 2.5 mg/kg for 








Table 4.16 Model predictions of pharmacokinetic parameters and itraconazole dose rate 
required to attain steady-state target concentration of 2.4 mg/L at 20oC. 
Weight (kg) Volume (L) Clearance (L/h/kg) Loading dose (mg) Dose rate (mg/kg/day) 
0.1 0.27 0.019 0.64 1.08 
0.2 0.53 0.016 1.28 0.90 
0.3 0.80 0.014 1.91 0.82 
0.4 1.06 0.013 2.55 0.76 
0.5 1.33 0.012 3.19 0.72 
0.6 1.59 0.012 3.83 0.69 
0.7 1.86 0.011 4.46 0.66 
0.8 2.13 0.011 5.10 0.64 
0.9 2.39 0.011 5.74 0.62 
1 2.66 0.010 6.38 0.60 
70 186.00 0.004 446.40 0.21 
 
Figure 4.9 Predicted and observed itraconazole concentrations at 20oC following dosing 
at 2.5 mg/kg SID. Green line:  Individual prediction. Dashed line: population prediction. 




Pharmacokinetic modelling simulations were run to illustrate the difference between 
predicted itraconazole concentrations at both temperatures. An example is provided 
below (Table 4.10), where a 0.75kg tuatara is administered 0.25 mg/kg of itraconazole 
once daily. 0.25 mg/kg is the dose rate predicted to result in steady-state concentrations 
of 2.4 mg/L at 12oC. As drug elimination is slower at colder temperatures, higher 
itraconazole concentrations are reached at 12oC than at 20oC. 
 
Figure 4.10 Time vs concentration profile of a 0.75 kg tuatara administered 0.25 mg/kg 
itraconazole SID at 12oC and 20oC. 















































Health screening results 
Health screening was conducted during the study as described in Section 2.3.2. 
Abnormalities in haematology, bile acids and uric acid are outlined below. Itraconazole 








White blood cell numbers remained within normal limits during this part of the study. 
Animal 105 had occasional reactive monocytes on day 27, accompanied by mild 
anisocytosis and occasional binucleated red blood cells. All other haematology and 
biochemistry values for this animal were normal. No other animals had any 
haematologic abnormalities during this part of the study. 
 
Biochemistry 
Of the biochemistry panel, the only abnormal values during treatment were bile acids 
and uric acid. Due to the limits of quantitation it was not possible to definitively 
determine a bile acids reference range for tuatara (see Section 6.3.2). The reference 
range for uric acid is 51.8-163.6, with some differences based on sex (Section 6.3.2). 
Biochemistry results are summarised in Table 4.17. 
 
Animal 112 lost weight during the study, and continued to lose weight despite cessation 
of itraconazole administration. On day 23 the decision was made to move him back to 
his normal enclosure in the hope that being in a more natural environment would aid 
his return to health. Two days after moving to the new enclosure he had regained much 
of his lost weight, suggesting the weight loss may have been caused by inappetence or 
dehydration. As the animal was improving it was decided to not disturb him for an 








Table 4.17 Summary of bile acids and uric acid concentrations (µmol/L) for multiple dose 
studies conducted at 20oC. - = no sample. * = animal moved to ambient temperature. 
The final itraconazole dose was administered to all animals on day 13. Results 
considered definitively abnormal are coloured in red. 
 Days after first dose 
Animal ID Sex Biochemical 
analyte 
13 20 27 41 89 
101 F Bile acids 42 <35 - - - 
Uric acid 341 177 - - - 
104 M Bile acids 50 80 <35 - - 
Uric acid 227 427 60 - - 
105 F Bile acids <35 <35 - - - 
Uric acid 92 107 - - - 
107 F Bile acids 77 38 <35 - - 
Uric acid 110 135 108 - - 
109 F Bile acids <35 <35 - - - 
Uric acid 132 80 - - - 
112 M Bile acids >200 194 132 87* <35* 
Uric acid 128 100 115 93 102 
 
 
4.3.2.3 Statistical comparisons 
The elimination half-life of itraconazole was suitable for statistical comparison. 
Following log transformation, using the paired t-test the p-value was 0.0083, indicating 




4.3.2.4 Combined pharmacokinetic modelling results of single and multiple dose 
studies at both temperatures 
Bootstrap estimates of other model parameters and confidence intervals were able to 
be determined, and these are illustrated in the table below (Table 4.18). 
 
Table 4.18 Select population pharmacokinetic parameters for tuatara receiving 
itraconazole. RUV = residual unexplained variability. RSE = relative standard error 
expressed as a percentage. 
Statistics Mean 95% CI RSE % 
Clearance (L/h/70kg) 0.259 0.200-0.315 11 
Volume of distribution (L/70kg) 192.3 150.4-236.8 13 
Absorption half-life (hours) 5.30 3.461-7.733 21 
Fold decrease in clearance relative to 
20oC 
2.864 2.438-3.489 10 
RUV proportional 0.189 0.089-0.284 29 
RUV additive (mg/L) 0.158 0.002-0.306 69 
 
Residual unexplained variability (RUV) is a measure of random error, which is always 
present in modelling and is unpredictable. Quantifying RUV gives a measure of how 




4.4.1 Pharmacokinetics and temperature 
 
Single dose studies were both conducted using itraconazole dosages of 3 mg/kg, while 
multiple dose studies were both conducted using dose rates of 2.5 mg/kg. This allowed 
direct comparison of the effect of temperature on pharmacokinetic parameters. Results 
181 
 
show that these dosages were excessive at both temperatures, and resulted in high 
itraconazole plasma concentrations and significant adverse effects. 
 
Time to maximal plasma concentration 
In single dose studies at 12oC, time to maximal plasma concentration was not able to be 
estimated, as most animals were not in the itraconazole terminal elimination phase at 
48 hours. At 20 oC the Tmax was estimated to be between 4-8 hours. While it was not 
appropriate to make statistical comparisons because of the lack of definitive data at 12 
oC, it is apparent there is a marked difference in Tmax at the two temperatures using 
the 3 mg/kg dose rate. The Tmax of itraconazole in reptiles has not been reported 
previously, but in humans was 5.7 hours (Willems et al. 2001), and in birds was 4 hours 
in domestic pigeons, 3.7 hours in black-footed penguins, and varied between 3.7-6.9 
hours in Amazon parrots (Lumeij et al. 1995, Orosz et al. 1996, Smith et al. 2010). These 
studies administered itraconazole of various formulations, at different dose rates to this 




The absorption half-life of itraconazole in tuatara was estimated at 5.30 hours based on 
modelling analysis. This is slow absorption, and indicates that 50% of the administered 
oral dose is absorbed in 5.3 hours. Absorption is considered to be a largely passive 
process, and not markedly influenced by temperature, so the estimate is the same for 







In the multiple dose studies itraconazole had a mean ± SD elimination half-life of 22.0 ± 
9.4 hours at 12 oC, and 7.65 ± 2.2 hours at 20 oC.  This difference was statistically 
significant (p=0.0083), indicating that half life was significantly lower at 20oC than 12oC. 
Modelling indicated that elimination kinetics were first-order (non-saturable), as 
observed in other species. 
 
Clearance 
Pharmacokinetic modelling predicted clearance at 12 oC of 0.010L/h, and at 20 oC 
0.0037L/h for a 1kg animal with a target itraconazole concentration of 2.4 mg/L (Tables 
4.9 and 4.14). The clearance differs between temperatures by a factor of 2.86, which is 
very similar to the observed proportional difference in mean elimination half-lives at 
both temperatures (Tables 4.8 and 4.13) of 2.88. 
 
Modelling and simulation to estimate itraconazole dosage regimens in tuatara 
The observed itraconazole concentrations matched reasonably well with those 
predicted by modelling, indicating that itraconazole has predictable pharmacokinetics, 
and there can be a reasonable level of confidence in the modelling predictions.  
 
It is apparent from these data administering the same dosage of medication at different 
temperatures produces markedly different plasma itraconazole concentrations. This 
indicates that ambient temperature control is an essential part of a hospitalisation and 
treatment protocol using itraconazole in tuatara. Simulations show that at 12oC, 
itraconazole is not predicted to reach steady-state concentrations by the end of 
simulations at 70 days, as it continues to accumulate. This makes 12oC an inappropriate 
temperature at which to treat tuatara with itraconazole, as therapeutic concentrations 
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would not be reached in an appropriate timeframe, and accumulation of the drug means 
adverse effects become more likely as treatment progresses. Therefore it is 
recommended animals are treated at 20oC, the higher end of their POTZ. 
 
4.4.2 Adverse effects 
 
Adverse effects were noted in both the 12oC and 20oC multiple dose studies, with 
elevated bile acids being the most common problem. Bile acids are produced by the liver 
to aid digestion, and are considered a specific test for hepatic insufficiency (Campbell 
2014). In a study in healthy green iguanas (Iguana iguana), pre-prandial bile acids were 
7.5 ± 7.8 µmol/L, and post-prandial bile acids were 33.3 ± 22.0 µmol/L (McBride et al. 
2006). At the time of our study there were no reference ranges for bile acids in tuatara, 
and healthy tuatara at Auckland Zoo had previously had bile acids ranging from <35 (the 
lower limit of detection of the analyser) to 41 µmol/L. Gastric emptying time in tuatara 
is unknown, and animals in the study were able to feed at any time of day, so no 
distinction between pre- and post-prandial bile acids concentrations could be made 
during the study. At the time of the study bile acids concentrations lower than 40 µmol/L 
were considered normal, between 40-60 µmol/L marginal, and above 60 µmol/L 
elevated, based on clinical experience and extrapolation from other reptile species.  
 
At 12oC, elevations in bile acids (64 µmol/L) were noted in one animal on day 13 (subject 
104, male), this was associated with a plasma itraconazole concentration of 15.8 mg/L, 
and a hydroxy-itraconazole concentration of 3.76 mg/L. On day 20 subject 105 (female), 
was found to have elevated bile acids (100 µmol/L); this was associated with an 
itraconazole plasma concentration of 13.3 mg/L, and a hydroxy-itraconazole 
concentration of 2.43 mg/L. On day 22 another animal (subject 112, male) was found to 
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have elevated bile acids (>200 µmol/L), the closest itraconazole measurement in this 
animal was 18.7 mg/L on day 20 (the last drug dose was administered on day 21), and 
the hydroxy-itraconazole concentration was 3.14 mg/L. Other tuatara had plasma 
itraconazole concentrations ranging from 10.9-22.9 mg/L and hydroxy-itraconazole 
concentrations of 1.86-4.76 mg/mL on day 20, and did not show elevations in bile acids. 
Subject 104’s bile acids normalised to <35 µmol/L on day 22, despite itraconazole 
treatment only ceasing on day 21, raising the possibility that the observed elevation on 
day 13 was not directly related to antifungal therapy.  
 
In the 20oC multiple dose study two animals (subjects 107 – female, and 112 – male) had 
elevations in bile acids on day 13, with corresponding itraconazole concentrations of 
4.893 mg/L and 6.606 mg/L, and hydroxy-itraconazole concentrations of 3.651 and 
2.748 mg/L respectively. Subject 112 had persistently elevated but decreasing bile acids 
until day 41. One tuatara (subject 104) had marginal bile acids of 50 µmol/L on day 13, 
and went on to develop high bile acids of 80 µmol/L on day 20. Unaffected tuatara had 
itraconazole concentrations between 4.921-10.621 mg/L, and hydroxy-itraconazole 
concentrations of 3.53-6.129 mg/L.  
 
Elevations in bile acids occurred earlier in the 20oC study, despite lower plasma 
itraconazole concentrations at the time compared to the 12oC study (4.893-6.606 mg/L 
versus 13.3-18.7 mg/L respectively). Hydroxy-itraconazole concentrations were similar 
in both studies when adverse effects were noted (2.748-3.651 mg/L and 2.43-3.14 
mg/L). It is possible that hydroxy-itraconazole, or a different metabolite of itraconazole, 
is responsible for the increased bile acids (rather than the parent compound), as 
hydroxy-itraconazole attained higher concentrations more rapidly in the 20oC study. It 
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is also possible that, despite apparently normal bile acids concentrations on health 
screening prior to the 20oC study, that the 12oC study had caused subclinical liver 
damage, making the liver more sensitive to itraconazole in the 20oC study. 
 
In humans and rats, itraconazole has been noted to cause dose-dependent 
hepatocellular necrosis, bile duct hyperplasia, cholestasis and biliary cirrhosis, with 
elevation in liver enzyme activity and bilirubin (Talwalkar et al. 1999, Somchit et al. 2004, 
Lou et al. 2011). In one human case report, symptoms and biochemistry abnormalities 
including elevated bilirubin and liver enzymes continued to worsen after the cessation 
of itraconazole treatment, ultimately resolving four months after stopping itraconazole 
(Talwalkar et al. 1999). In bearded dragons administered itraconazole 5 mg/kg PO SID, 
five out of seven bearded dragons died, with elevations in AST reported in four of these 
animals (van Waeyenberghe et al. 2010); no histologic abnormalities were found in the 
liver on post-mortem. Bile acids were not reported in this study, and neither was CK 
(muscle damage can raise both CK and AST).  
 
Uric acid concentrations were also increased in several animals in both the 12oC and 
20oC studies. Uric acid is the primary product of protein catabolism in tuatara (Hill and 
Dawbin 1969), and is produced by the liver and excreted via the kidneys. Uric acid can 
be elevated in renal disease and in dehydrated animals. Prior to this study there were 
no published normal concentrations of uric acid in tuatara, however our subsequent 
analyses showed concentrations of 42-232 µmol/L were detected in clinically healthy, 
well hydrated animals (Chapter 6). During the multiple dose studies, uric acid 
concentrations between 40-250 µmol/L were considered normal, 250-350 µmol/L 
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marginal, and above 350 µmol/L abnormal, based on clinical experience at Auckland 
Zoo. 
 
In the 12oC study, one animal (subject 104) had marginally increased uric acid 
concentrations on day 13, of 292 µmol/L, and progressed to more dramatic elevations 
on days 22 and 28, with concentrations of 436 µmol/L and 540 µmol/L, respectively. This 
animal also lost weight during this period, which was regained within two days of 
returning him to his normal enclosure, indicating that dehydration was likely the cause 
of both weight loss and the uric acid elevation. Tuatara obtain most of their water from 
dietary sources (Cree 2014), and it is possible that itraconazole therapy resulted in 
nausea and inappetence, as this is a commonly reported adverse effect in humans 
(Manire et al. 2003). It is also possible the study environment and regular handling may 
have contributed to altered behaviour and dietary intake, however this was not 
observed in voriconazole-treated animals (Chapter 5). Subject 101 also showed elevated 
uric acid (486 µmol/L) at the same time when marginal bile acids (52 µmol/L) were 
noted, on day 22. These had both resolved at the next sampling point on day 28. 
 
In the 20oC studies subject 101 had marginal uric acid (341 µmol/L) on day 13 (the last 
day of medication administration), which had normalised by day 20. Subject 104 had 
elevated uric acid (427 µmol/L) on day 20, which had normalised on day 27. 
 
Animals with elevated bile acids did not always have concurrently elevated uric acid and 
vice versa. 
 
White cell counts were elevated in two animals (subjects 104 and 112, both male) in the 
12oC study. White blood cells are part of the immune system, and elevations commonly 
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indicate inflammation. Both tuatara had elevations in heterophils and monocytes, 
indicative of granulocytic inflammation. These elevations were first noted on day 22, 
and persisted through day 41, but had resolved by day 55. During the 20oC study white 
cell numbers remained normal for all animals, however animal 105 had one instance of 
reactive monocytes on day 27 which were not observed again. 
Overall, subjects 104 and 112 suffered the most severe adverse effects throughout both 
studies, as evidenced variously by elevated white cells, bile acids and uric acid 
concentrations. These animals had the highest plasma itraconazole concentrations and 
were the heaviest of the group, meaning that on an allometrically-scaled basis, these 
animals received more itraconazole (despite the same mg/kg dosage) than their smaller 
counterparts. It is possible that this higher dosage is responsible for the increased 
incidence of adverse effects, however sex-specific differences in itraconazole 
metabolism cannot be ruled out without further studies involving more animals of 
varying weights.  
 
It appears that in tuatara, itraconazole toxicity manifests primarily as presumed 
cholestasic disease characterised by elevations in bile acids and, in more severe cases, 
white blood cells. Uric acid elevations, likely related to dehydration, were also present 
in several cases.  
 
4.4.3 Itraconazole : hydroxy-itraconazole ratio 
 
Hydroxy-itraconazole and itraconazole have a similar anti-fungal spectrum of activity, 
and very few fungi differ significantly in their in vitro susceptibility to the two antifungals 
(Odds and Bossche 2000). In human subjects, hydroxy-itraconazole plasma 
concentrations and AUC exceed that of itraconazole, after both single and multiple 
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doses (Meinhof 1993, Barone et al. 1998, Suarez-Kurtz et al. 1999). This was also the 
case in Humboldt penguins (Bunting et al. 2009). In Kemp’s ridley sea turtles, hydroxy-
itraconazole concentrations were markedly lower than itraconazole concentrations 
(Manire et al. 2003), while in horses, hydroxy-itraconazole was not detected at all 
following itraconazole administration, indicating a different pathway was involved in 
itraconazole metabolism (Davis et al. 2005).  
 
In tuatara, hydroxy-itraconazole concentrations were significantly lower than 
itraconazole concentrations at all time points in the single dose studies. In multiple dose 
studies at 12oC, hydroxy-itraconazole concentrations were observed to continue to 
increase for 13 days in all animals following cessation of treatment and, in two animals, 
were still increasing at the end of sampling, 33 days after stopping treatment. Hydroxy-
itraconazole concentrations exceeded itraconazole concentrations in three animals at 
the end of the sampling period. Similar data were obtained in the 20oC studies, with 
hydroxy-itraconazole concentrations exceeding those of the parent drug 4 days after 
finishing treatment in one animal, 6 days after finishing treatment in 4 animals, and in 
all 6 animals at the end of sampling, 14 days after cessation of therapy. These prolonged 
elevations in hydroxy-itraconazole concentration, along with itraconazole’s persistence 
in skin (Cauwenbergh et al. 1998, Heykants et al. 1989), may account for the success of 
pulse therapy documented in humans (De Doncker et al. 1997) as the hydroxy-
itraconazole concentrations observed at the end of sampling were above the target 






4.4.4 Recommended treatment protocol 
 
From these data it can be concluded that it is not appropriate to treat tuatara at 12oC 
with itraconazole, due to the prolonged time taken to approach steady-state, the 
accumulation of drug, and the potential for adverse effects that this presents. Tuatara 
undergoing itraconazole treatment should be maintained at 20oC and the treatment 
regime based on their weight (Table 4.19), with careful monitoring of haematology and 
biochemistry every 2 weeks, or more frequently if symptoms such as inappetence or 
weight loss become apparent. Particular attention should be paid to changes in bile 
acids, uric acid and white cell count. Elevations in bile acids should result in the cessation 
of therapy, with careful monitoring and supportive care if necessary until all 
haematology and biochemistry parameters return to normal. Administration of a 
loading dose will reduce the time required to reach target plasma itraconazole 
concentrations. 
 
Table 4.19 Recommended daily itraconazole dosage for tuatara weighing between 0.1-
1.0kg maintained at 20oC.  
Weight (kg) 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 
Loading dose 
(mg) 
0.64 1.28 1.91 2.55 3.19 3.83 4.46 5.10 5.74 6.38 
Maintenance 
dosage (mg/kg) 




These studies show that tuatara should be treated at the high end of their POTZ, at 20oC. 
Itraconazole has the potential to cause elevations in bile acids, uric acid and white blood 
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cell concentrations, and haematology and biochemistry should be monitored at regular 
intervals in tuatara undergoing treatment. Ideally, further pharmacokinetic studies and 
clinical trials at the recommended dose rates should be conducted to ensure target 
concentrations are met and desired clinical outcomes achieved. The proposed 
itraconazole treatment regimes based on MIC and PK data from this study have the 

















Voriconazole is a second-generation triazole antifungal, synthetically derived from 
fluconazole (Theuretzbacher 2006). It is commonly used in human medicine to treat and 
prevent invasive aspergillosis and Candida infections in immunocompromised patients. 
In mammals voriconazole undergoes hepatic metabolism, and does not have any 
pharmacologically active metabolites (Theuretzbacher 2006). Voriconazole has complex 
clinical pharmacology in humans, with non-linear pharmacokinetics and variable hepatic 
metabolism by CYP2C19 enzymes. Studies in humans and most animals show that 
voriconazole has saturable metabolism at therapeutic doses, though linear 
pharmacokinetics were observed in children under 12 and in Amazon parrots 
(Theuretzbacher 2006, Sanchez Migallon-Guzman et al. 2010). 
 
There are few reports of voriconazole use in reptiles in the literature, however oral 
voriconazole has been used successfully to treat infections caused by members of the 
CANV complex in lizards at a dosage of 10 mg/kg SID (Hellebuyck et al. 2010, van 
Waeyenberghe et al. 2010). This voriconazole dose regimen appeared well tolerated and 
effective in the majority of cases, though one bearded dragon treated with this regimen 
died.  In this case it was not clear on histopathologic examination if the mortality was 
caused by voriconazole-related hepatotoxicity or a consequence of fungal invasion (L. 
Van Waeyenberghe, pers. comm.).  
 
The aim of this study was to investigate the pharmacokinetics of voriconazole after 
administration of the oral suspension. Single and multiple dose studies were conducted 
at high and low ends of the tuatara’s POTZ to investigate variability in pharmacokinetics 





Single dose studies were conducted first, and the results of these informed the methods 
of the multiple dose studies. For general methods relating to animal selection, 
environmental conditions, drug assay method and pharmacokinetic analysis, see 
Chapter 2. 
 
Mixed effects pharmacokinetic modelling was performed using NONMEM v7.3.0 with 
the Fortran Compiler v11. Modelling for voriconazole concentration-time date in tuatara 
assumed one compartment pharmacokinetic model, mixed-order elimination and first-
order absorption (see Chapter 2 and Appendix 6).  
 
Animal ethics approvals were obtained from Murdoch University, Auckland Zoo and the 
Department of Conservation (see Section 2.2). 
 
Plasma antifungal concentrations were determined using Liquid Chromatography and 
tandem Mass Spectrometry (LCMS/MS). Drug assay methods and HPLC conditions are 
described in Section 2.6 and Appendices 3 and 4. 
 
5.2.1 Single dose studies 
 
Dose determination 
Tuatara have a low metabolic rate compared to other reptiles (Thompson and 
Daugherty 1998), and voriconazole has a low MIC (<0.008-0.015 mg/L, Section 3) for 
studied P. australasiensis isolates. For these reasons a voriconazole dosage of 5 mg/kg 




Drug formulation and administration 
The voriconazole formulation was a powder for reconstitution with tap water (VFEND 
powder for oral suspension, Pfizer, NZ). It is designed to be reconstituted to 40 mg/mL. 
However, after verifying with technical staff at Pfizer that absorption and uniformity of 
suspension would not be affected, a concentration of 15 mg/mL was chosen. The lower 
concentration ensured more accurate dosing, and volumes administered were similar 
to those for the itraconazole-treated animals (Section 4.2.1).  Medication was 
administered orally as described in Chapter 2. 
 
Blood sampling intervals 
Blood sampling intervals were the same as those in the itraconazole single dose study 
(Chapter 4), at 2, 4, 8, 12, 24 and 48 hours following oral voriconazole dosing. 
 
5.2.2 Multiple dose studies 
 
Dose determination 
All animals in the study weighed over 400 grams (range 458-899 g), so this weight was 
chosen as the weight for which the target concentration of 0.16 mg/L would be 
determined. The predicted dose rate to achieve the target concentration of 0.16 mg/L 
in a 400 g animal at 20 oC is 0.17 mg/kg/day (Table 5.6), based on the PK modelling from 
the single dose studies. This is far lower than the 10 mg/kg used in other reptile studies 
(Hellebuyck et al. 2010, van Waeyenberghe et al. 2010), and lower than the 5 mg/kg 
used in the single dose studies. There were no adverse effects attributed to the use of 
voriconazole at 10 mg/kg in the aforementioned studies, so this suggests that 




As there is the potential for voriconazole to be used in tuatara to treat fungal organisms 
with MICs higher than that of the current P. australasiensis isolates, it was elected to 
use a higher dosage than the predicted 0.17 mg/kg/day. A dose rate of 1 mg/kg once 
daily was selected for the 12oC study for the reasons outlined above, and based on the 
ease of medication administration at this dose. Because a different dose was being used 
to that in the single dose studies, and given voriconazole’s non-linear pharmacokinetics, 
it was expected that pharmacokinetic parameters and indices would be significantly 
different in the multiple dose studies than in the single dose studies. 
 
Pharmacokinetic modelling simulations conducted with the aid of the 12oC multiple 
dose studies indicated that using the same dosage of 1 mg/kg at 20oC was likely to result 
in very low, possibly undetectable concentrations of voriconazole in most animals. The 
modelling predicted that a dose rate of 1.8 mg/kg would be required for animals to reach 
plasma voriconazole concentrations above the target of 0.16 mg/L at 20oC. 
Consequently a dose rate of 2 mg/kg was chosen for ease of drug dose calculation for 
this part of the study.    
 
Drug formulation and administration 
The VFEND powder for oral suspension (Pfizer, NZ) was reconstituted to a concentration 
of 4 mg/mL for ease of administration, and so drug volumes were similar to those used 
in the itraconazole studies (Chapter 4). Medication was stored at room temperature and 
disposed of after 14 days, as per manufacturer recommendations, and a new suspension 
was made up for the following two weeks. 
 
In the 12oC study, voriconazole was to be administered at 1 mg/kg PO SID for 42 days. 
However as there was no evidence of plasma concentrations approaching steady state, 
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drug administration was ceased on day 21. The medication was given at approximately 
the same time each day for each animal (with up to 5 minutes variation between days), 
between the hours of 7am and 8am. At 12oC, animals were fed once weekly in the 
afternoon, to minimise any effect of food on absorption of medication. The gastric pH 
and gastric emptying time of tuatara is unknown. 
 
In the 20oC study, VFEND was reconstituted to a concentration of 8 mg/mL so that 
administration volumes were similar to those used in the 12oC study. Medication was 
administered using the same method as in the 12oC study, for a total of 42 days. Animals 
were fed twice weekly in the afternoons, on the same days each week. 
  
Blood sampling intervals 
In order to measure trough voriconazole concentrations, blood samples were taken just 
prior to medication administration. The first day of medication was designated as day 
zero, and it was planned to take samples for trough voriconazole concentrations on days 
2, 4, 6, 13, 20, 27, 24 and 41 in the 12oC study.  Results from the first two weeks showed 
that voriconazole concentrations were increasing with no evidence of approaching 
steady state. It was unlikely that further beneficial pharmacokinetic information would 
be generated if the study was continued, and the risk of voriconazole toxicity increased 
with increasing plasma drug concentrations. The decision was made to cease 
voriconazole administration and take further blood samples to measure drug 
elimination. The last dose of voriconazole was given on day 21, and samples were taken 
to measure drug elimination on days 22, 23, 24 and 25. Blood samples were taken for 




In the 20oC study, sampling was undertaken on days 6, 13, 20, 27 and 41 to measure 
trough voriconazole concentrations. Samples to measure elimination were taken on day 





5.3.1 Results for single dose studies 
 
5.3.1.1 Single dose studies conducted at 12oC ambient temperature 
Plasma antifungal concentrations 
Voriconazole was administered to four tuatara at a dose rate of 5 mg/kg PO, at time 
zero. Plasma samples were analysed using LCMS/MS and were run in duplicate to ensure 
accuracy, with the averages displayed below (Table 5.1 and Figure 5.1) 
 
Table 5.1 Voriconazole plasma concentration (mg/L) at time from voriconazole 
administration (hours) at 12oC in tuatara. NS = no sample. 
Animal ID Sex 2h 4h 8h 12h 24h 48h 
202 F 1.935 2.030 3.070 3.225 6.315 4.745 
203 M 0.497 0.956 NS 1.580 1.500 3.645 
206 F 1.195 2.405 1.990 1.820 0.822 0.650 




Figure 5.1 Voriconazole plasma concentration (mg/L) at time from voriconazole 
administration (hours) at 12oC in tuatara. 
 
 
Pharmacokinetic data and analysis 
Two of the four subjects in the 12oC study appeared to be in the terminal elimination 
phase by the last time point at 48 hours. For subjects 202 and 208, there were only two 
data points (at 24 and 48 hours) in the elimination curve, and this does not provide 
enough data to accurately calculate the elimination constant.  In subject 203, no 
elimination was observed 48 hours post- medication administration. As the elimination 
constant could not be accurately calculated in subjects 202, 203 and 208, it was not 
possible to obtain data to calculate elimination half-life, AUC0-∞, apparent clearance, or 
apparent volume of distribution. The only index able to be reliably calculated for all four 
subjects was AUC0-48 (Table 5.2). Elimination in subject 206 was sufficient to allow 
calculation of AUC0-∞, however the extrapolated percentage was >20 %, precluding the 




Table 5.2 Selected pharmacokinetic indices for voriconazole at 12oC. NC = not 
calculated.  
Animal ID AUC0-48 (mg/L*h) AUC0-∞ (mg/L*h) AUC % extrapolated 
202 218.6 NC NC 
203 92.3 NC NC 
206 56.2 81.2 30.1 
208 131.6 NC NC 
    
Mean ± SD 124.68 ± 60.43 NC NC 
       
Approximate maximal plasma concentration (Cmax) and time to maximal plasma 
concentration (Tmax) were highly variable, and were not able to be determined for 
subject 203. As maximal concentrations were observed late in the sampling period, it is 
not appropriate to estimate Cmax and Tmax, as the sampling intervals at this stage were 
long. The true values of voriconazole Cmax and Tmax for subjects 202 and 208 may have 
occurred a significant number of hours either side of the sampling points, so these data 
has not been analysed.  
 
Pharmacokinetic modelling results 
Using mixed effect modelling (see Section 2.11), it was possible to estimate the drug 
dosages required to reach the target concentration of 0.16 mg/L (see Chapter 3) at 12oC 
for animals of different weights. It was also possible to estimate pharmacokinetic 






Table 5.3 Pharmacokinetic modelling results for attaining steady-state plasma 
concentrations of 0.16 mg/L of voriconazole at 12oC. 
Weight kg Volume  (L) Clearance (L/h/kg) Dose rate (mg/kg/ day) 
0.1 0.06 0.0188 0.07 
0.2 0.11 0.0158 0.06 
0.3 0.17 0.0143 0.05 
0.4 0.22 0.0133 0.05 
0.5 0.28 0.0126 0.05 
0.6 0.33 0.0120 0.05 
0.7 0.39 0.0116 0.04 
0.8 0.44 0.0112 0.04 
0.9 0.50 0.0109 0.04 
1 0.55 0.0106 0.04 
 
5.3.1.2 Single dose studies conducted at 20oC ambient temperature 
Plasma antifungal concentrations 
Samples were run in duplicate to ensure accuracy, with the averages displayed below 
(Table 5.4 and Figure 5.2). 
 
Table 5.4 Voriconazole plasma concentration (mg/L) at time from voriconazole 
administration (hours). NS = no sample. * = duplicate samples significantly different, 
data point not used in calculations. 
Animal ID Sex 2h 4h 8h 12h 24h 48h 
202 F 2.230 7.765 6.665 NS NS NS 
203 M 2.385 3.305 5.085 4.475 2.900 0.828 
206 F 2.615 3.820 5.435 5.510 1.890 0.162 
208 F 2.525 NS *3.535 2.700 *3.245 0.222 
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Figure 5.2 Voriconazole plasma concentration-time profile in the tuatara after 5 mg/kg 
oral voriconazole dose. 
 
      
Pharmacokinetic data and analysis 
All four subjects were undergoing elimination by the last time point. Sampling for 
subject 202 was interrupted due to a physical injury sustained during sample collection, 
and no further data was available for this subject during this part of the study. As only 
two data points were in this subject’s elimination curve, this precluded calculation of all 
pharmacokinetic parameters and indices for this subject. 
 
The extrapolated percentage of AUC was <20 for subjects 203, 206 and 208, permitting 
the calculation of elimination half-life, apparent clearance and apparent volume of 
distribution (Table 5.5). Approximate time to maximal plasma concentration (Tmax), and 
approximate maximal plasma concentration (Cmax) were moderately variable. Tmax 
appears to occur 4-12 hours following oral administration of voriconazole. Cmax appears 
to be between 2.7 and 7.765 mg/L, however this lower value may be misleading, as 
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plasma concentrations for the associated tuatara (208) were not able to be determined 
at 4 and 8 hours, as sufficient blood could not be obtained for analysis. 
 
The elimination half-life of voriconazole at 20oC ranged from 7.03-14.55 hours, with a 
mean ± SD of 10.52 ± 3.1 hours. The apparent clearance ranged from 0.0334-0.0592 
L/h/kg, with a mean ± SD of 0.045 ± 0.01 L/h/kg. The apparent volume of distribution 
ranged from 0.209-0.628 L/h, with a mean ± SD of 0.66 ± 0.18 L/h.  
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Table 5.5 Selected pharmacokinetic parameters and indices for voriconazole at 20oC. NC = not calculated.  




Apparent volume of 
distribution (L/kg) 
202 NC NC NC NC NC NC 
203 133.0 150.3 11.6 14.55 0.0334 0.699 
206 118.5 120.1 1.4 7.03 0.0415 0.421 
208 81.2 84.4 3.8 9.99 0.0592 0.853 
       
Mean ± SD 110.90 ± 21.8 118.27 ± 26.9 5.60 ± 4.4 10.52 ± 3.1 0.045 ± 0.01 0.66 ± 0.18 
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Pharmacokinetic modelling results 
Using mixed effect modelling (see Section 2.11), it was possible to estimate the drug 
dosages required to reach the target concentration of 0.16 mg/L (Chapter 3) at 20oC for 
animals of different weights. It was also possible to estimate pharmacokinetic 
parameters and indices of voriconazole for different animal weights at 20oC (Table 5.6). 
 
Table 5.6 Pharmacokinetic modelling results for attaining steady-state plasma 
concentrations of 0.16 mg/L of voriconazole at 20oC. 
Weight (kg) Volume (L) Clearance (L/h/kg) 
 
Dose rate (mg/kg/ day) 
 
0.1 0.06 0.063 0.24 
0.2 0.11 0.053 0.20 
0.3 0.17 0.048 0.18 
0.4 0.22 0.045 0.17 
0.5 0.28 0.042 0.16 
0.6 0.33 0.040 0.15 
0.7 0.39 0.039 0.15 
0.8 0.44 0.037 0.14 
0.9 0.50 0.036 0.14 
1 0.55 0.035 0.14 
        
It can be seen that the dosages required to attain the target steady-state concentration 
are higher at 20oC than at 12oC, and are higher for animals of lower weights (Tables 5.3 
and 5.6). It must be noted that, due to the lack of good elimination data at 12oC, the 




5.3.1.3 Statistical comparisons 
The only parameter suitable for statistical comparison between temperatures was AUC0-
48. Using the paired t-test the p-value was 0.662, indicating the data at 12oC and 20oC 
were not significantly different.  
 
5.3.1.4 Combined pharmacokinetic modelling results 
Other pharmacokinetic parameters and indices derived from the single dose studies are 
provided in Table 5.7. Although not practically applicable to tuatara, data for a 70kg 
animal is included in the below results as this is the standard employed in human 
medicine to allow comparisons between medications, as generally speaking, 
pharmacokinetic parameters and indices differ on an allometrically scalable basis 
(Huang and Riviere 2014). 
 
Table 5.7 Estimates of modelling-derived voriconazole PK parameters and indices from 
single dose studies. 
Statistics Estimate 
Vmax (mg/h/70kg) 2.21 
Km (mg/L)  0.01 
Volume of distribution (L/70kg) 64 
Absorption half-life (hours) 4.22 








5.3.2 Results for multiple dose studies 
 
5.3.2.1 Multiple dose studies conducted at 12oC ambient temperature 
Plasma antifungal concentrations 
Voriconazole was administered to six tuatara at a dose rate of 1 mg/kg PO once daily 
until the last dose on day 21. Blood samples were obtained as described in Section 
5.3.1.3. Samples were analysed using LCMS/MS, and results are displayed below (Table 
5.8 and Figure 5.3). 
 
Table 5.8 Voriconazole plasma concentration (mg/L) at time from voriconazole 
administration (days) at 12oC. NS = no sample. * = too low to quantitate. 
 Days after first dose 
Animal 
ID 
Sex 2 4 6 13 20 22 23 24 25 
202 F 0.022 0.208 0.551 2.02 1.9 2.28 1.53 0.722 0.52 
203 M 0.16 0.349 0.642 0.353 NS 5.74 4.49 4.01 3.42 
206 F * NS 0.147 1.63 2.33 1.83 1.08 0.725 0.416 
208 F * * * 0.0695 0.607 0.713 0.287 0.113 0.0554 
210 M 0.135 0.626 1.04 3.25 4.92 5.87 5.77 5.08 4.53 











Figure 5.3 Vorconazole plasma concentration (mg/L) at time from voriconazole 
administration (days) at 12oC. 
 
 
Pharmacokinetic data and analysis 
The only index that could be calculated using traditional pharmacokinetic analysis was 
elimination half-life. The mean ± SD half-life of voriconazole was 2.55 ± 1.78 hours. 
 
        Table 5.9 t1/2 of voriconazole at 12oC. 








Mean ± SD 2.55 ± 1.78 
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Pharmacokinetic modelling results 
The modelling data below (Table 5.10) describes select pharmacokinetic parameters and 
indices, and the mg/kg per day dosage of voriconazole required to achieve a plasma 
target concentration of 0.16 mg/L for tuatara weighing between 0.1-1.0 kg maintained 
at 12oC. Dose rates range from 0.70-1.25 mg/kg. As in the itraconazole study (Chapter 
4), data for a 70kg animal is included to allow standard comparisons between tuatara, 
humans and other species. 
 
Table 5.10 Model predictions of pharmacokinetic parameters and voriconazole dose 
rates required to attain steady-state target concentration of 0.16 mg/L at 12oC. 
Weight (kg) Volume (L) CL/kg (L/h/kg) Dose rate (mg/kg/ day) 
0.1 0.002 0.3262 1.25 
0.2 0.005 0.2743 1.05 
0.3 0.007 0.2479 0.95 
0.4 0.009 0.2307 0.89 
0.5 0.011 0.2182 0.84 
0.6 0.014 0.2084 0.80 
0.7 0.016 0.2006 0.77 
0.8 0.018 0.1940 0.74 
0.9 0.020 0.1884 0.72 
1 0.023 0.1835 0.70 
70 1.580 0.0634 0.24 
 
Modelling based on both the single and multiple dose data illustrate the predicted and 
observed concentrations of voriconazole at the administered dose rate of 1 mg/kg for 




Figure 5.4 Predicted and observed voriconazole concentrations at 12oC following 
dosing at 1 mg/kg SID. Green line: individual prediction. Dashed line: population 
prediction. Red symbols: observed concentrations.
 
Health screening results 
Health screening was conducted on days 13 and 22 during the study, as described in 
Section 2.3.2. No significant changes in haematology or biochemistry were detected in 
any animal. 
 
5.3.2.2 Multiple dose studies conducted at 20oC ambient temperature 
Plasma antifungal concentrations 
Voriconazole was administered to six tuatara at a dose rate of 2 mg/kg PO once daily 
until the last dose on day 21. Blood samples were obtained as described in Section 
5.3.1.3. Samples were analysed using LCMS/MS, and results are displayed below (Table 
5.11 and Figure 5.5). An unexpected decrease in voriconazole concentrations was 




Table 5.11 Voriconazole plasma concentration (mg/L) at time from voriconazole 
administration (days).  
 Days after first dose 
Animal ID Sex 6 13 20 27 41 41.42 41.67 42 
202 F 0.765 1.907 0.595 2.098 0.143 0.441 0.209 0.125 
203 M 1.071 7.356 2.467 6.758 3.611 2.783 2.309 2.04 
206 F 0.607 1.31 0.23 1.186 0.125 0.271 0.155 0.132 
208 F 0.068 0.857 0.204 0.486 1.662 1.674 1.124 0.591 
210 M 1.623 6.557 2.349 2.774 1.948 1.162 1.598 1.047 
211 F 1.257 1.472 0.524 0.884 0.114 0.374 0.173 0.13 
 
Figure 5.5 Voriconazole plasma concentration (mg/L) at time from voriconazole 
administration (days). Inset on right shows close-up of elimination. 
 
Pharmacokinetic data and analysis 
The only index that could be calculated using traditional pharmacokinetic analysis was 





        Table 5.12 t1/2 of voriconazole at 20oC.  








Mean ± SD 0.60 ± 0.36 
     
 
Pharmacokinetic modelling results 
The modelling data below (Table 5.13) describe select pharmacokinetic parameters and 
the mg/kg per day dosagee of voriconazole required to achieve a plasma target 
concentration of 0.16 mg/L for tuatara weighing between 0.1-1.0 kg maintained at 20oC. 












Table 5.13 Model predictions of pharmacokinetic parameters and itraconazole dose 
rates required to attain steady-state concentration of 0.16 mg/L at 20oC. 
Weight kg Volume (L) Clearance (L/h/kg) Dose rate (mg/kg/day) 
0.1 0.002 0.688 2.64 
0.2 0.005 0.579 2.22 
0.3 0.007 0.523 2.01 
0.4 0.009 0.487 1.87 
0.5 0.011 0.460 1.77 
0.6 0.014 0.440 1.69 
0.7 0.016 0.423 1.63 
0.8 0.018 0.409 1.57 
0.9 0.020 0.397 1.53 
1 0.023 0.387 1.49 
70 1.580 0.134 0.51 
 
Modelling based on both the single and multiple dose data illustrate the predicted and 
observed concentrations of voriconazole at the administered dose rate of 2 mg/kg PO 












Figure 5.6 Predicted and observed voriconazole concentrations at 20oC following dosing 
at 2 mg/kg SID. Green line: individual predition. Dashed line: population prediction. Red 
symbols: observed concentrations. 
 
Pharmacokinetic modelling simulations were run to illustrate the difference between 
predicted voriconazole concentrations at both temperatures. An example is provided 
below, where a 0.75kg tuatara is administered voriconazole at 1 mg/kg PO SID (Figure 
5.7). 
 
Figure 5.7 Time vs concentration profile of a 0.75 kg tuatara administered 1 mg/kg 
voriconazole SID at 12oC and 20oC. 
















































Health screening results 
Health screening was conducted on days 13, 27 and 41 during the study, as described in 
Section 2.3.2. No significant changes in haematology or biochemistry were detected in 
any animal. No significant weight changes were noted in any animal. 
 
5.3.2.3 Statistical comparisons 
Elimination half-life was suitable for statistical comparison between temperatures. 
Following log transformation, using the paired t-test the p-value was 0.0017, indicating 
the t1/2 at 12oC and 20 oC were significantly different (p<0.05). 
 
5.3.2.4 Combined pharmacokinetic results of single and multiple dose studies at both 
temperatures 
Bootstrap estimates of other model parameters and indices and confidence intervals 
were able to be determined, and these are illustrated in the table below (Table 5.14). 
 
Table 5.14 Select population pharmacokinetic parameters and indices for tuatara 
receiving voriconazole. RUV = residual unexplained variability. RSE = relative standard 
error expressed as a percentage. 
Statistics Mean 95% CI RSE % 
Vmax (mg/h/70kg) 1.619 1.490-2.091 9 
Km (mg/L) 0.030 0.001-0.426 361 
Volume of distribution (L/70kg) 77.911 61.675-95.850 12 
Absorption half-life (hours) 3.20 1.290-6.618 56 
Fold decrease in clearance relative to 20oC 2.133 2.050-2.240 3 
Bioavailability decrease factor day 17 20oC 0.737 0.659-0.900 7 
RUV proportional 0.268 0.197-0.318 12 
RUV additive (mg/L) 0.502 0.275-0.609 20 
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Vmax is the maximum metabolic rate of voriconazole in tuatara, and depends on the 
mass of the hepatic metabolic enzymes, which become saturated. Km is the 
voriconazole plasma concentration at 50% of Vmax. The unexpected decrease in 
voriconazole concentrations observed on day 20 was accounted for in the modelling by 
a decrease in bioavailability from day 17 (see Sections 5.3.4.1 and 5.3.5.2). Residual 
unexplained variability (RUV) is a measure of random error, which is always present in 
modelling and is unpredictable. Quantifying RUV gives a measure of how reliable a 




5.4.1 Pharmacokinetics and temperature 
 
Overall, there were distinct trends in voriconazole plasma concentration at the two 
different temperatures. Subject 206 had similar voriconazole plasma concentration 
curves at 12oC and 20oC in the single dose studies. It is unknown why this is the case, as 
the subject’s temperature was measured at the start of each study, and reflected the 
ambient temperature. As subject 206’s curve at 20oC is similar to that of other subjects 
at 20oC, it is likely that the 12oC data is the anomalous data set. The animal’s metabolic 
rate may have been elevated for an unknown reason, such as increased activity level. 
With such a small sample size, it cannot be certain that subject 206’s 12oC data is a true 
outlier, so it was included in pharmacokinetic calculations and modelling.  
 
Time to maximal plasma concentration 
Single dose studies were both conducted using voriconazole dosages of 5 mg/kg, 
allowing direct comparison of the effect of temperature on pharmacokinetic parameters 
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and indices. At 12oC time to maximal plasma voriconazole concentration was highly 
variable, ranging from 4-24 hours in three animals, with the fourth animal’s apparent 
peak at 48 hours. There was limited sampling after 12 hours, so the peak in the fourth 
animal’s voriconazole concentration may have occurred any time from 24 hours after 
dosing. At 20oC Tmax was between 4-8 hours for all animals. It was not appropriate to 
make statistical comparisons for Tmax given the limited sample size and the uncertainty 
of apparent Tmax at 12oC in one subject, however it is apparent there is a marked 
difference in Tmax at the two temperatures at a 5 mg/kg dosage. The Tmax of 
voriconazole in humans is less than two hours (Theuretzbacher et al. 2006), and in 
various avian species ranged between 1-4 hours (Flammer et al. 2008, Beernaert et al. 
2009, Sanchez-Migallon Guzman et al. 2010). In mammals voriconazole Tmax varies 
significantly, from one hour in female rats to up to 12.9 hours in horses, with mice, dogs, 
guinea pigs, rabbits and male rats in between (Roffey et al. 2003, Colitz et al. 2007). 
These studies administered voriconazole at dose rates ranging from 6-30 mg/kg, and the 
study in Amazon parrots showed a significantly different Tmax when different dosages 
were used (two hours and four hours at 6 mg/kg and 12 mg/kg respectively), making 
direct interspecies comparisons using different dosages inappropriate.  
 
Absorption half-life 
The absorption half-life was estimated at 3.20 hours based on the modelling. This is a 
long half-life, and indicates that 50% of the administered oral dose is absorbed in 3.2 
hours. The RSE for absorption half-life was 56%, so this value may not be a reliable 
estimate. Absorption is considered to be a largely passive process, and not markedly 





In the single dose studies, the elimination half-life of voriconazole was not able to be 
calculated at 12oC. At 20oC, elimination half-life had a mean ± SD of 10.52 ± 3.1 hours. 
In the multiple dose studies voriconazole had a mean ± SD elimination half-life of 2.55 ± 
1.78 hours at 12oC with a dose rate of 1 mg/kg, and a mean ± SD half-life of 0.60 ± 0.36 
hours at 20oC with a dose rate of 2 mg/kg. As voriconazole displays mixed-order kinetics 
(saturable elimination) it is not appropriate to directly statistically compare elimination 
half lives at different dosages, however modelling and simulations confirm that half-life 
is shorter at 20oC than 12oC, when the same dose is administered. This is likely because 
although the Vmax remains the same at both temperatures (it reflects a metabolic 
enzyme mass), the Km (which reflects the affinity of voriconazole for the enzyme) is 
reduced at lower temperatures, resulting in slower clearance of the drug.  
 
The marked difference in elimination half-life in single and multiple dose studies is a 
function of the different dosages used in both studies, and illustrates voriconazole’s non-
linear pharmacokinetics. The observed short half-life in multiple dose studies results in 
significant fluctuations in drug concentration throughout the day, though this is 
considered acceptable as long as trough concentrations remain above the target and 
there are no adverse effects from the transiently high maximal plasma concentrations. 
Although half-lives were able to be determined using compartmental PK methods, it 
should be noted that it is not really possible to accurately describe the elimination half-




In humans, voriconazole half-life is approximately 6 hours but is dose-dependent 
(Theuretzbacher et al. 2006), while in birds it ranges from 1.1-10 hours depending on 
dose and species (Burhenne et al. 2008, Flammer et al. 2008, Beernaert et al. 2009). 
 
The two male tuatara in the study had markedly higher voriconazole plasma 
concentrations than the females, but the males weighed significantly more than the 
females, so it is likely this difference was related to weight rather than sex. Allometrically 
scaled dosage recommendations provided by the modelling would avoid this disparity 
occurring in the future. True sex differences in voriconazole metabolism cannot be ruled 
out without further studies. 
 
Clearance 
Modelling predicted clearance at 12oC of 0.184L/h, and at 20oC of 0.387L/h for a 1kg 
animal with a target voriconazole concentration of 0.16 mg/L. There was a 2.13-fold 
decrease in clearance at 12oC relative to 20oC as estimated by modelling, further 
emphasising the difference in pharmacokinetics between these two temperatures. 
Given the level of complexity of the models and the assumptions already being made, it 
was not possible to determine whether auto-induction of voriconazole metabolism 
occurred in tuatara, as has been reported in several other species, but not humans 
(Roffey et al. 2003, Beernaert et al. 2009). 
 
Maximal voriconazole metabolism (Vmax) and Michaelis-Menten constant (Km) 
Modelling using the combined single and multiple dose data estimated the maximum 
metabolic rate of voriconazole as 1.619 mg/h/70kg. In humans Vmax has been 
estimated at 37.67 mg/h (Hope 2012) and at 43.9 mg/h (Dolton et al. 2014). The maximal 
metabolic rate of voriconazole is significantly lower in tuatara than in humans, likely as 
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a function of the tuatara’s low physiologic metabolic rate. Similarly, the Km 
(voriconazole concentration at 50% of Vmax) in tuatara was estimated at 0.030 mg/L; in 
humans it has been estimated as 2.07 mg/L (Hope 2012) and 3.33 mg/L (Dolton et al. 
2014). It must be noted that the RSE for the Km was 361%, meaning the estimates 
provided by modelling are likely to be unreliable. 
 
Volume of distribution 
Modelling estimated the volume of distribution as 64 L/70 kg, and as 0.55L in a 1kg 
animal. Voriconazole’s volume of distribution in humans is 2.0-4.6 L/kg, and in birds 
ranges from 1.05-3.5 L/kg, varying with species and dose (Burhenne et al. 2008, 
Beernaert et al. 2009, Flammer et al. 2008, Theuretzbacher et al. 2006). Volume of 
distribution was lower in tuatara than in other animals, indicating that voriconazole may 
not distribute as extensively into tissues in tuatara as in other animals.  
 
Modelling and simulation to estimate voriconazole dose regimens in tuatara 
The observed voriconazole concentrations matched variably with those predicted by 
modelling. In some animals concentrations matched very well, in others there was 
limited association. This is likely a function of the high inter-individual variability 
observed in voriconazole concentrations and pharmacokinetics, a phenomenon well-
recognised in humans (Beernaert et al. 2009). In humans, therapeutic drug monitoring 
is commonly used as a tool to guide dosage adjustments, however this is rarely practical 
in veterinary medicine. High variability in humans is attributed to differences in the 
amount of the hepatic enzyme CYP2C19, which is involved in voriconazole metabolism. 
It is possible that the tuatara in this study also had widely different amounts of CYP2C19, 
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however no studies have been conducted on tuatara to determine the composition or 
amounts of their hepatic enzymes.  
 
5.4.2 Discrepancy in observed and expected voriconazole concentrations on day 20 of 
multiple dose study 
 
On day 20 of the 20oC multiple dose study there was an unexpected decrease in 
voriconazole concentrations in all animals, compared to those on the sampling points 
on either side on days 13 and 27. All samples for days 13, 20 and 27 were re-tested, and 
the drop in concentration on day 20 was shown to be a true decrease and not a 
measuring error. There were several potential causes for this: one or more missed 
medication doses, a temporarily increased metabolic rate likely caused by an increase 
in ambient temperature, or an error in medication reconstitution resulting in a different 
voriconazole concentration to the desired 4 mg/mL. A change in ambient temperature 
was ruled out based on datalogger records. We consider the most likely cause to be one 
or more missed medication doses, as during the experimental period from days 13-21 
there was increased unplanned sampling of itraconazole animals, and it is possible that 
during this extra activity medication doses were overlooked in the voriconazole animals. 
The decrease in plasma voriconazole concentrations was modelled by assuming a 
decrease in bioavailability from day 17, and this allowed satisfactory modelling 
predictions to be made with the available data.  
 
5.4.3 Recommended treatment protocol 
 
Despite the inter-individual variability in voriconazole concentrations and 
pharmacokinetics observed in our study, all animals exceeded the target voriconazole 
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concentration at 20oC and 2 mg/kg SID by day 13, and no animal experienced observable 
adverse effects despite two animals reaching concentrations above 6.5 mg/L. The 
modelling predictions for the dose rate required to attain a steady-state concentration 
(Css) of 0.16 mg/L range from 1.49-2.64 mg/kg SID. At these dosages and with 
voriconazole’s short half-life, modelling predicts that some animals would likely spend 
significant time with trough concentrations below the therapeutic target. It is also worth 
noting that many fungal pathogens have voriconazole MICs higher than those found in 
this study for P. australasiensis, including other CANV complex fungi (Van 
Waeyenberghe et al. 2010), and our recommended dosages may be too low to treat 
these other pathogens. Modelling simulations show that increasing the voriconazole 
dosage to maintain trough concentrations above 0.16 mg/L may result in very high 
voriconazole concentrations in some animals as metabolic enzyme saturation and drug 
accumulation occurs. During our study no adverse effects were observed at dosages 
higher than those modelled in the aforementioned simulations, so using higher dosages 
may be acceptable when combined with careful health monitoring. In humans, trough 
voriconazole concentrations above 5.5 mg/L resulted in encephalopathy in 31% of 
patients, and above 8 mg/L had an estimated 90% probability of resulting in 
neurotoxicity (Pascual et al. 2008). Various studies in humans have recommended 
trough concentrations remain below 4.0-5.5 mg/L to reduce the likelihood or 
neurotoxicity (Dolton et al. 2014). In racing pigeons, clinically significant hepatotoxicity 
was detected in animals with trough voriconazole plasma concentrations of 5.85 (± 3.12) 
mg/L (Beernaert et al. 2009), and in various species of penguins neurological signs of 
toxicity were noted in multiple animals with trough concentrations above 5.5 mg/L 




The medication dose rates required to maintain Css of 0.16 mg/L at 20oC for tuatara 
between 0.1-1.0 kg are shown below (Table 5.15). Given the high inter-individual 
variability observed, it is possible these dosages may result in subtherapeutic 
voriconazole concentrations in some animals. In clinical cases this may not be a 
significant problem as medication dosages can be increased as required, but it would be 
inappropriate to use these modelling-derived dose rates in clinically normal animals as 
part of a quarantine treatment protocol. This may be overcome by using higher dosages 
than those recommended by modelling, however as a small increase in dose will result 
in a disproportionately large increase in plasma voriconazole concentration due to the 
non-linear kinetics, close monitoring for adverse effects must be undertaken. It is worth 
remembering there were no adverse effects detected in either of our studies, despite 
trough plasma voriconazole concentrations reaching up to 7.4 mg/L. 
 
Table 5.15 Modelling recommended daily voriconazole dosage for tuatara weighing 
between 0.1-1.0 kg maintained at 20oC. 
Weight 
(kg) 
0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 
Dosage 
(mg/kg) 




These studies show that, as with itraconazole, there is significant variation in 
pharmacokinetics with temperature, and that tuatara should be treated at 20oC, at the 
high end of their POTZ. Voriconazole has non-linear pharmacokinetics in tuatara, as in 
many other species. While there were no adverse effects associated with voriconazole 
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treatment in our study, caution and careful monitoring are warranted if dosages higher 
than those recommended by modelling are used, as small dose increases can result in 
large increases in plasma voriconazole concentrations. As in humans, high inter-
individual variation in plasma voriconazole concentrations were noted, and this may 
result in treatment failure or adverse effects in some individuals even when 
recommended dosages are used. The proposed treatment regimes based on MIC and 










6. Chapter 6: Development of haematological 






Reference ranges for haematological and biochemical parameters provide a set of 
‘normal’ blood values with which to evaluate the health of individuals of the same 
species. Evaluation of reptile haemograms and biochemistry can be problematic, as 
values can change with season, age, sex, environment and nutritional status (Mader 
1999, Campbell 2014). It has been suggested that serial blood values from the same 
animal, or values from a healthy conspecific held under the same conditions, may have 
the most use in evaluating blood values in reptiles (Mader 1999, Hernandez-Divers 
2006). However in the absence of these, as is often the case in wildlife, reference ranges 
assist greatly in interpreting values from individual animals. 
 
Tuatara are an iconic endemic New Zealand reptile, but there are only limited 
haematological and biochemical data available for this species (Boardman and 
Blanchard 2006, Gartrell et al. 2006, Species360 2013). The Species360 (2013) data 
provides ranges only for white blood cell numbers, calcium and phosphorous, with wide 
reference intervals and no information on how the values were derived. These data are 
compiled from member institutions, and information on sample handling, testing 
methodology, age and signalment of participant animals is not consistently available, 
limiting the use of these reference ranges. The data from Boardman and Blanchard 
(2006) has similar limitations, though testing was performed by a single laboratory and 
more biochemical parameters were included, and the data from Gartrell et al. (2006) is 
limited to haematologic parameters from estimated white cell counts.  
 
This chapter provides haematology and plasma biochemistry values for a small 
population of captive tuatara, collected as part of a wider study on the pharmacokinetics 
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of antifungal agents reported in this thesis. It also evaluates the data and describes any 
significant variations in haematologic and biochemistry values based on the variables of 




6.2.1 Study population 
 
The study population contained twelve adult tuatara comprising eight females and four 
males. Animals ranged in age from 21 years to unknown-aged adults. Several females 
were gravid at various times throughout the study, as determined by the presence of 
eggs on radiographic examination, or if eggs were laid in the nine months following 
health screening. Physical examination and x-ray were carried out as described in 
Section 2.3.2. All animals were in good health and no pharmacologically active agents 
had been administered in the two months prior to blood sampling.  
 
Tuatara were housed in naturalistic outdoor enclosures, with no supplementary heating 
or UV lighting. Blood samples were collected in May-June of 2014 and 2015 (reported 
as ‘winter’ samples), and December 2014 (reported as ‘summer’ samples). Ambient 
temperatures in Auckland in May-June in both years had a mean of 12.9oC (range -2.3-
23.7 oC), and in December 2014 a mean of 18.4 oC (range 6.4-26.9 oC) (National Institute 
of Water and Atmospheric Research 2016). Several samples were also collected in 






6.2.2 Blood sampling, processing and analysis 
 
Blood sampling and haematology and biochemistry measurements were performed as 
described in Chapter 2. 
 
White cell counts and morphology 
For some samples, insufficient blood was available for a white cell count using the 
haemocytometer, and an estimated count from a smear was performed. During the 
pharmacokinetic studies it was noted that counts from smears were consistently higher 
than those using the chamber method. Consequently, both haemocytometer and 
estimated white cell counts were performed on a subset of animals. These samples were 
from animals receiving medication, so the data is not included in the reference ranges, 
but was used to illustrate and attempt to quantify the difference in white cell count 
between the haemocytometer and estimated white blood cell count methods. 
Haemocytometer counts and estimated counts were performed by the same technician, 
with the smears submitted from the same sample but under a different ID, so the 
technician was unaware of the haemocytometer method results. 
 
Photomicrographs of white blood cells were taken using an Olympus BX41 microscope 
and Olympus DP27 camera with DP2-SAL controller (Olympus, Australia). Dimensions of 
cells were recorded using the measurement tool in the DP2-SAL controller. 
 
Statistical analysis 
The dataset was initially inspected visually for outliers, resulting in the removal of one 
sample from the data for analysis. All analyses were performed in GraphPad Prism 
version 6.07 (GraphPad Software, USA). The Shapiro-Wilk test was used to check the 
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datasets for normality, with tests for significance using the two-tailed t test for normally 
distributed data, or the Mann Whitney test for non-parametric data. Results were 
grouped according to sex: male (n=12 for haematology, n=13 for biochemistry) and 
female (n=21 for haematology, n=22 for biochemistry) for analysis. Results from female 
tuatara were further grouped according to reproductive status: gravid (n=6 for 
haematology, n=5 for biochemistry) and non-gravid (n=15 for haematology, n=17 for 
biochemistry). An animal was considered gravid at the time of blood testing if she laid 
eggs in the following 9 months. Results were also grouped according to the season in 
which they were obtained: winter (n=20 for haematology, n=21 for biochemistry) and 
summer (n=12 for haematology and biochemistry). Means, medians, standard 
deviations and 10th-90th percentiles were calculated for all groups using GraphPad Prism. 




All animals underwent health screening on multiple occasions. In all tables n = the 
number of individual tuatara that were tested for each parameter, and the number that 





A total of 31 individual samples from 12 tuatara were available for analysis. Not all 
parameters were available for all animals, due to limitations in blood sample volume. 
Table 6.1 displays the results for all samples. Statistically significant differences in 
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parameters based on sex or temperature are discussed further below. There were no 
significant differences in any haematologic parameters based on reproductive status. 
 
Table 6.1 Haematology values for captive tuatara. PCV = packed cell volume, Hb = 
haemoglobin, MCHC = mean corpuscular haemoglobin concentration. * Some data were 
outside the range of quantitation, see text for details. † Statistically significant difference 
based on sex, season or reproductive status, see text for details.  




PCV † % 34.4 (34.0) 6.9 25-52 (26.0-47.4) 12 (25) 
Hb g/L 73.9 (71.5) 12.0 58-102 (60.8-92.9) 12 (28) 
MCHC g/L 220.5 (229.0) 40.4 133-285 (165.4-281.0) 12 (25) 
Fibrinogen g/L * * <0.1-1.9 (*) 12 (24) 
Total white cell 
count † 
x 109/L 1.68 (1.5) 0.82 0.4-3.5 (0.7-3.1) 12 (27) 
Heterophil † x 109/L 0.53 (0.5) 0.35 0.1-1.3 (0.10-1.12) 12 (27) 
% 32.5 (32.0) 14.4 8-63 (15.2-53.4) 12 (31) 
Lymphocyte  x 109/L 0.56 (0.6) 0.35 0.0-1.6 (0.18-1.00) 12 (27) 
% 32.1 (30.0) 14.6 5-61 (11.2-53.8) 12 (31) 
Monocyte x 109/L 0.32 (0.3) 0.23 0.0-1.0 (0.08-0.74) 12 (27) 
% 20.0 (19.0) 10.4 1-47 (5.4-35.4) 12 (31) 
Eosinophil  x 109/L 0.19 (0.1) 0.19 0.0-0.7 (0.0-0.52) 12 (27) 
% 10.4 (9.0) 7.9 1-35 (1.20-21.80) 12 (31) 
Basophil x 109/L 0.08 (0.0) 0.11 0.0-0.4 (0.0-0.3) 12 (27) 






Red blood cells 
The packed cell volume ranged from 25-52%, with a mean of 34.4% (Table 6.1). 
Erythrocytes were ellipsoidal cells with a homogenous pink-red cytoplasm. Occasional 
small, pink-staining cytoplasmic inclusions were noted; these did not resemble known 
haemoparasites and were presumed to be artefacts related to slide preparation. No 
intraerythrocytic parasites or mitotic figures were observed. Mild anisocytosis and 
polychromasia were occasional findings, and rare binucleated red blood cells were 
observed. Erythrocyte nucleoli were oval and frequently irregular, with dark blue 
staining chromatin. Erythrocytes were 23-28µm in length and 12-16µm wide. There was 
a statistically significant difference in PCV between sexes, with males having a higher 
PCV than females (p=0.0034) (Table 6.2). There was no significant difference in PCV 
between seasons. 
 
Table 6.2 Differences in PCV based on sex in a population of captive tuatara. 






% 34.4 (34.0) 6.9 25-52 (26.0-47.4) 12 (25) 
PCV (males) % 39.1 (36.5) 7.7 30-52 (30.2-51.9) 4 (10) 
PCV (females) % 31.3 (31.0) 4.3 25-39 (25.6-37.8) 8 (15) 
 
Total white blood cells 
Total white blood cell numbers ranged from 0.4-3.5 x 109/L, with a mean of 1.68 x 109/L 
(Table 6.3). White blood cell morphology and differential counts are discussed further 
below. There was a statistically significant difference in leukocyte numbers based on 
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season, with samples taken in winter having higher WBC counts than those in summer 
(p=0.0112). This is detailed in Table 6.3. 
 
Further analysis revealed that the higher leukocyte counts in winter were attributable 
to female tuatara. There was a significant difference in white blood cell count in females 
between summer and winter (p=0.0112), but not in males (Table 6.4). There was no 
statistically significant difference in total white blood cell numbers attributable to 
reproductive status.  
 
Table 6.3 Differences in total white blood cell count based on season in a population of 
captive tuatara. 
Parameter Unit Mean (Median) SD Min-Max (10th-90th 
Percentile) 
n (samples) 
WBC (combined) x 109/L 1.68 (1.50) 0.82 0.4-3.5 (0.7-3.1) 12 (27) 
WBC (summer) x 109/L 1.22 (1.10) 0.46 0.4-1.8 (0.46-1.80) 11 (11) 
WBC (winter) x 109/L 2.21 (1.75) 1.2 0.7-3.5 (0.98-3.29) 12 (16) 
 
Table 6.4 Differences in total white blood cell count based on season in a population of 
captive female tuatara. 
Parameter Unit Mean (Median) SD Min-Max (10th-90th 
Percentile) 
n (samples) 
WBC (female combined) x 109/L 1.59 (1.40) 0.86 0.4-3.2 (0.64-3.12) 8 (17) 
WBC (female summer) x 109/L 1.00 (1.00) 0.38 0.4-1.5 (0.40-1.50) 7 (7) 
WBC (female winter) x 109/L 2.01 (2.05) 0.86 0.7-3.2 (0.74-3.19) 8 (10) 
 
Heterophils 
Heterophils and lymphocytes were the most common white blood cells observed, 
though there was considerable variation in the numbers of each cell type between 
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samples. Heterophils comprised 8-63% of WBCs (Table 6.1) and were large, round cells 
with pale purple to non-staining eccentrically placed, lobulated nuclei and pink, 
fusiform-shaped granules (Figure 6.1, A). Heterophils were the largest of the leukocytes 
seen, with diameters of 18-24µm. There was a statistically significant difference in 
heterophil numbers (p=0.0075) and differential percentage (p=0.0067) between 
females in winter and the remaining samples (females in summer + all males). This is 
detailed in Table 6.5. 
 
Table 6.5 Differences in heterophil numbers based on sex and season in a population of 
captive tuatara. 
Parameter Unit Mean 
(Median) 




Heterophils (combined) x 109/L 0.53 (0.5) 0.35 0.1-1.3 (0.10-1.12) 12 (27) 
Heterophils (females in 
winter) 
x 109/L 0.79 (0.85) 0.40 0.2-1.3 (0.2-1.29) 8 (10) 
Heterophils (females in 
summer + all males) 
x 109/L 0.37 (0.40) 0.20 0.1-0.6 (0.1-0.6) 12 (17) 
Heterophils (combined) % 32.5 (32) 14.4 8-63 (15.2-53.4) 12 (31) 
Heterophils (females in 
winter) 
% 40.2 (40.5) 10.8 16-54 (20.2-53.1) 8 (12) 
Heterophils (females in 
summer + all males) 
% 27.6 (25) 14.5 8-63 (10.0-59.0) 12 (19) 
 
Lymphocytes 
Lymphocytes comprised 5-61% of WBCs (Table 6.1). They were small, round cells with 
purple-staining, round nuclei which took up most of the cell. Scant blue-staining 
cytoplasm was present around the periphery of the nucleus (Figure 6.1, B). Lymphocytes 
were the smallest of the leukocytes seen, with diameters of approximately 7-9µm. There 





There was considerable variation in monocyte number between samples. Monocytes 
comprised 1-47% of WBCs, but were usually less numerous than heterophils and 
lymphocytes (Table 6.1). Monocytes were generally round, with a horseshoe-shaped 
nucleus and blue-staining cytoplasm (Figure 6.1, C). Monocytes were approximately 15-
20 µm in diameter. There was no statistically significant difference in monocyte numbers 
based on sex or season. 
 
Eosinophils 
Eosinophils comprised 1-35% of WBCs, but were generally found in lower numbers than 
heterophils, lymphocytes and monocytes (Table 6.1). Eosinophils were round to oval, 
with a lobulated blue-staining nucleus, pale blue cytoplasm and round, pink cytoplasmic 
granules (Figure 6.1, D). Eosinophils were approximately 15-22µm in diameter. There 
was no significant difference in eosinophil numbers based on sex or season.  
 
Basophils 
Basophils were the rarest of the white blood cells, comprising 0-23% of WBCs seen 
(Table 6.1). Basophils were round with prominent dark purple-staining cytoplasmic 
granules that obscured the nucleus (Figure 6.1, E), and were approximately 13-17µm in 
diameter. There were no statistically significant differences in basophil numbers based 
on sex or season. 
 
Thrombocytes and fibrinogen 
Thrombocytes were found both in clumps and singly. Thrombocytes resembled 
lymphocytes, and were round to oval, often with an irregular, sometimes indistinct 
outline (Figure 6.1, F). Their nuclei were purple-staining and often slightly irregular in 
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shape. Their cytoplasms were a much paler blue than that of the lymphocytes. 
Thrombocytes were generally slightly larger than lymphocytes, with a diameter of 9-






Figure 6.1 Tuatara white blood cells and thrombocytes, Leishman’s stain. A = heterophil, 





 White cell count method 
A subset of 28 samples had both chamber counts and estimated white cell counts 
performed on the same sample. These samples were taken from animals undergoing 
pharmacokinetic studies and are not, therefore, suitable for use in reference ranges, but 
can be used to illustrate the difference in white blood cell numbers between counting 
methods. Estimated white cell counts were significantly higher than chamber counts by 
factors of 2-7 (p<0.0001) (Table 6.6). 
 
Table 6.6 Differences in white blood cell count based on counting method. 
Count method Unit Mean (Median) SD Min-Max  n (samples) 
Haemocytometer count x 109/L 1.94 (1.80) 1.04 0.4-5.5 12 (28) 




A total of 33 individual samples from 12 tuatara were available for analysis, and results 
are summarised in Table 6.7. Using the Abaxis Vetscan the lower limit of quantitation 
for bile acids is 35 µmol/L, and as all but one result were reported as <35, no further 
data on mean, median or range is available for this parameter. Similarly, several total 
calcium readings were over the upper limit of quantitation of 4 mmol/L, and several 
potassium readings were below the lower limit of quantitation of 1.5 mmol/L, 
precluding calculation of summary statistics. All parameters were tested in all 33 
samples, however some readings for bile acids and CK came back as zero. These were 
below the limit of quantitation as described by Abaxis, and these values are not included 
in the reference tables or calculations. Statistically significant differences in parameters 
based on sex, season and reproductive status are discussed further below. 
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Table 6.7 Biochemistry values for captive tuatara. * Some data were outside the range 
of quantitation, see text for details. † Statistically significant difference based on sex, 
season or reproductive status, see text for details. 
Parameter Unit Mean (Median) SD Min-Max (10th-90th 
Percentile) 
n (samples) 
AST IU/L 22.8 (15.7) 15.5 7-80 (9.0-46.4) 12 (33) 
Bile acids µmol/L *  * <35-41* (<35)* 12 (30) 
CK IU/L 1548 (1726) 1698 36-6519 (55-4639) 12 (28) 
Uric acid † µmol/L 102.5 (97.0) 44.4 42-232 (51.8-163.6) 12 (33) 
Glucose † mmol/L 5.02 (4.7) 1.10 3.3-7.6 (3.50-6.78) 12 (33) 
Total calcium † mmol/L 2.98 (2.86)* 0.63* 2.1-4.0* 12 (27) 
Phosphorous † mmol/L 1.76 (1.67) 0.59 0.57-3.49 (1.14-2.61) 12 (33) 
Total protein g/L 38.6 (36.0) 8.7 27-64 (28.4-51.2) 12 (33) 
Albumin g/L 20.8 (20.0) 4.2 14-30 (15.4-28.2) 12 (33) 
Globulin † g/L 17.7 (17.0) 5.9 10-37 (11.0-24.0) 12 (33) 
Potassium mmol/L 3.19 (3.4)* 1.10* <1.5-6.1* 12 (26) 
Sodium mmol/L 133.6 (133.0) 4.2 126-143 (128.0-139.8) 12 (33) 
 
There were no statistically significant differences in AST, bile acids, creatine kinase, total 
protein, albumin, potassium or sodium concentrations based on sex or season. Glucose 
concentrations differed between season, while uric acid, total calcium, phosphorous 
and globulins differed based on sex (Tables 6.8-6.12). 
 
Glucose 
Glucose was the only parameter to differ significantly between season, with 




Table 6.8 Differences in glucose concentration based on season in a population of 
captive tuatara. 
Parameter Unit Mean (Median) SD Min-Max (10th-90th 
Percentile) 
n (samples) 
Glucose (combined) mmol/L 5.02 (4.7) 1.10 3.3-7.6 (3.50-6.78) 12 (33) 
Glucose (winter) mmol/L 4.47 (4.50) 0.73 3.3-5.6 (3.50-5.48) 12 (12) 
Glucose (summer) mmol/L 5.97 (6.10) 1.04 4.3-7.6 (4.42-7.42) 12 (21) 
 
Uric acid 
Uric acid concentrations were significantly higher in females than males, with a mean of 
80.0 µmol/L in males, and 113.7 µmol/L in females (p=0.037) (Table 6.9). 
 
Table 6.9 Differences in uric acid concentration based on sex in a population of captive 
tuatara. 
Parameter Unit Mean 
(Median) 




Uric acid (combined) µmol/L 102.5 (97.0) 44.4 42-232 (51.8-163.6) 12 (33) 
Uric acid (male) µmol/L 80.0 (81.0) 18.9 49-104 (51.0-103.6) 4 (11) 
Uric acid (female) µmol/L 113.7 (111.5) 49.3 42-232 (51.1-187.1) 8 (22) 
 
Total calcium 
Total calcium concentrations were significantly higher in females than males. There 
were five females with readings >4.00 mmol/L (the upper limit of quantitation of the 
Vetscan analyser), so it was not possible to calculate true means and standard deviations 
for the combined group or for females. However even with these five values excluded, 
females had a significantly higher total calcium concentration than males (p=0.0021) 





Table 6.10 Differences in total calcium concentration based on sex in a population of 
captive tuatara. * Five samples had calcium concentrations >4.00 mmol/L and were 
excluded from these calculations. 
Parameter Unit Mean (Median) SD Min-Max (10th-90th 
Percentile) 
n (samples) 
Calcium (combined) mmol/L 2.98 (2.86)* 0.63* 2.1-4.0* 12 (27) 
Calcium (male) mmol/L 2.54 (2.46) 0.33 2.10-3.28 (2.13-3.20) 4 (11) 
Calcium (female) mmol/L 3.32 (3.53)* 0.61* 2.19->4.00* 8 (17) 
 
Phosphorous 
Phosphorous concentrations were significantly higher in females than males, with a 
mean of 1.43 mmol/L in males, and 1.92 mmol/L in females (p=0.0228) (Table 6.11). 
There was no difference between gravid and non-gravid females. 
 
Table 6.11 Differences in phosphorous concentration based on sex in a population of 
captive tuatara. 
Parameter Unit Mean (Median) SD Min-Max (10th-90th 
Percentile) 
n (samples) 
Phosphorous (combined) mmol/L 1.76 (1.67) 0.59 0.57-3.49 (1.14-2.61) 12 (33) 
Phosphorous (male) mmol/L 1.43 (1.41) 0.29 0.97-1.85 (1.00-1.84) 4 (11) 
Phosphorous (female) mmol/L 1.92 (1.79) 0.64 0.57-3.49 (1.29-2.87) 8 (22) 
 
Globulins 
Globulin concentrations were significantly higher in males than females, with a mean of 




Table 6.12 Differences in globulins concentration based on sex in a population of captive 
tuatara. 
Parameter Unit Mean (Median) SD Min-Max (10th-90th 
Percentile) 
n (samples) 
Globulins (combined) g/L 17.7 (17.0) 5.86 10-37 (11.0-24.0) 12 (33) 
Globulins (male) g/L 22.1 (22.0) 5.74 16-37 (16.2-34.6) 4 (11) 




This study is the most comprehensive analysis of tuatara haematology and biochemistry 
values to date. The development of reference ranges is of considerable value in 
evaluating the health status of individual animals. In doing so, due consideration must 
be given to influencing factors such as season, sex, diet and physiologic state when 
assessing haematology and biochemistry in reptiles (Campbell 2014). The animals in this 
study were from a single population maintained under identical husbandry conditions, 
allowing comparison between individuals in the absence of the confounding factors of 
different diets or environments. 
 
The PCVs of tuatara in this study were in agreement with those reported by Boardman 
and Blanchard (2006), with tuatara in this study having slightly higher Hb and MCHC. 
Data from two other sources (Gartrell 2006 and Species360 2013) do not include red cell 
parameters. Tuatara have among the largest red blood cells of all reptiles (Frye 1991), 
and the length and width measurements in this study are consistent with those reported 
elsewhere (Desser 1978, Frye 1991). Male tuatara had significantly higher PCVs than 
females, which may indicate an increased oxygen carrying capacity in males. Male 
tuatara are more active than females during the breeding season as they vigorously 
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defend their territory and actively pursue females (Gillingham et al. 1995), and this may 
explain the requirement for increased oxygen carrying capacity in males compared to 
females. Intraerythrocytic haemogregarine parasites (Hepatozoon tuatarae) have been 
observed in other tuatara (Godfrey et al. 2011), but none were seen in this population. 
 
White blood cell numbers were markedly lower than those reported in several other 
sources (Boardman and Blanchard 2006, Gartrell et al. 2006, Species360 2013). Two of 
these studies reported only estimated white cell counts  from blood films (Boardman 
and Blanchard 2006, Gartrell 2006), and the Species360 count methods are not 
reported. As seen in the data here and reported elsewhere (Russo et al. 1986), estimated 
white cell counts are often significantly higher, and considered less accurate, than those 
determined by haemocytometer on recently drawn blood. Estimated white blood cell 
counts from the same sample can vary significantly depending on sample handling and 
preparation, laboratory technique, and between individual technicians (Campbell 2014). 
The methodology used in this study aimed to minimise these influences. 
 
Total white blood cell counts were higher in winter than summer. When white cell count 
was analysed by sex and season, it became apparent the higher concentration in winter 
was attributable to females rather than males, but there was no significant difference 
between white blood cell concentrations in winter between gravid and non-gravid 
females. Other studies in reptiles have reported seasonal variation in white blood cell 
numbers in reptiles, some higher in winter (Yu et al. 2013) and some higher in summer 
(Troiano et al. 1997), but the reasons for this are not well established. A report in a single 
tuatara documented a 30% decrease in circulating white cells when the animal was 
undergoing hibernation, compared to those obtained in summer (Desser 1979). The 
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increase in white cells in in the current study was attributable to higher heterophil 
numbers. These cells were increased in total number and as part of the differential 
percentage; no other leukocytes showed significant changes in cell number or 
differential percentage. While the differences in leukocyte numbers between sex and 
season were statistically significant, care should be taken in interpreting these results as 
sample sizes were small. Further study is required to ascertain if these results are 
consistent findings in other captive as well as wild tuatara populations.  
 
Heterophils and lymphocytes were the most common white blood cells and were 
present on average in almost equal proportions. This is in contrast to most other reptiles, 
where lymphocytes are considered the predominant leukocyte (Campbell 2014). Other 
published data show heterophil to lymphocyte ratios of approximately 1.5:1 (Jakob-Hoff 
1996) and 2:1 (Species360 2013) in tuatara of unspecified age, and 1:9 in juvenile tuatara 
(Gartrell et al. 2006). These wide variations illustrate the limitations of reference ranges 
in reptiles, and reinforce the utility of analysing a sample from a healthy conspecific 
when evaluating an unwell reptile (Campbell 2014).  
 
The sizes of the various white blood cells measured in this study is in agreement with 
those published for tuatara (Desser 1978, Frye 1991). Monocytes are usually the largest 
leukocytes in other reptiles (Campbell 2014), but this is not the case in tuatara. 
Heterophils were the largest white blood cells, followed by (in descending order) 
eosinophils, monocytes, basophils and lymphocytes. In comparison with other reptiles, 
tuatara were found to have the largest eosinophilic granulocytes, basophilic 
granulocytes and erythrocytes of the reptiles studied (Frye 1991). The aforementioned 
text did not evaluate relative sizes of monocytes or lymphocytes, and did not 
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differentiate specifically between heterophils and eosinophils, referring to both as 
‘eosinophilic granulocytes’. The significance of the larger leukocytes in tuatara is 
unknown. 
 
The only biochemistry value to show significant seasonal variation was glucose, with 
higher concentrations recorded in summer in both sexes. As all samples were handled, 
transported and stored using the same methods prior to testing, it is considered unlikely 
that an extrinsic factor contributed to the difference in glucose concentrations.  Tuatara 
have a higher metabolic rate and are more active in summer; it is also the time of year 
when nesting and mating takes place. The increased glucose concentration in summer 
may be associated with higher activity levels and physiological stress (Scheelings and 
Jessop 2011) associated with territorial defence and reproduction.  It should be noted 
that although samples were refridgerated and analysed within three hours of 
acquisition, red cells would still have been utilising glucose during the transport and 
storage interval. As a result, the glucose ranges reported here may be slightly lower than 
the actual concentration in circulating tuatara blood. 
 
Several biochemical values were significantly different between sexes. Calcium and 
phosphorous were higher in females, a phenomenon that is also observed in other 
reptiles and is related to females’ reproductive status (Campbell 2014). In other reptiles 
elevated calcium occurs during vitellogenesis and shell deposition, and can be used as 
an indicator that a female is gravid (Simkiss 1967, Campbell 2014). This has not been the 
case in tuatara, and in one study of 29 wild tuatara, the animal with the highest calcium 
concentration was a female with atretic ovarian follicles (Cree et al. 1991). Vitellogenesis 
occurs slowly in wild tuatara over a period of 2-4 years on Stephens Island (Cree 2014), 
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but tuatara in our captive population have laid eggs in consecutive years, indicating 
more rapid follicle development and maturation can occur. This may be related to 
greater food availability and higher metabolic rate in the warmer captive environment 
at Auckland Zoo when compared to wild populations on the more southerly and cooler 
Stephens Island. Further study is required to determine the specific timing and cause of 
calcium and phosphorous elevations in the tuatara’s reproductive cycle. Calcium and 
phosphorous concentrations in this study were similar to those reported by Boardman 
and Blanchard (2006). 
 
While uric acid concentrations were significantly higher in females than males (p=0.037), 
further analysis showed that the two highest uric acid values were attributable to the 
one tuatara, and with these values removed there was no significant difference between 
sexes. Furthermore, there was no significant difference in uric acid concentration based 
on the reproductive status of female tuatara. Based on these data, there is no current 
indication that separate reference ranges are required for uric acid concentrations in 
tuatara based on sex. It is likely that the statistically significant difference in uric acid 
concentrations was related to the small sample sizes in this study. Uric acid is an end-
product of protein catabolism in reptiles, and an indicator of renal function (Campbell 
2014). Uric acid concentrations can increase with dehydration and with renal 
compromise; no tuatara in this study showed evidence of either of these conditions. Uric 
acid concentrations reported here were similar to those published by Boardman and 
Blanchard (2006). 
 
Globulins were significantly higher in males than females, however the reason for this is 
unknown. There was no corresponding increase in leukocyte numbers in males, 
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suggesting antigenic stimulation is an unlikely reason for the observed higher globulins. 
Further study is required to determine whether this is a consistent finding, and if so, 
protein electrophoresis may prove valuable in assessment of globulins in both sexes. 
There are no other published studies that report globulin concentrations in tuatara.   
 
Bile acids were all recorded as <35 mmol/L, except for one value of 41 mmol/L. Bile acid 
composition is different between reptile species, and it was initially considered possible 
that the Vetscan analyser may not be able to detect tuatara bile acids. This was proven 
not to be the case, as concentrations of over 200 were detected in animals undergoing 
itraconazole treatment (see Chapter 4). Bile acids are produced by the liver to aid 
digestion, and are considered a specific test for hepatic insufficiency (Campbell 2014). 
Pre- and post-prandial 3α-hydroxy bile acid concentrations were measured in male 
green iguanas (Iguana iguana) and were found to be 7.5 ± 7.8 mmol/L and 33.3 ± 22.0 
mmol/L respectively (McBride et al. 2006). Additional study is required to further 
quantitate bile acids concentrations in tuatara, and the relationship of bile acids 
concentrations to food intake. 
 
It is important to note that biochemistry results in reptiles can differ between analysers. 
Studies in sea turtles and various squamate species have shown variable correlation 
between the VetScan and commercial laboratory analysers (Wolf et al. 2008, McCain et 
al. 2010), though in most cases the differences would not have significantly influenced 
clinical interpretation of results. The ranges here are best suited for use in captive 
tuatara kept in conditions similar to those described here, and in samples analysed using 






This study provides preliminary haematologic and clinical biochemical reference ranges 
for a population of captive tuatara. The data indicate that sex and environmental 
temperature can influence results, and these factors should be taken into account when 
assessing blood values from individual animals. As tuatara inhabit environments 
significantly colder than those experienced by this captive population, it is likely that 
further significant temperature-related changes in blood values would be detected in 
other populations. Calcium and bile acids both had measurements outside the limit of 
quantitation of the analyser used in this study, and it is recommended that further 
studies be undertaken to determine the true values of these parameters.  
 
Blood values in reptiles can differ significantly based on analytical method used, so this 
must be consistent when comparing values to reference populations. Of particular note 
is the use of estimated white cell counts, which can result in far higher values than those 
obtained using a haemocytometer. This may lead the clinician to misinterpret leukocyte 
count results if careful attention is not paid to the method used in both study and 
reference populations. Comparison of blood values obtained using the same method, 
and ideally the same laboratory and technician, will reduce the chances of this type of 
error occurring. The captive population in this study was small, so reference ranges and 
differences based on sex or season must be interpreted with caution. Comparison of 
blood values with a healthy conspecific that shares the same environment and diet 
remains the best way to assess the health of an individual reptile (Mader 1999, 
Hernandez-Divers 2006). Further studies to determine haematologic and biochemical 
parameters of larger populations of both captive and wild tuatara are warranted to 

















7. Chapter 7: Summary of findings and 




Tuatara (Sphenodon punctatus) are the last extant members of the order 
Rhyncocephalia, and are unique, cold-adapted reptiles found only in New Zealand. 
Recently, captive tuatara have been found to be affected by an emerging fungal 
pathogen, Paranannizziopsis australasiensis. P. australasiensis causes dermatitis in 
tuatara. Its presence has prevented the release of captive tuatara to offshore islands, 
and has negative implications for the long-term health and welfare of the animals. A 
review of the literature highlighted that little is known about the epidemiology and 
treatment of infections caused by P. australasiensis and related reptile fungal 
pathogens, with attempts at treatment in other species sometimes resulting in fatal 
hepatotoxicity (Van Waeyenberghe et al. 2010).  
 
In vitro fungal growth experiments undertaken in this study, indicated that the optimal 
growth temperature for P. australasiensis encompasses the range from 20oC-30oC, with 
scant growth at 12oC, moderate growth at 15oC, and no growth at 37oC. Isolates of P. 
australasiensis were also subject to MIC testing to determine what doses of voriconazole 
and itraconazole were required to inhibit growth of the pathogen. The relatively low 
MICs are similar to reports of susceptibility testing results in related reptile fungal 
pathogens (Abarca et al. 2008, Hellebuyck et al. 2010, Van Waeyenberghe et al. 2010). 
These MICs were used to determine target concentrations for plasma antifungal levels 
for the pharmacokinetic study. There was no significant difference in MICs tested at 12oC 
and 20oC, indicating that the same target concentrations could be used for the 
pharmacokinetic studies at different temperatures. The robustness of this process could 
be improved by conducting MIC testing on more P. australasiensis isolates, and by using 
a haemocytometer rather than an approximation of optical density to measure fungal 
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spore concentration in the fungal inoculum. However, resource constraints precluded 
the application of these methods at the time of the study. 
 
Further investigation into the epidemiology of P. australasiensis and related infections 
is warranted, including determining whether P. australasiensis is present in wild 
populations of tuatara, and the ecology of the fungus itself. This work will significantly 
enhance our understanding of emerging fungal disease ecology, and will inform future 
conservation management plans for tuatara and other reptiles.  
 
Itraconazole has been used in the treatment of P. australasiensis in tuatara, and related 
reptile fungal pathogens in other reptiles, at dose rates ranging from 3-5 mg/kg PO SID 
with varying success, and sometimes fatal adverse effects (Van Waeyenberghe et al. 
2010, Masters et al. 2016). This study shows that itraconazole-treated tuatara should be 
maintained at 20oC to facilitate more rapid attainment of target concentrations, and to 
enhance drug elimination. Administration of a loading dose will assist with reaching 
target concentrations sooner. Adverse effects may occur at the modelling-derived 
dosages, and careful monitoring of tuatara weight, and haematologic and biochemistry 
parameters (particularly bile acids, uric acid and white blood cell count) are 
recommended during treatment. Observed itraconazole concentrations showed good 
agreement with pharmacokinetic modelling, and there was limited inter-individual 
variability in plasma itraconazole concentrations when compared to voriconazole-
treated animals. 
 
Prior to this study, voriconazole had not been used in the treatment of P. australasiensis 
in tuatara, but had been used successfully to treat a related fungal infection in two lizard 
species (Hellebuyck et al. 2010, Van Waeyenberghe et al. 2010). This study shows that, 
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as with itraconazole treatment, voriconazole-treated tuatara should be maintained at 
20oC. However as target concentrations of voriconazole are rapidly achieved, no loading 
dose is required. There was significant inter-individual variability in voriconazole plasma 
concentrations between tuatara, a phenomenon that is also observed in humans. This 
would likely result in some tuatara receiving a given dosage having sub-therapeutic 
voriconazole plasma concentrations, while other tuatara may have unnecessarily high 
concentrations. No adverse effects were seen in this study, however it is important that 
routine health monitoring be undertaken during treatment. Treatment failure may be 
due to subtherapeutic plasma concentrations, and increasing the administered 
voriconazole dose may remedy this.  
 
In both itraconazole and voriconazole studies, oral drug absorption was prolonged. 
Further study of gastric emptying times and the effect of food on drug absorption in 
tuatara would assist understanding of the factors influencing drug absorption. 
Intravenous pharmacokinetic data would enable the determination of oral 
bioavailability, which would assist with more accurate determination of other 
pharmacokinetic parameters on which to base recommended antifungal dosages. 
 
The findings of this study will be important in the development of a quarantine 
treatment protocol for tuatara, to ensure they are not subclinical carriers of P. 
australasiensis prior to release to wild sites. Itraconazole has the more predictable 
pharmacokinetics of the two drugs, so is well suited to this role, but adverse effects may 
limit its use. Voriconazole appears to be the safer of the two drugs, however variable 
inter-individual pharmacokinetics mean some animals may reach sub-therapeutic 
voriconazole concentrations. This may be remedied by increasing the administered 
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dose, but this increases the likelihood of adverse effects occurring. Further, it would not 
be appropriate to use voriconazole in this manner, associated with treatment during 
quarantine periods, until it has been established that voriconazole successfully treats 
clinical infection of P. australasiensis in tuatara. Proprietary voriconazole is currently 
significantly more expensive than itraconazole, and this must also be taken into account 
when assessing the utility of both antifungals. Ideally, pharmacokinetic studies would be 
conducted on clinically affected tuatara, to determine if illness influences the antifungal 
pharmacokinetics, and to ensure the modelling-derived dose rates n this study are 
clinically effective in diseased animals. 
 
Establishing haematologic and biochemical reference ranges for a species assists in the 
evaluation of health and disease in individual animals. The ranges established in this 
study provide data from a population of known sex structure, environmental and 
seasonal status. These data provide a basis for future studies in both captive and wild 
populations, to increase the robustness and utility of these ranges.  
 
This research is the first of its kind to use population pharmacokinetic modelling of 
antifungal treatments in reptiles, and provides a framework for future research in this 
area. It demonstrates the utility of population-based modelling in circumstances of 
sparse data sampling and high variability in drug concentrations, which are often the 
case in non-domestic species where small sample sizes and volumes can limit the 
amount of data collected. Fungal diseases have been associated with significant 
population declines of amphibians, reptiles and mammals worldwide, and it is crucial 










8.1 Appendix 1 – Culture method for fungal isolates 
 
Media/Reagents 
• Enrofloxacin solution 20 µg/ml (working solution) 
• Sabourauds Dextrose agar (SDA) plates with and without antibiotics, Mycobiotic 
agar 
• Sabourauds Dextrose agar slopes with cycloheximide - used for sending cultures 
overseas for confirmation, and to Canterbury Health Laboratories (CHL, 
Christchurch) for MIC testing. 
 
Method 
• Using sterile scalpel, aseptically divide the sample and cut into small pieces ~ 3-
4 mm.  
• Dip pieces into Baytril solution (allow submersion for ~30secs).  
• Remove and further cut into 1-2 mm sizes (aim for 5-6 pieces for each medium 
used).  
• Place pieces onto culture medium (use scalpel end to mark 5-6 areas in the agar 
first)  
• Make sure they are all firmly pressed onto the agar.  
• Use sellotape to seal all agar plates.  
• Incubate plates/slopes at 25 or 30oC  




8.2 Appendix 2 – Preparation of inoculum for antifungal susceptibility testing 
 
Each fungal isolate was subcultured onto an SDA slant, and the following process 
performed to prepare the inoculum for MIC testing. 
 
• Remove fungus from the slant using a sterile loop 
• Deposit in a test tube with 2 mL of saline and mix to produce a uniform 
suspension 
• Adjust amount of saline and fungus present to produce an inoculum with optical 
density of 1.5 McFarland (approximately 4.5 x 108 cells), as assessed visually 
• Inoculate 20 µL of solution to a SDA slope as a sterility check 
• Inoculate 100 µL to an 11 mL RPMI 1640 solution and mix to form uniform 
suspension 
• Transfer suspension aseptically to a sterile plastic reagent reservoir  
• Add 100 µL of suspension to each well in the sensititre plate 
• Cover plate with adhesive plastic sheet, to prevent contamination from 




8.3 Appendix 3 – Drug assay procedure 
 
Reagents used in the assays were as follows: 
- Ammonium formate solution, 1 mol/L. This was prepared by dissolving 63 g of 
ammonium formate in deionised water, and making up to 1 L with deionised 
water. 
- Formic acid, 88% 
- Eluent A. This was prepared using 4 mL of the 1 mol/L ammonium formate 
solution and 4 mL of formic acid, and making up to 2 L with deionised water. 
- Eluent B. This was prepared using 4 mL of the 1 mol/L ammonium formate 
solution and 4 mL of formic acid, and making up to 2 L with acetonitrile. 
 
Standards were prepared as follows: 
- Voriconazole stock standard, 1.0 mg/mL. 10.0 mg of voriconazole powder was 
dissolved in 10 mL of methanol, and stored at 4oC until use. 
- Itraconazole stock standard, 0.4 mg/mL. 10.0 mg of itraconazole powder was 
dissolved in 25 mL of methanol, and stored at 4oC until use. 
- Hydroxy-itraconazole stock standard, 0.1 mg/mL. 10.0 mg of hydroxy-
itraconazole powder was dissolved in 100 mL of methanol, and stored at 4oC until 
use. 
- Antifungal standards in plasma. The standards were produced using a mix 
comprised of 0.1 mL voriconazole stock standard, 0.25 mL itraconazole stock 
standard, and 1.0 mL hydroxy-itraconazole stock standard, as prepared above. 
This was made up to 10 mL with drug-free plasma, producing a standard 
containing 0.1 mg of each antifungal in 10 mL, or 10 mg/L, as ST 10. Other 
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standards were produced by sequentially diluting ST 10 in drug-free plasma, to 
produce standards of 5.0, 2.5, 1.25, 0.625 and 0.3125 mg/L. A blank standard, of 
drug-free serum only, was also prepared. 
- Working internal standard solutions of 1 mg/L. These were prepared by diluting 
50 µL of a stock solution of a commercial preparation of each antifungal (Toronto 
Research Chemicals Inc, Canada) to 50 mL with acetonitrile. The stock solutions 
were deuterated standards of voriconazole-d3, itraconazole-d5, and Hydroxy-
itraconazole-d5 as 1.0 mg/mL solutions in methanol.  
 
Sample preparation was as follows: 
- Place 30 µL of sample, QC, drug free plasma or standard into a 1.5 mL plastic 
centrifuge tube 
- Add 30 µL of working internal standard (1 mg/L in acetonitrile) 
- Vortex for 30 seconds and centrifuge at 15,000 g for 5 minutes 
- Transfer 20 µL to HPLC autosampler injection vial or 96 well microtitre plate 
- Add 280 µL of water and mix gently 






8.4 Appendix 4 – Inter-run and intra-run statistics for assay validation and precision 
 
Below are the inter- and intra-run statistics for voriconazole, itraconazole and hydroxy-
itraconazole. 
 




Analyte level Low Medium High 
Average 0.48 1.07 2.20 
Target value 0.5 1.0 2.0 
CV% 10.0 5.4 7.6 
 
Intra-run 
Analyte level Low Medium High 
Average 0.44 0.78 2.05 
Target value 0.5 1.0 2.0 




Analyte level Low Medium High 
Average 0.58 1.04 2.07 
Target value 0.5 1.0 2.0 





Analyte level Low Medium High 
Average 0.57 0.99 2.12 
Target value 0.5 1.0 2.0 




Analyte level Low Medium High 
Average 0.52 1.04 2.17 
Target value 0.5 1.0 2.0 
CV% 12.6 5.8 6.8 
 
Intra-run 
Analyte level Low Medium High 
Average 0.52 1.05 2.09 
Target value 0.5 1.0 2.0 









8.5 Appendix 5 - Chromatograms of tuatara plasma 
 









The highest peak on the blank sample did not correspond to any transition pairs being 
monitored at the retention time, thus there are no peaks that would be misidentified as 
antifungal drugs that could interfere with the assays. 
262 
 
8.6 Appendix 6 – Control stream for pharmacokinetic modelling 
 
Mixed effects modelling was performed using NONMEM v7.3.0 with the Intel Fortran 
Compiler v11. The control stream is provided below: 
 
NM-TRAN Control Stream for PK Model for Single Dose Model 03 
$PROB Tuatara Sarah Alexander 13 Jan 2014 
$INPUT 
ID ; numerical ID 
Number=DROP Name=DROP SEX=DROP Gravid=DROP DRUG=DROP MGKG=DROP 
TYPE=DROP 
DAT1=DROP ; dd/mm/yyyy 
TIME ; 0 - 48 h  
TRT ; 1=itraconozole, 2=voriconazole 
TEMP ; Celsius 
WTKG ; kg 
M1F0 ; male=1, female=0 
Pregnant ; 0=No, 1=Yes or Likely 
DVID ; 0=dose, 1=itraconazole, 2=voriconazole 
AMT ; mg oral 
CMT ; 1=itraconozole, 2=voriconazole 
DV ; mg/L concentration 




$EST METHOD=COND INTER 







(0,0.908,) ; POP_CL_IT L/h/70kg 
(0,202.,) ; POP_V_IT L/70kg 
(0,4.87,)  ; POP_TABS_IT h 
 
(0,0.858,) ; POP_CL_VR L/h/70kg 
(0,38.7,) ; POP_V_VR L/70kg 
(0,6.92,)  ; POP_TABS_VR h 
 
(0,0.1,) FIX ; RUV_PROP_IT 
(0,0.3,) FIX ; RUV_ADD_IT mg/L 
 
(0,0.1,) FIX ; RUV_PROP_VR 
(0,0.3,) FIX ; RUV_ADD_VR mg/L 
 
(1,6.73,10)  ; FCL_20_IT 
(0,1.,) FIX ; FTAB_20_IT 
 
(1,3.35,10)  ; FCL_20_VR 
(0,1.,) FIX ; FTAB_20_VR 
 
$OMEGA BLOCK(3) 
0.00001 ; BSV_CL_IT 
0. 0.121 ; BSV_V_IT 
0. 0. 0.00001 ; BSV_TABS_IT 
 
$OMEGA BLOCK(3) 
0.00003 ; BSV_CL_VR 
0. 0.00001 ; BSV_V_VR 
0. 0. 0.00001 ; BSV_TABS_VR 
 
$OMEGA BLOCK(3) 
0.00001 ; BOV_CL_IT_1 
0. 0. ; BOV_V_IT_1 
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0. 0. 0.364 ; BOV_TABS_IT_1 






0. ; BOV_CL_VR_1 
0. 0.739 ; BOV_V_VR_1 
0. 0. 2.25 ; BOV_TABS_VR_1 





$SIGMA 1. FIX ; EPS1 
 








IF (TEMP.EQ.12) THEN 
   FCLTMPIT=1/FCL_20_IT 
   FTABTMPIT=1/FTAB_20_IT 
   FCLTMPVR=1/FCL_20_VR 
   FTABTMPVR=1/FTAB_20_VR 
ELSE 
   FCLTMPIT=1 
   FTABTMPIT=1 
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   FCLTMPVR=1 










IF (TEMP.EQ.12) THEN 
   BOVCLIT=BOV_CL_IT_1 
   BOVVIT=BOV_V_IT_1 
   BOVTABIT=BOV_TABS_IT_1 
   BOVCLVR=BOV_CL_VR_1 
   BOVVVR=BOV_V_VR_1 
   BOVTABVR=BOV_TABS_VR_1 
ENDIF 
IF (TEMP.EQ.20) THEN 
   BOVCLIT=BOV_CL_IT_2 
   BOVVIT=BOV_V_IT_2 
   BOVTABIT=BOV_TABS_IT_2 
   BOVCLVR=BOV_CL_VR_2 
   BOVVVR=BOV_V_VR_2 




























DADT(3)=RATEIT - CLIT*CENIT 







IF (DVID.LE.1) THEN 
   PROPIT=CONCIT*RUV_PROP_IT 
   ADDIT=RUV_ADD_IT 
   SDIT=SQRT(PROPIT*PROPIT + ADDIT*ADDIT) 
   Y=CONCIT + SDIT*EPS1 
ELSE 
   PROPVR=CONCVR*RUV_PROP_VR 
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   ADDVR=RUV_ADD_VR 
   SDVR=SQRT(PROPVR*PROPVR + ADDVR*ADDVR) 
   Y=CONCVR + SDVR*EPS1 
ENDIF 
 
$TABLE ID TIME TRT TEMP AMT WTKG 
CLIT VIT TABIT CLVR VVR TABVR 
Y 
ONEHEADER NOPRINT FILE=tuatara.fit 
 
NM-TRAN Control Stream for PK Model for Single and Multiple Dose Model 013 
$PROB Tuatara Sarah Alexander 20 Dec 2015 
$INPUT 
ID ; numerical ID 
Number=DROP Name=DROP SEX=DROP Gravid=DROP DRUG=DROP MGKG=DROP 
TYPE=DROP STUDY=DROP 
DAT1=DROP ; dd/mm/yyyy 
TIME ; 0 - 48 h  
TRT ; 1=itraconozole, 2=voriconazole 
S1M2 ; 1=single Dose=1, 2=multiple dose 
TEMP ; Celsius 
WTKG ; kg 
M1F0 ; male=1, female=0 
Pregnant ; 0=No, 1=Yes or Likely 
DVID ; 0=dose, 1=itraconazole, 2=voriconazole 
AMT ; mg oral 
CMT ; 1=itraconozole, 2=voriconazole 
DV ; mg/L concentration 
MDV ; 0=observation 1=missing observation 
II ; dosing interval hours 
ADDL ; additional doses after first 






$EST METHOD=COND INTER 





(0,0.254,) ; POP_CL_IT L/h/70kg 20C 
(0,186.,) ; POP_V_IT L/70kg 
(0,5.47,15)  ; POP_TABS_IT h 
 
(0,0,) FIX ; POP_CL_VR L/h/70kg 20C 
(0,1.58,25) ; POP_VM_VR mg/h/70kg 20C 
(0.001,0.00866,7.5)  ; POP_KM_VR mg/L 20C 
(0,79.7,) ; POP_V_VR L/70kg 
(0,3.,15)  ; POP_TABS_VR h 
 
(0,0.178,)  ; RUV_PROP_IT 
(0,0.198,)  ; RUV_ADD_IT mg/L 
 
(0,0.275,)  ; RUV_PROP_VR 
(0,0.541,)  ; RUV_ADD_VR mg/L 
 
(1,2.86,1000)  ; FCL_12_IT 
(0,1.,) FIX ; FTAB_12_IT 
 
(1,2.11,1000)  ; FCL_12_VR 
(0,1.,) FIX ; FTAB_12_VR 
 





0.0394 ; BSV_CL_IT 
0. 0.0112 ; BSV_V_IT 
$OMEGA BLOCK(1) 
0. FIX ; BSV_TABS_IT 
$OMEGA BLOCK(1) 
0.0355 ; BSV_F_IT 
 
$OMEGA BLOCK(2) 
0.00122 ; BSV_CL_VR 
0. 0.0136 ;BSV_V_VR 
$OMEGA BLOCK(1) 
0.00008 ; BSV_TABS_VR 
$OMEGA BLOCK(1) 
0.00028 ; BSV_F_VR 
 
$OMEGA BLOCK(2) 
0.0139 ; BOV_CL_IT_1 
0. 0.0628 ; BOV_V_IT_1 




0.636 ; BOV_TABS_IT_1 
$OMEGA BLOCK(1) SAME 
;; BOV_TABS_IT_2 
$OMEGA BLOCK(1) 
0. FIX ; BOV_F_IT_1 




0. ; BOV_CL_VR_1 





0.0395 ; BOV_V_VR_1 
$OMEGA BLOCK(1) SAME 
;; BOV_V_VR_2 
$OMEGA BLOCK(1) 
0.791 ; BOV_TABS_VR_1 
$OMEGA BLOCK(1) SAME 
;; BOV_TABS_VR_2 
$OMEGA BLOCK(1) 
0. FIX ; BOV_F_VR_1 
$OMEGA BLOCK(1) SAME 
;; BOV_F_VR_2 
 
$SIGMA 1. FIX ; EPS1 
 








IF (TEMP.EQ.12) THEN 
   FCLTMPIT=1/FCL_12_IT 
   FTABTMPIT=FTAB_12_IT 
   FCLTMPVR=1/FCL_12_VR 
   FTABTMPVR=FTAB_12_VR 
ELSE 
   IF (TEMP.EQ.16) THEN 
      FCLTMPIT=2/FCL_12_IT 
      FTABTMPIT=FTAB_12_IT/2 
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      FCLTMPVR=2/FCL_12_VR 
      FTABTMPVR=FTAB_12_VR/2 
   ELSE 
      FCLTMPIT=1 
      FTABTMPIT=1 
      FCLTMPVR=1 
      FTABTMPVR=1 












IF (TIME.GT.TBIO.AND.TEMP.EQ.20) THEN 
   FBIOFVR=FBIOF_20_VR 
ELSE 
   FBIOFVR=1 
ENDIF 
    
 
IF (TEMP.LT.20) THEN 
   BOVCLIT=BOV_CL_IT_1 
   BOVVIT=BOV_V_IT_1 
   BOVTABIT=BOV_TABS_IT_1 
   BOVFIT=BOV_F_IT_1 
   BOVCLVR=BOV_CL_VR_1 
   BOVVVR=BOV_V_VR_1 
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   BOVTABVR=BOV_TABS_VR_1 
   BOVFVR=BOV_F_VR_1 
ENDIF 
IF (TEMP.EQ.20) THEN 
   BOVCLIT=BOV_CL_IT_2 
   BOVVIT=BOV_V_IT_2 
   BOVTABIT=BOV_TABS_IT_2 
   BOVFIT=BOV_F_VR_2 
   BOVCLVR=BOV_CL_VR_2 
   BOVVVR=BOV_V_VR_2 
   BOVTABVR=BOV_TABS_VR_2 































DADT(3)=RATEIT - CLIT*CENIT 







IF (DVID.LE.1) THEN 
   PROPIT=CONCIT*RUV_PROP_IT 
   ADDIT=RUV_ADD_IT 
   SDIT=SQRT(PROPIT*PROPIT + ADDIT*ADDIT) 
   Y=CONCIT + SDIT*EPS1 
ELSE 
   PROPVR=CONCVR*RUV_PROP_VR 
   ADDVR=RUV_ADD_VR 
   SDVR=SQRT(PROPVR*PROPVR + ADDVR*ADDVR) 




IF (S1M2.EQ.2) THEN ; 10 day offset for plotting 
   DAYS=DAYS+10 





IF (TEMP.EQ.16) THEN 
   T1220=12 ; Was originally in 12 C group but moved to 16 (ambient) 
ELSE 
   T1220=TEMP 
ENDIF 
$TABLE ID TIME HOURS DAYS S1M2 TRT T1220 AMT WTKG 
CLIT VIT TABIT CLVR VVR TABVR 
Y 
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